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Abbreviations frequently used and/or novel to this thesis are listed below.
Ab antibody
Ag antigen
ATCC arnerican type culture collection
BPI bactericidal/permeability increasing protein
ch50 haemolytic complement value
cho carbohydrate
cfu colony forming units
CP capsular polysaccharide
DIC disseminated intravascular coagulation
ECV extracellular vesicles
EDL electron dense layer
ELISA enzyme-linked immunosorbent assay
EPS extracellular polysaccharide
FCS foetal calf serum
HDL high density lipoprotein
HISS heat inactivated sheep seium
IL interleukin
KDO 3-deoxy-D-manno-octulosonic acid





MPRL departmental stock culture
mwt molecular weight
NB nutrient broth
NCTC national type culture collection
nk natural killer
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PCP phenol-chloroform-petroleum extraction method
PF pyrogen free
PMN polymorphonuclear neutrophils
PPY proteose peptone yeast extract broth
PW phenol-water extraction method
SIRS systemic inflammatory response syndrome
sTNFr soluble tumour necrosis factor receptor
TNI tumour necrosis factor
Triton triton-Mg2+ extraction method
VT Van Tassell &Wilkins minimal defined media
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Abstract
Lipopolysaccharide (LPS), a major constituent of Gram-negative bacteria, is
implicated as the key factor in the development of the Systemic Inflammatory
Response Syndrome (SIRS). LPS can arise from an underlying bacteraemia, but given
that the majority of patients with SIRS have no detectable bacteraemia, then LPS
derived from the gut must be considered. Bacteroides species outnumber the
enterobacteria such as E. coli in the gut by approximately 1000-fold. Although
Bacteroides LPS is less endotoxic, by simple arithmetic there must be as much
biological potential from the LPS of Bacteroides as from E. coli. This thesis re¬
examines the biological activity of Bacteroides LPS and its possible role in the
development of SIRS.
LPSs were extracted fr om seven Bacteroides species by three different techniques: the
phenol-water (PW), the phenol-chloroform-petroleum (PCP) and Triton-Mg2+. The
biological activity of these Bacteroides LPSs was compared to that of an E. coli
018K" LPS control. In general, Bacteroides LPSs prepared by the PW method were
found to have a significantly higher activity in a mouse lethality model, LAL assay,
TNF and IL-8 induction assays, than LPS extracted by the PCP or Triton methods.
Bacteroides LPS extracted by the PCP method had consistently low activity in all
assays. LPS from B. fragilis NCTC 9343 and B. caccae had a consistently higher
activity than LPS from B. vulgatus and B. thetaiotaomicron in most assays.
Differences in activity between B. fragilis NCTC 9343 LPS grown in different media
was seen. The PW method selected for greater amounts of carbohydrate and KDO
and the PCP the least. Further information from sub-population studies, Percoll
profiles, chemotype on PAGE and chemical analysis failed to account for differences
in biological activity between extraction methods and Bacteroides species.
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Comparing PW-LPS from Bacteroides with that from E. coli, cytokine induction
was examined from three different cell populations: human mononuclear leukocytes
(MNL), THP-1 cells (with and without enhancement for CD 14 by vitamin D3) and
peritoneal macrophages from C3H/HeJ (LPS-non-responder) and C3H/HeN (LPS-
responder) mice. In brief, E. coli 018K" LPS produced multiple peaks of TNF
production through a CD14 dependent pathway, while B. fragilis NCTC 9343 LPS
could only produce one peak of TNF through a pathway independent of CD 14. In
contrast, E. coli LPS induced a single peak of EL-8, whereas Bacteroides LPS
induced two peaks. Both LPSs induced IL-8 through a CD14 dependent pathway. In
IL-6 production, both E. coli 018K" and B. fragilis NCTC 9343 LPS induced a
single peak through a pathway independent of CD 14. Cytokine induction by capsular
polysaccharide (CP) was also examined. Most activity was seen in the low mwt CP
(which contained more carbohydrate and KDO) but on a scale much lower than LPS.
An excess of Bacteroides LPS (extracted by all three methods) or CP masked the
effect of E. coli LPS in producing the cytokines TNF, IL-8 and IL-6. Several anti-
Bacteroides mAbs inhibited TNF production by both E. coli and B. fragilis NCTC
9343 LPS but did not inhibit IL-8 production.
Finally, studies into the mitogenicity of Bacteroides LPS and CP indicate that B.
vulgatus and high mwt CP were more mitogenic than B. fragilis NCTC 9343 LPS hi
mixed spleen cells, B cells and T cells from LPS-responder mice.
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Summary
Lipopolysaccharide (LPS), a major constituent of Gram-negative bacteria, is
implicated as the key factor in the development of the Systemic Inflammatory
Response Syndrome (SIRS). LPS can arise from an underlying bacteraemia, but given
that the majority of patients with SIRS have no detectable bacteraemia, then LPS
derived from the gut must be considered. Bacteroides species outnumber the
enterobacteria such as E. coli in the gut by approximately 1000-fold. B. fragilis is
the most common anaerobe hi clinical infections such as intra-abdominal abscesses.
Although Bacteroides LPS is less endotoxic, by simple arithmetic there must be as
much biological potential from the LPS ofBacteroides as from E. coli.
This thesis re-examines the biological activity of Bacteroides LPS and its possible role
in the development of SIRS.
LPSs were extracted from seven Bacteroides species by three different techniques-
the phenol- water (PW), the phenol-chloroform-petroleum (PCP) and Triton-Mg2+.
The strains selected included two different B. fragilis strains, one ofwhich was grown
in two different media. A batch of sodium salt-form LPS was also prepared. The
biological activity of these Bacteroides LPSs was compared to that of an E. coli
018K" LPS control.
In general, Bacteroides LPSs prepared by the PW method were found to have a
significantly higher activity in a mouse lethality model, LAL assay and TNF and IL-8
induction assays, than LPS extracted by the PCP or Triton methods. Bacteroides LPS
extracted by the PCP method had consistently low activity in all assays. LPS fr om B.
fragilis NCTC 9343 and B. caccae had a consistently higher activity than LPS fr om
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B. vulgatus and B. thetaiotaomicron in most assays. In the LAL assay and mouse
lethality model, native LPS was approximately two-fold more active than sodium salt-
form LPS. There was no clear difference in activity between native and sodium salt-
form LPS in the TNF induction assay. Differences in activity between B. fragilis
NCTC 9343 LPS grown in different media were seen. The PW method selected for
greater amounts of carbohydrate and KDO and the PCP the least. Further information
from sub-population studies, Percoll profiles, chemotype on PAGE and chemical
analysis failed to account for differences in biological activity between extraction
methods and Bacteroides species.
Comparing PW-LPS from Bacteroides with that from E. coli, in the mouse lethality
model, the E. coli LPS was approximately 5000-fold more active than the most
active Bacteroides LPS. However in the LAL assay, B. fragilis NCTC 9343 and B.
caccae LPS had higher activities (up to 30-fold) than E. coli LPS, with the other
Bacteroides species being up to 15-fold less active than the E. coli LPS.
Cytokine induction was examined from three different cell populations:- human
mononuclear leukocytes (MNL), THP-1 cells (with and without enhancement for
CD 14 by vitamin D3) and peritoneal macrophages from C3H/HeJ (LPS-non-
responder) and C3H/HeN (LPS-responder) mice.
The stimulation of TNF production by E. coli LPS was between 2 and 4-fold more
than Bacteroides LPS in MNL, in THP-1 cells (with enhancement for CD 14) and in
peritoneal macrophages from C3H/HeN mice. In THP-1 cells (without enhancement
for CD 14) there was no significant difference in TNF production between E. coli and
Bacteroides LPS. In peritoneal macrophages from C3H/HeJ mice E. coli LPS
stimulated no TNF production, but there was no significant difference in TNF
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production from peritoneal macrophages from C3H/HeJ and C3H/HeN mice by
Bacteroides LPS. In all cell populations, there was a peak of TNF production after
approximately 4 h stimulation with all LPSs tested. However, other peaks of TNF
production were seen in MNL and THP-1 cells (with enhancement for CD 14) after
stimulation with E. coli LPS only. An anti-CD 14 monoclonal antibody (mAb) did not
inhibit Bacteroides LPS stimulated TNF production. However, E. coli LPS
stimulated TNF release was inhibited by a CD 14 mAb, most noticeably hi MNL and
THP-1 cells (with enhancement for CD14).
In contrast, E. coli LPS induced a single peak of IL-8 at 6 h, whereas Bacteroides
LPS induced two peaks at 9 and 12 h from human MNL. EL-8 production by both E.
coli LPS and Bacteroides LPS could be slightly inhibited by a CD14 mAb in all cell
populations tested. EL-6 production by human MNL was comparable between E. coli
LPS and B. fragi/is NCTC 9343 LPS. Both LPSs induced a single peak of IL-6 at 6 h
and IL-6 production by both LPSs was not inhibited by a CD 14 mAb.
As it was presumed that Bacteroides LPS preparations in this thesis may not be pure
but heterogeneous with capsular polysaccharide (CP), the ability of CP from B.
fragilis NCTC 9343 to induced cytokine production was examined. Most cytokine
induction activity was seen in the low mwt CP (which contained more carbohydrate
and KDO) but on a scale much lower than LPS. In human MNL, CP produced a
single peak of TNF at 6 h. Low mwt CP induced one peak of IL-8 at 10 h whereas
high mwt CP induced increasing quantities of EL-8 over time with maximum levels
observed after 24 h stimulation. An excess of Bacteroides LPS (extracted by all three
methods) or CP masked the effect of E. coli LPS in producing the cytokines TNF,
EL-8 and IL-6. Several anti-Bacteroides mAbs inhibited TNF production by both E.
coli and B. fragilis NCTC 9343 LPS but did not inhibit IL-8 production.
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Studies into the mitogenicity of Bacteroides LPS and CP indicate that B. vulgatus
and high mwt CP were more mitogenic than B. fragilis NCTC 9343 LPS in mixed
spleen cells, B cells and T cells from LPS-responder mice. However, firm conclusions
cannot be drawn from the mitogenicity studies due to lack of flow cytometry evidence
that homogeneous cell populations were prepared.
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Lipopolysaccharide (LPS) is a major constituent of the outer membrane of Gram-
negative bacteria. It is imphcated as the key factor hi the development of the
Systemic Inflammatory Response Syndrome (SIRS). This is a common generalised
condition and the mortality rate still remains high after the onset of shock despite
recent advances in antimicrobial therapy and in our understanding of the
pathophysiology of SIRS. In approximately 50 per cent (Bone 1993, Gibb 1993) of
patients with SIRS the source of LPS is thought to originate from the gut.
Bacteroides species are the predominant Gram-negative organisms of the gut flora,
with B. fragilis the most common anaerobic organism isolated from clinical infections.
The Bacteroides species and their LPS are now reviewed with regards to their
possible role in SIRS.
1.2 THE GENUS BACTEROIDES
The genus Bacteroides recently underwent taxonomic change (Shah & Collins 1989)
and was restricted to those species in which the DNA base composition was within
the range G + C 30-40 % homology. The genus now contains the following eleven
species- B. fragilis, B. vulgatus, B. eggerthii, B. thetaiotaomicron, B. merdae, B.
caccae, B. variabilis, B. uniformis, B. ovatus, B. distasonis and B. stercoris, with
other organisms being reassigned to such genera as the Prevotella and
Porphyromonas. They are all non-motile, non-spore forming, Gram-negative rods or
cocco-bacilli, bile tolerant and strict anaerobes. They are also all saccharolytic,
produce major amounts of acetate and succinate as metabolic end products, they
possess enzymes of the hexose monophosphate shunt and the pentose phosphate
pathway (Duerden & Drasar 1991, Shah & Collins 1990).
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1.3 BACTEROIDES AS COMMENSALS
Bacteroides species are normal constituents of the faecal flora. Anaerobes make up
approximately 99-99.9% of the faecal bacterial mass, outnumbering the facultative
aerobes by a factor of 100-1000. Bacteroides species are the predominant organisms
in the human intestine accounting for 30% of the species isolated (Duerden & Drasar
1991), being present at a concentration of approximately 1011 organisms/g of faeces
(Hentges 1993, Finegold 1995).
The most common Bacteroides species isolated from faeces is B. vulgatus. Namavar
and colleagues (1989) estimated that in faeces B. vulgatus accounted for 44% of
isolates and B. fragilis at 4%, accounting for only a minor proportion of isolates.
However, in the colonic mucosa B. fragilis was found to be the most predominant
organism at 44%, compared to 35% of B. vulgatus.
The proportion of the organisms relative to other faecal organisms varies greatly with
diet. Bacteroides species are found in greater numbers in the western diet where bile
production is stimulated by food with a high fat content compared to countries where
a vegetarian diet is more common (Drasar 1974).
1.4 BACTEROIDES AS PATHOGENS
B. fragilis is the anaerobe most frequently isolated from clinical infections such as
bacteraemia, brain, liver and lung abscesses and most commonly from intra-abdominal
abscesses. One study reported that B. fragilis was present in approximately 90% of
cases of peritonitis (Tally & Ho 1987) and Escherichia coli (E. coli) in approximately
60% of cases. Although the incidence of B. fragilis in bacteraemia is higher than
other Bacteroides species, it has been reported that the relative mortality rates are
greater with B. distasonis, B. thetaiotaomicron and B. vulgatus (Brook 1989).
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1.5 GENERAL VIRULENCE FACTORS ASSOCIATED WITH
BACTEROIDES SPECIES
The majority of literature published on the pathogenicity of Bacteroides species has
concentrated on B. fragilis since it is the most frequently associated with clinical
infection.
Possible virulence determinants of B. fragilis include fimbriae, production of
enterotoxins and degradative enzymes, synergy with E. coli, capsular polysaccharides
and lipopolysaccharides, with the latter three thought to be the most important
(Patrick 1993).
1.5.1 Fimbriae
The presence of fimbriae expressed by B. fragilis was first reported in 1984 by
Pruzzo et al who described fimbriae of approximately 30 nm in diameter. They
showed that a fimbriated strain adhered better to human epithelial cells than did non-
fimbriated strains, suggesting a role for fimbriae in the colonisation of the intestinal
tract. Later in 1987, Van Doom and colleagues described fimbriae of 4-5 nm in
diameter. They showed that fimbrial expression was reduced at low iron
concentrations and at low temperatures. This observation helps explain why the
presence of fimbriae in Bacteroides species recovered from abscesses and normal flora
was greater than those recovered from the blood in a study by Brook et a! (1992).
Their findings suggest a role for these organisms to adhere to mucous membranes
better than their ability to spread systemically.
1.5.2 Enterotoxins
Enterotoxigenic strains of B. fragilis have been isolated in a study from 8 out of 44
patients with diarrhoea. As few as 5 x 103 cfU of enterotoxigenic B. fragilis caused
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fatal enteric disease in a rabbit model (Myers et al 1987). An enterotoxin from strains
of B.fragilis has been isolated (Van Tassell et al 1992) which has a strong secretory
response in the lamb ileal-loop assay as well as a cytotoxic response on HT-29 colon
carcinoma cells. Recently, this enterotoxin has been found to be a metalloprotease
(Moncrieffet al 1995).
1.5.3 Degradative Enzymes
B. fragilis can release extracellular enzymes that can degrade the components of the
hosts extracellular matrix such as hyaluronidase and chondroitin sulphatase. They can
also produce DNAse, lipases, proteases and neuraminadases which can break down
the host cells and tissues (Gibson & MacFarlane 1988, Hofstad 1984).
Neuraminadase production is high in clinical isolates of B. fragilis (Hofstad 1984).
This enzyme cleaves sialic acid from oligosaccharides on host cell glycoproteins and
glycolipids. Sialic acid is commonly found on cells of the immune system and
therefore released neuraminadases may disrupt the normal function of the immune
system (Imai et al 1991). Finally, a growing number ofBacteroides species have been
shown to produce penicillinases which may protect Bacteroides strains being
eradicated by (3-lactam antibiotics (Horn et a! 1992).
1.5.4 Synergism
B. fragilis species are most often isolated from intra-abdominal abscesses in
conjunction with other anaerobes and/or facultative bacteria. Numerous investigators
have reported a synergistic relationship between B. fragilis and E. coli (Tanaka et al
1994, Rotstein et al 1989, Onderdonk et al 1976, Brook 1994, Finlay-Jones et al
1991).
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It is thought that the aerobic bacteria such as E. coli provides nutrients, low pH and
oxidation-reduction potential which allows the B. fragilis to grow. Intra-abdominal
abscesses will not form unless both organisms are present (Onderdonk et al 1976).
The ability ofB. fragilis to inhibit phagocytic killing ofE. co/i by polymorphonuclear
neutrophils (PMN) has been well described and appears to be mediated by at least two
mechanisms (Rotstein et al 1985). Bacteroides species are able to deplete both heat
stable and heat labile opsonins resulting in impaired opsonisation of their aerobic
partner and thus inhibiting phagocytic killing of the aerobe. What component of
Bacteroides is causing this effect has not been clearly defined. Secondly, short chain
fatty acids (SCFA) (mainly succinic, acetic, lactic, formic and fumaric acids) produced
by B. fragilis during the stationary phase of growth have been shown to cause the
impairment of the microbicidal activity of PMNs. The observation that inhibition was
maximal at low extracellular pH led to the finding that the SCFA mediated this effect
by shuttling protons from the extracellular to the cytoplasmic space, thereby causing
intracellular acidification with resulting cell dysfunction (Rotstein 1993).
A further potential mechanism by which anaerobes may contribute to the
pathogenicity of mixed infections, is by virtue of their ability to induce local fibrin
deposition (Rotstein & Kao 1988, McRitchie et a! 1991). Fibrin depositions are
capable of capturing bacteria that are not cleared by the lymphatic system or killed by
macrophages and leukocytes.
The majority of research into the virulence factors ofBacteroides has concentrated on




The purified capsular polysaccharide (CP) of B. fragilis has been found to produce
abscesses even in the absence of viable organisms (Onderdonk et al 1977).
Immunisation with a crude polysaccharide has been found to protect against abscess
formation (Onderdonk et al 1982).
Due to work by Patrick and colleagues we now recognise the fact that a culture of B.
fragilis has been shown to be morphologically heterogeneous with respect to size and
antigenicity of its capsule.
The substitution of Proteose Peptone Yeast extract (PPY) medium for the minimal
medium of Van Tassell & Wilkins' (VT) (1978) resulted in greatly enlarged capsules
as observed by light microscopy. Accurate quantification of bacteria bearing large
capsules was made possible by Percoll density gradient centrifugation (Patrick & Reid
1983).
Light microscopy revealed that on the Percoll gradient, the 0-20% interface enriched
for large capsule, the 20-40% for small capsule, 40-60% for a mixture of small
capsule and non-capsulate bacteria and the 60-80% interface for non-capsulate
bacteria only. Electron microscopy further revealed that the non-capsulate bacteria
had an electron dense layer (EDL) outwith the outer membrane. Subsequent studies
with monoclonal antibodies (Lutton et al 1991, Reid et al 1987) revealed that the
small capsule was not simply a smaller amount of the large capsule but carried
antigenically distinct epitopes.
Recently Tzianabos et al (1992) showed that the CP of B. fragilis comprises two
ionically linked polysaccharides termed polysaccharide A and polysaccharide B which
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are present in the ratio 1:3.3. More recently they found that the ability of
polysaccharide A and B to induce abscess formation was diminished by alteration of
the positive and negative charge (Tzianabos et al 1994).
The role of the capsule may be to impair phagocytic uptake and killing by human
PMNs probably by mopping up host opsonins. It is known that large capsulate
bacteria impairs phagocytic killing but the EDL population is readily phagocytosed in
vitro although it is resistant to killing by normal human serum (Patrick & Lutton
1990, Patrick 1993). It is also known that B. fragilis secretes large amounts of
extracellular polysaccharide (EPS) or extracellular vesicles (ECV). ECV can cause
haemagglutination and both EPS and ECV can cause the depletion of opsonins and
perhaps the activation of complement at a distance from the bacteria (Patrick 1993).
The capsule is not thought to enhance resistance to complement (Reid & Patrick
1984). Previous studies have shown that Bacteroides strains isolated from infections
are more resistant to complement than those isolated from faeces (Casciato et a/
1979). Clinical isolates of B. fragilis are more resistant to complement than clinical
isolates of other Bacteroides species (Rotimi & Eke 1984). Recent studies in our
laboratory found that Bacteroides species became more resistant to complement after
growth in VT medium and heat inactivated sheep serum (HISS) as compared to
growth in PPY (Allan & Poxton 1994). These differences were not found to correlate
with any significant changes in the CP or lipopolysaccharides.
The CP may also evoke production of proinflammatory cytokines (Cross 1994) and
directly influence phagocyte movement.
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1.5.6 Lipopolysaccharides
Lipopolysaccharides (LPS) or endotoxin is a complex amphipathic macromolecule
firmly bound to the outer membrane of Gram-negative bacteria (Fig 1), which is a
lipid bilayer containing proteins and phospholipids with large amounts of LPS being
found on the outer leaflet. LPS has an important functional role in Gram-negative
bacteria. It provides the cell with selective permeability, protects against phagocytosis
and is a major bacterial surface antigen (Rycroft 1984, Galanos & Luderitz 1984). It
is when LPS is introduced into the bloodstream and interacts with cells of the immune
system that it can exert its most powerful biological effects (Table 1) which can lead
to irreversible vascular damage, shock and death. The interaction of LPS and the host
is discussed in greater detail in section 1.9. What follows is an oveiview of the
structure of LPS and the characteristics of Bacteroides LPS.
1.6 GENERAL STRUCTURE OF LPS
LPS comprises three major regions, the O-specific polysaccharide, the core
polysaccharide and lipid A (Fig 2). Each of these components is under separate
genetic control and structures vary with respect to their biological activity (Luderitz et
al 1982).
1.6.1 Lipid A
Lipid A is the most conserved region of LPS. It consists of a phosphorylated
glucosamine-disaccharide backbone to which long chain fatty acids are bound
(Galanos & Luderitz 1984, Doran 1992). The lipid A is embedded in the outer
membrane of the Gram-negative cell envelope and is well recognised as being the
most toxic component of the LPS molecule. Small changes in the structure of lipid A
can lead to a marked reduction in toxicity (Proctor et al 1986, Raetz 1993, Astiz et al
1994).
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Fig 1: The Gram-negative cell envelope ( Taken from Hancock & Poxton 1988)
LP: lipoprotein, LPS: lipopolysaccharide, P: protein, PL: phospholipid.




The core region is divided into inner and outer sub-dornains. The outer core is
comprised primarily of D-glucose, D-galactose and N-acetyl-D-glucosamine. The imier
core contains 3-deoxy-D-manno-octulosonic acid (KDO), heptose as well as
phosphate and phosphate bound ethanolamine (Galanos & Ludertiz 1984, Jansonn et
al 1981). The KDO residue is bound to lipid A by an acid labile ketosidic linkage.
1.6.3 O-Polysaccharides
The O-polysaccharide or " O-antigen" is a highly variable part of the LPS molecule
which may or may not be present. It consists of repeating units of oligosaccharide,
each comprised of 2-6 monosaccharides. The type and number of repeating units of
the O side chain determines the serologic (antigenic) specificity of the O-antigen. The
number of repeating units is not fixed, but can show considerable variation under
different physiological conditions (McGroarty & Rivera 1990). LPS is often referred
to as being "smooth" if the O-antigen is present and "rough" if the O-antigen is absent.
Mutant bacteria which lack the O-antigen and produce partial core structures have
been discovered (Ra-Re mutants) and have been of great value in biological
investigations. It appears that the minimum structural requirements for LPS to
mediate endotoxic activity is lipid A linked to KDO.
1.6.4 Bacterial Release of LPS
LPS may be released by viable bacteria during the log phase of growth or in
conditions of sub-optimal growth (Tesh & Morrison 1988). LPS is also released after
bacterial death as a result of antibiotic therapy or after lysis by the complement
cascade. It might be expected that antibiotic treatment may lead to increased levels of
LPS during bacteraemia and therefore worsen the clinical situation. However, several
studies indicate that this may not be the case in vivo, as LPS levels have been found
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to decline in the blood following antibiotic therapy (Brandtzaeg et al 1989) and any
transient increase in LPS levels found have not been associated with poor clinical
outcome (Danner et al 1991, Shenep et al 1988).
1.6.5 Physical State of LPS
LPS is an amphipathic molecule due to its hydrophilic polysaccharide and
hydrophobic lipid A. Purified LPS has poor solubility in aqueous solutions because of
self aggregation and exists in a highly aggregated form (Galanos & Luderitz 1984).
The physical state of LPS is dependent on the presence of inorganic cations and low
molecular weight basic amines which neutralise negatively charged groups on the
LPS. Electrodialysis of LPS improves its solubility by reducing the amount of
positively charged groups. Subsequent conversion of the native acidic LPS to a salt
results in a preparation with a lower degree of aggregation (Galanos & Luderitz
1975).
Circulating endotoxin probably never occurs as free LPS, but remains strongly
associated with outer membrane proteins. With exposure to serum, the LPS becomes
disaggregated and interacts with high density lipoproteins (HDL) (Doran 1992,
Ulevitch et al 1981). LPS bound to HDL has been demonstrated to be less endotoxic
(Cavaillon et al 1990). The presentation of LPS in inflammatory serum may be altered
due to an increase of circulating lipopolysaccharide binding protein (LBP) which
forms high affinity complexes with LPS and presents it to monocytes and
macrophages. The interaction between LBP/LPS and monocytes/macrophages is
discussed in greater detail in sections 1.9.3 and 1.9.4.
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1.7 THE CHARACTERISTICS OF BACTEROIDES LPS
Studies 011 the LPS from Bacteroides species have concentrated on B. fragilis since it
is the most frequently isolated anaerobe in clinical infections. Early studies yielded
many confusing and contradictory results which was due in part to the ill-defined LPS
preparations used. Studies on the biological activity of Bacteroides LPS (Lindberg et
al 1990, Kasper 1976, Jotwaui et al 1994) have reached the generally accepted
conclusion that it is less endotoxic (100 to 1000-fold less depending on the assay)
than enterobacterial LPS.
1.7.1 Nature of the Polysaccharides
For many years it was thought that the LPS from B. fragilis was of the rough type
with no O-antigen present (Kasper et al 1983). However, the presence of repeating
oligosaccharide units was reported over the years by other investigators (Cousland &
Poxton 1983, Poxton & Brown 1986, Lutton et al 1991).
In the paper by Poxton & Brown (1986), the authors concluded that the majority of
LPS from B. fragilis was of the smooth type with chain lengths of varying molecular
mass. The rough form of LPS was common to all strains examined and also contained
a low molecular weight common polysaccharide which migrated behind the rough
front on polyacrylamide gel analysis which they termed the "common antigen".
Other workers have not been able to detect smooth type LPS (e.g. Weintraub et a!
1985), and this is due in part to the extraction method employed and to the emergence
of the fact that sub-populations which are antigemcally distinct exist within a culture
of B. fragilis.
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Lutton et al (1991) showed that ladders of repeating polysaccharide subunits were
evident mainly in the EDL population. The authors suggest that a variety of
populations exist ranging from those where most of the polysaccharide has been
released as cell free material, to those in which it remains associated with the bacterial
cell.
Sugar analysis of the LPS of B. fragilis shows that it contains glucose, galactose,
fucose, rhamnose, xylose, glucosamine, galactosamine, ribose, arabinose and mannose
(Lindberg et al 1990).
There have also been conflicting reports on the presence/absence of L-glycero-D-
manno-heptose and KDO which are both present in enterobacterial LPS. Studies by
Weintraub et al in 1985 failed to detect heptose residues in 17 B. fragilis strains
tested. KDO is present but in a phosphorylated form, rendering it undetectable in the
standard thiobarbituric acid assay (Beckmann et al 1989, Kumada et a! 1993).
1.7.2 Nature of the Lipid A
Variation in the fatty acid content of lipid A between strains of B. fragilis was
examined by Lindberg et al (1990). Only trace amounts of 3-hydroxytetradecanoic
acid, the predominating fatty acid in enterobacterial LPS was found. Other major
differences between the lipid A of B. fragilis and that of E. coli were:
(a) B. fragilis has an average of 5 fatty acids per lipid A whereas E. coli has 6.
(b) B. fragilis has long chain fatty acids C15-C17 whereas E. coli has C12 -C16.
(c) B. fragilis has branching hydroxylated fatty acids and non-hydroxylated fatty
acids which are lacking in E. coli.
(d) The bis-glucosamine backbone ofB. fragilis has only one phosphate group, at the
reducing end, compared to two in E. coli.
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It is not known whether the above features are unique to B. fragilis LPS or are also
present in other Bacteroides species.
1.8 THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
1.8.1 Clinical Features
LPS has been implicated as the principal trigger of the Systemic Inflammatory
Response Syndrome (SIRS). This is a characteristic clinical response manifested by
two or more of the following symptoms (Darville et al 1993, Bone 1993):
temperature > 38°C, hypotension, increase in heart rate, increase in respiratory rate,
white blood count > 12,000 cells/mm3 or < 4,000 cells/mm3.
The term SIRS was proposed by Members of the American College of Chest
Physicians in 1992 in an attempt to standardise the definition and terms used to
describe this condition. When SIRS is the result of a confirmed infection, it is termed
sepsis. Shock associated with SIRS is accompanied with hypotension, declining
cardiac output, disseminated intravascular coagulation (DIC) and multi-organ failure
(MOF) which can lead onto death.
1.8.2 Incidence of SIRS
Sepsis is a leading cause of death and accounts for estimates of 300,000 cases in the
US alone. Mortality from sepsis ranges from 20-50% but in those patients who
develop the complications of shock and MOF the mortality rate can reach 90% (Bone
1991).
The increased use of invasive procedures and immunosuppressive treatments are
among factors contributing to a growing number of chronically ill and
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immunocompromised patients who are at an increased risk from sepsis. Despite the
use ofmore potent and effective antibiotics and technological advances, the mortality
rate from septic shock has not changed significantly over the past decade (Bone
1993).
1.8.3 The Source of LPS in Triggering SIRS
Bacteraemia
hi a significant proportion ofpatients with SIRS the source of LPS is thought to arise
fr om an underlying bacteraemia caused by Gram-negative bacteria. E. coli is the most
common organism isolated with Klebsiella, Enterobacter and Pseudomonas species
being encountered less frequently. The incidence of bacteraemia is reported to be as
low as 12% (Wilhats et al 1994) to 50% (Bone 1993, Gibb 1993) of cases of SIRS. In
a local study by the Sepsis Intervention Group, Edinburgh this figure is around 25%
(IR Poxton, Personal Communication). Not all bacteraemias are due to Gram-
negative bacteria. In one study of patients with septic shock, 39% had bacteraemias
with only 19% caused by Gram-negative organisms (Damier et al 1991).
The Gut
In those patients who have SIRS without any bacteraemia, the source of the LPS is
thought to arise from the gut. The commensal flora of the gut can be thought as a
large pool of endotoxin which may pose a threat to the host. Endotoxin does not
appear to absorbed in health (Van Deventer et al 1988). However, due to a large fluid
loss (e.g. burns, trauma, surgery) there could be a lack of oxygenated blood flow to
the gut allowing the mucosal barrier to breakdown. Endotoxin and bacteria could then
translocate into the bloodstream via the portal vein and the mesenteric lymph nodes
(Runcie & Ramsay 1990).
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The translocation of bacteria from the gut to the mesenteric lymph nodes of mono-
associated ex-gemi free mice was studied by Berg (1995). Studies found that Ps.
aeruginosa, Klebsiella species and E. coli were most effective at translocating, with
B. fragilis and B. vulgatus the least effective. There appeared to be a relationship
between translocation and sensitivity to killing by 02. Other viable translocated
anaerobic bacteria have not been detected in experimental models to date by other
workers. It may not be possible to culture viable anaerobes in such experiments due to
killing by 02, but as other bacteria and latex beads can be seen to translocate it can be
assumed the Bacteroides or their cellular components could also translocate (Mora et
al 1991, Mainous et al 1991, Wells et al 1988). At present no antibody probes have
been developed to detect translocated anaerobes or tbefr cellular components.
1.8.4 Which LPSs Are Involved In SIRS?
Despite the fact that LPS is thought to play the central role in the development of
SIRS, few studies if any have tried to examine what type of LPS is circulating during
SIRS. This is due to the major practical difficulties in actually performing such an
assay (Cohen 1989).
If a patient with SIRS has a Gram-negative bacteraemia then LPS from cultured
organisms must be considered. But given that the majority of patients with SIRS have
no detectable bacteraemia (Bone 1993, Gibb 1993) then LPS derived fr om organisms
in the gut must be considered.
Bacteroides species out number the enterobacteria such as E. coli in the gut by
approximately 1000-fold (Duerden & Drasar 1991). Although Bacteroides LPS is less
endotoxic (100 to 1000-fold less depending on the assay) (Lindberg et al 1990,
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Jotwani et al 1994), by simple arithmetic there must be at least as much biological
potential from the LPS of Bacteroides as from E. coli.
1.9 THE PATHOPHYSIOLOGY OF SIRS: HOW LPS INTERACTS WITH
THE HOST
1.9.1 General Overview
It is generally agreed that most of the adverse effects of LPS result from its ability to
cause the release of various endogenous mediators which act on a number of
important biochemical pathways. LPS is a potent activator of B cells and other cells
responsive to LPS, including monocytes/macrophages, PMNs, endothelial cells and
epithelial cells (Table 1). An overview of the biological responses to LPS in the
pathogenesis of SIRS is illustrated in Fig 3. The interaction of LPS with complement
and with monocytes/macrophages to produce the cytokine cascade is discussed in
more detail below.
1.9.2 Interaction With Complement
LPS can activate both the classical and alternative pathways of complement in the
absence of specific antibody. LPS activates the classical pathway by its lipid A region
(Vukajlovich 1986) and the alternative pathway by its polysaccharide region
(Grossman & Leive 1984). An overview of the complement cascade is illustrated in
Fig 4. Activation of the complement cascade results in the lysis of pathogens, the
opsonisation of pathogens and the recruitment of phagocytic cells to the site of
complement activation (Janeway & Travers 1994).
19
Fig 3: Biological responses to LPS in the pathogenesis of SIRS (Adapted from
Bone 1993, Runcie & Ramsay 1991, Rietschel & Brade 1992).
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Fig 4: The complement pathway (Adapted from Janeway & Travers 1994).
CLASSICAL PATHWAY ALTERNATIVE PATHWAY








1.9.3 Interaction With Serum Proteins
It was recognised around two decades ago that serum proteins (such as antibodies,
HDL, LBP and sCD14) bind to LPS influencing the subsequent activation of cells
responsive to LPS (Ulevitch et al 1981, Cavaillon & Haeflher-Cavaillon 1985).
Antibodies
Antibodies to the O Ag, core and hpid A region of Bacteroides and E. coli LPS are
found naturally in the circulation of healthy subjects. Barclay and colleagues have
carried out extensive studies investigating the magnitude and kinetics of serum
antibody response to LPS core from enterobacteria and closely related species in
sepsis patients (Barclay 1990, Windsor et al 1993, Barclay et al 1989). It was found
that non-survivors were more likely to have low endogenous levels of IgG which
failed to recover. In both survivors and non-survivors, a sudden consumption of
antibody appeared to be indicative of a recent episode of endotoxaemia. In a recent
study hi our laboratory anti-Bacteroides LPS IgG levels were measured in healthy
adults and sepsis patients (Allan et al 1995). All subjects demonstrated to antibodies
to Bacteroides LPS and trends in antibody kinetics indicate that Bacteroides LPS may
be significant hi sepsis.
LBP/BPI
Lipopolysaccharide-binding protein (LBP) was discovered during studies into the
regulation of LPS binding to HDL (Tobias et al 1986). LBP is a 60 kD protein
synthesised in hepatocytes as an acute phase reactant. It binds with high affinity to the
lipid A region of the LPS (Tobias et al 1989). The concentration of LBP is estimated
to be 5-10 pg/ml in resting serum and up to 200 pg/ml in acute phase serum fr om
humans (Theofan et al 1994).
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The ability of LPS to bind to LBP enables it to act as an opsonin (Wright et al 1989,
Wright 1991). LBP binds to free LPS, Gram-negative bacteria or LPS coated
erythrocytes for example and strongly enhances their attachment to macrophages.
Human LBP has been cloned and sequenced and is found to be approximately 44%
homologous to human bactericidal/permeability increasing protein (BPI) (Schumann
et al 1990, Schumann et al 1994). BPI is produced in the primary granules of PMNs
and like LBP, BPI binds to isolated LPS or to Gram-negative bacteria via lipid A.
Some differences between BPI and LBP are summarised in Table 2 (Elsbach & Weiss
1993, Marra et al 1992). The main differences are BPI neutralises the ability of
isolated LPS to stimulate cells, whereas LBP enhances the effects of LPS on cells.
BPI is directly bactericidal whereas LBP functions as an opsonin when it binds to
intact bacteria.
Septins
A further group of plasma proteins termed septins that bind to LPS were reported by
Wright et al (1992). It was proposed that deposition of "septin-1" and "septin-2" on
the surface of LPS coated particles activates a latent protease activity required for
opsonisation. Because this plasma function could be inhibited by serine protease
inhibitors, septins may play a role in presenting free LPS to macrophages.
High Density Lipoprotein
As noted earlier in section 1.6.5 HDL also binds LPS. In a recent study (Wurtel et al
1994) it was shown that HDL-like particles reconstituted from purified material
cannot neutralise LPS themselves, but the LPS-neutralising capacity of these particles
can be realised by the addition of purified LBP. These results suggest that LBP
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Table 2: Comparison of the properties of LBP/BPI (Taken from Elsbach & Weiss
1993).
PROPERTY LBP BPI
Binding to lipid A/LPS yes yes
Binding to Gram-negative bacteria yes yes
Synthesis hepatocyte PMN precursor
Localisation plasma PMN granules
Opsonisation for LPS particles yes no
Bactericidal no yes
Enhances LPS effects yes no
Inhibits LPS effects no yes
Molecular weight 60 kD 50 kD
Amino acid sequence homology > 40%
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functions catalytically as a transfer protein that facilitates binding of LPS not only to
CD14 (discussed below in section 1.9.4) but also to hpoproteins.
Soluble CD14
LPS can also bmd to sCD14 which is discussed in greater detail in section 1.9.4.
When we consider that LPS exists in tight association with bacterial outer membrane
proteins and these proteins themselves may be macrophage stimuli, it remains to be
determined what role these proteins may have in modulating LPS interactions with
serum proteins.
1.9.4 Interaction With CD14 as a Receptor For LPS/LBP Complexes
CD 14 is a 55 kD glycosylphosphatidyl inositol (GPI) anchored membrane
glycoprotein expressed on monocytes, macrophages and to a lesser extent on PMNs.
It is also present as a soluble serum glycoprotein lacking the GPI anchor (Bazil et al
1986, Haziot et al 1988).
It was determined by Wright et al in 1990 that CD 14 acts as a receptor for LPS/LBP
complexes. CD 14 will bind LPS in the absence of LBP but at a much lower rate. The
bhiding of LPS to LBP is thought to occur when LPS concentrations are low (< 1
ng/ml). The interaction between LPS and LBP is not thought to be so crucial when
LPS concentrations are high as LPS will be able to interact more easily with CD14
(Hailrnan et al 1994). As mentioned earlier LBP acts catalytically to facilitate binding
of LPS to CD 14. Recently it has been discovered that the region of CD 14 spanning
amino acids 57-64 is responsible for binding LPS (McGinley et al 1995, Juan et al
1995).
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CD 14 has been shown to play an important role in mediating LPS-induced effects in
human monocytes/macrophages, since an anti-CD 14 monoclonal antibody (mAb)
blocks LPS induced production of TNF-a, IL-6 and IL-8 and oxygen radicals (Chaby
& Girard 1993, Ulevitch & Tobias 1994, Manthey & Vogel 1994, Courtier et al
1992, Landmann et al 1995a). The importance ofCD14 in controlling LPS responses
was emphasised by Lee et al (1992) who transfected the murine 70Z/3 pre- B cell line
with human CD 14 cDNA and observed that the amount of LPS required to activate
the cells was lowered by up to 10,000-fold.
CD 14 may not be the true signalling receptor for LPS as it lacks transmembrane and
cytoplasmic regions. Evidence shows that binding of LPS to CD 14 is followed by
subsequent interaction of additional membrane components that enable
transmembrane signalling (Lee et al 1993). Whether or not CD 14 is internalised
together with LPS/LBP remains to be clarified. Studies by Kitchens et al (1992) show
that uptake of LPS that is dependent on membrane CD 14, is independent of the
function of this molecule in mediating cell activation. LPS can interact with membrane
bound CD 14 on monocytes which through the secretion of soluble mediators can
activate endothelial and epithelial cells (Pugin et al 1993a). The soluble mediators are
not yet known and evidence suggests that such an indirect method is more efficient.
Further evidence that CD 14 may transmit its signal to an unidentified signalling
receptor is due to the fact that cell types that do not express membrane CD 14 are still
responsive to LPS. Endothelial and epithelial cells appear to be directly sthnulated by
LPS/LBP complexes binding to soluble CD 14 (sCD14) (Pugin et a! 1993b, Frey et a!
1992). sCD14 is thought to originate from enzymatic cleavage of membrane bound
CD 14 via the action of specific proteases (Bazil et al 1989). Concentration of sCD14
in normal human plasma have been estimated at 6 pg/ml and LPS and TNF have been
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shown to produce dose-dependent increases in sCD14 (Schutt et al 1992) An
increased amount of circulating sCD 14 has been associated with a high mortality in
Gram-negative septic shock (Landmann et al 1995b).
PMNs possess less CD 14 which can be upregulated by IFN-y, formyl peptides and
LPS (Haziot et al 1993, Weingarten et al 1993). They express and shed CD14, and
respond to LPS/LBP complexes via CD14 just like monocytes and macrophages.
1.9.5 Other LPS Receptors
In addition to CD 14, other LPS receptors include a 73 kD LPS binding protein,
scavenger receptors and the leukocyte antigen CD 18.
A 73 kD protein described by Lei & Morrison (1988) present on the surface of
murine and human lymphoid and myeloid cells was discovered using a radio-iodinated
photoactivatable LPS probe. Further studies using a hamster rnAb to this 73 kD
protein activates macrophages in a manner that mimics certain actions of LPS,
suggesting that this protein may be a functional LPS receptor (Chen et al 1990).
Tire scavenger receptor that binds LPS is found in large amounts hi the liver (Kupffer
cells and shiusoidal endothelial cells) and is thought to remove endotoxin entering the
circulation through pinocytosis and digestion (Wright 1991). It is a trimeric
transmembrane glycoprotein composed of cysteine rich carboxy terminal exoplasmic
domains connected to a transmembrane domain by a collagen like stalk (Kodanra et at
1990).
Another well characterised LPS receptor is the CD 18 antigen. E. coli is bound weakly
by macrophages between LPS and adhesion-promoting receptors that share CD 18 as
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a common (3-subunit (Wright & Jong 1986). This then promotes clearance of LPS by
phagocytosis and digestion. The portion of LPS recognised by CD18 resides in the
lipid A region and in vitro studies have shown that anti-CD 18 mAb causes heightened
TNF secretion in response to low doses ofLPS (Wright et al 1990).
1.9.6 Production of Cytokines by LPS Stimulated Macrophages and Monocytes
Based on an increasing body of evidence, it is now agreed that many of the effects of
LPS are due to the actions of cytokines. Cytokines are proteins or glycoproteins of
less than 80 kD that influence the behaviour of the cell producing the cytokine or cell
types of a different lineage. They are involved in the development and maintenance of
immunity and inflammatory processes. They regulate the amplitude and duration of
the response, have many overlapping qualities and function mainly as short range
molecules.
Those molecules classed as cytokines, their main source and actions are illustrated in
Table 3. Several of the LPS induced cytokines which are thought to play an
important role in SIRS and that have been examined experimentally in tliis thesis are
now discussed in more detail.
Tumour Necrosis Factor
Tumour necrosis factor (TNF-a) was initially recognised as its name suggests because
of its cytotoxic and anti-tumour effects (Carswell et al 1975). It was later found to be
identical to a factor called cachectin (Tracey et aI 1986). TNF-a is produced primarily
by monocytes and macrophages but can also be produced by natural killer (NK) cells,
PMNs, T lymphocytes, smooth muscle cells and tumour cells. TNF-a is genetically
and structurally closely related to TNF-(3 (lymphotoxin) which is produced by TH,
lymphocytes. They are both trimers of around 17 kD and TNF-(3 shares 30%
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Table 3: Cytokines - Their main source and actions (Adapted from Janeway &
Travers 1994)
Cytokine Main Producers Main Actions
IL-I macrophages, epithelial cells fever, T cell activation, macrophage
activation
IL-2 T cells T cell proliferation
IL-3 T cells, thymic epithelial cells synergistic action in haematopoiesis
EL-4 T cells, mast cells B cell activation, IgG switch
IL-5 T cells, mast cells eosinophil growth, differentiation
IL-6 T cells, macrophages, neutrophils acute phase reaction,
T/B cell growth and differentiation
EL-7 bone marrow stroma growth ofpre-B and pre-T cells
IL-8 macrophages, monocytes, others chemotaxis for PMN and T cells
EL-9 T cells mast cell enhancing activity
IL-10 T cells, macrophages potent suppresser ofmacrophage
function
IL-11 stromal fibroblasts synergistic action with IL-3/IL-4 in
haematopoiesis
IL-12 B cells, macrophages activates natural killer cells, induces
CD4 T cell differentiation to Til,
like cells




TNF-(3 T cells, B cells kills T cells and fibroblasts,
endothelial activation
GMCSF macrophages, T cells stimulates growth of differentiation
ofmyelomonocytic lineage
MCP-1 macrophages, others chemotactic for monocytes
IFN-y T cells, NK cells macrophage activation,
increased MHC expression
IFN-a leukocytes, macrophages anti-viral,
increased MHC class I expression
IFN-(3 fibroblasts, macrophages anti-viral,
increased MHC class I expression
Where IL = interleukin, TNF = tumour necrosis factor, GMSCF = granulocyte
macrophage colony stimulating factor, MCP-1 = monocyte chemotactic peptide-1
and IFN = interferons.
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homology to TNF-a and binds to the same receptors (Darville et al 1993, Bendtzen
1988, Rees 1991).
TNF-a plays an important role in the events of SIRS as many of the sequelae of LPS
challenge can be reproduced by infusing purified TNF-a into animals and death occurs
after administration ofhigh doses of TNF (Tracey et al 1986). Passive immunisation
of mice with anti-TNF-a antibodies can protect against subsequent challenge with
LPS (Beutler et al 1985). Increased levels of TNF-a have been found in patients with
SIRS and intra-abdominal sepsis (Hamilton et al 1992, Michie et al 1988, MacDonald
et al 1990, Endo et al 1992).
TNF-a is produced early in the cytokine cascade after stimulation by LPS. To date it
appears to be the first cytokine produced in the serum and its production by
macrophages does not require the presence of other cytokines (Manthey & Vogel
1992). TNF-a possesses multi-functional activity summarised in Table 4.
The major local effect of TNF-a is to initiate an inflammatory response. It causes
vasodilation leading to increased blood flow, an increase in vascular permeability
leading to the local accumulation of fluid, as well as the accumulation of
immunoglobulin and complement. TNF-a also induces the expression of adhesion
molecules that bind to circulating monocytes and PMNs such as P-selectin which
appears a few minutes after TNF-a, E-selectin which appears later after a few hours
and ICAM-1. These molecules greatly enhance the rate at which these phagocytic
cells migrate into the tissues (Janeway & Travers 1994).
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Table 4: Multi-functional activity of TNF-a (Adapted ffomBendtzen 1988)
Activation in vitro of
















Although TNF-a is important in controlling a local infection, once an infection
spreads systemically the results can be devastating. The systemic release of TNF-a
causes vasodilation and loss of plasma volume due to increased vascular permeability.
This can lead to shock, DIC, MOF and consequently death as previously discussed in
section 1.8.
TNF mediates its cellular effects by cross linking to cell surface receptors that bind
both TNF-a and TNF-(3. Two TNF receptors have been identified as being the 55 kD
receptor (TNF r55) and the 75 kD receptor (TNF r75) (Tartaglia & Goeddel 1992).
In vitro experiments have shown that these receptors can be rapidly shed from PMNs
(Ding & Porteau 1992) and slowly from monocytes (Leeuwenberg et al 1994).
Higher levels of soluble TNF receptors (sTNFr) are found in patients with sepsis
(Shapiro et al 1993). The role of sTNFr is still speculative but it may play a role in
scavenging circulating TNF resulting in a decrease of the inflammatory reaction.
Human TNF r55 and TNF r75 share 28% homology and it has been shown that the
TNF r55 binds TNF-a and (3 with a four-fold lower affinity than the TNF r75 receptor
(Tartalgia et al 1991). Epithelial cells primarily express the TNF r55 receptor
whereas myeloid cells express both the TNF r55 and TNF r75 receptors (Brockhaus
et al 1990). Recent reports have shown that the signal through the TNF r55 is
necessary for most biological functions of TNF (Tartaglia et al 1991, Thoma et a!
1990, Pfeffer et al 1993). The role of the TNF r75 in TNF signalling is not well
understood but it has been proposed by Tartaglia et al (1991) that the TNF r75 acts
to capture TNF at the cell surface and thereby increases binding to the lower TNF r55
receptor. It is not known whether the different TNF receptors transduce the same
signal or different signals. It is also not known whether the multiple functions of TNF
are mediated through one or both receptors.
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biterleukin-6
Interleukin-6 (IL-6) exists in nature as a monomelic 26 kD protein. Chi the basis to its
various activities it was previously known as P2-interferon, B-cell stimulatory factor 2,
hybridoma/plasmacytoma growth factor and monocyte granulocyte inducer type 2
(Hirano et al 1990, Tafuto et al 1994). IL-6 is produced by monocytes,
macrophages, B/T lymphocytes, endothelial cells, keratinocytes, fibroblasts, bone
marrow stroma cells and various tumour cells (Bendtzen 1988, Tafuto et al 1994).
EL-6 has multi-functional activity summarised hi Table 5 but unlike TNF-a,
exogenous IL-6 administration does not cause haemodynamic compromise, regardless
of the amount given to experimental animals (Preiser et al 1991).
One of the most important activities of IL-6 is the initiation of the acute phase
response. It involves a shift in the proteins secreted by the liver into the blood and
results from the actions of EL-6 on hepatocytes. IL-6 induces the production of acute
phase proteins including serum amyloid protein, C-reactive protein (CRP), fibrinogen
and mannose-binding protein (MBP). CRP binds phosphorylcholine and MBP binds
mannose residues on bacterial surfaces. Both act as opsonins and activate
complement to lyse bacteria (Janeway & Travers 1994, Darville et al 1993, Tafuto et
al 1994).
Increased levels of IL-6 have been found in sepsis (Hack et al 1989) and studies have
shown that anti-IL-6 monoclonal antibodies protects from lethal E. coli infection as
well as from lethal amounts of TNF (Stames et al 1990). IL-6 acts on its target cells
via a specific dimeric 80 kD IL-6 receptor. Binding is followed by association of
the 80 kD protein with a 130 kD transmembrane protein providing signal transduction
(Boer & Herrmann 1991).
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Table 6: Multi-functional activity of IL-6 (Adapted from Bendtzen 1988)
Activation in vitro of












Abnormal production of EL-6 has also been suggested to be involved in the
pathogenesis of glomerulonephritis, multiple myeloma, Hodgkin's lymphoma and
Rheumatoid arthritis (Tafirto et al 1994, Bendtzen 1988).
Interleukin-1
Interleukin-1 (IL-1) is produced by monocytes, macrophages, NK cells, PMNs, B
cells, dendritic cells and endothelial cells. IL-1 consists of IL-1 a and IL-1 P which
are structurally related polypeptides that show 25% amino acid homology. Both are
produced as 31 kD precursors that are subsequently cleaved into 17 kD molecules.
IL-1 a remains in the cytosol of cells or is associated with the cell membrane whereas
IL-1 P is secreted (Bendtzen 1988). IL-1 has never been shown to be directly lethal
to animals as has TNF-a (Tracey et al 1987) but produces the same effects as TNF-a
and IL-6 (Tables 4, 5) to the same or lesser extent in vivo and in vitro.
Interleukin-8
Interleukin-8 (IL-8) exists as a dimeric 83 kD protein which is produced by
monocytes, macrophages, hepatocytes, PMNs, dermal fibroblasts and endothelial cells
in response to LPS, IL-lp and TNF-a (Janeway & Travers 1994, Liebler et al 1994,
Nielson et al 1994). IL-8 can also be produced by epithelial cells in direct response to
bacterial entry (Eckmann et al 1993). This may serve as an early signalling system to
host immune and inflammatory cells in the underlying mucosa following bacterial
entry.
Primarily, IL-8 is a chemoattractant for PMNs, inducing them to leave the
bloodstream and migrate into the surrounding tissues. Further biological functions of
IL-8 in vivo include induction of lymphocyte infiltration, increase of vascular
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permeability in the presence of prostaglandin E and destruction of the synovial
membrane (Neilson et a1 1994).
IL-8 belongs to a common supergene C-X-C family, in which the first two cysteines
are separated by a single amino acid residue. IL-8 shares 21% homology at the amino
acid level with monocyte chemotactic peptide-1 (MCP-1) which is a potent
chemoattractant for monocytes. MCP-1 belongs to the supergene C-C family in which
the first two amino acids are in juxtaposition (Baggioloni et al 1994).
It has been found that levels of circulating IL-8 are elevated in patients with sepsis and
this level is further elevated in those patients with shock (Hack et al 1992, Solomkin
et al 1994).
1.9.7 Production of Cytokines by LPS Stimulated Polymorphonuclear
Neutrophils
Polymorphonuclear neutrophils (PMN) are the most common leukocytes in human
blood and are the first cells to migrate into tissues in response to invading pathogens.
Since PMNs are short lived cells, terminally differentiated and incapable of
proliferation, their ability to synthesise cytokines might be viewed of little
significance (Janeway & Travers 1994, Cassatella 1995). However, in the last few
years several groups have shown that PMNs can release cytokines including TNF-a,
IL-1 (3, EL-1 receptor antagonist and IL-8 but on a scale much lower than
monocytes and macrophages (reviewed in Cassatella 1995).
As previously discussed in section 1.9.4, PMNs possess less CD 14 receptors than
monocytes and macrophages, and respond to LPS/LBP complexes to produce TNF-a
(Haziot et al 1993, Weingarten et al 1993, Dubravec et al 1990). PMNs can secrete
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TNF-a in response to high doses of LPS (5 (.ig/ml) compared to monocytes and
macrophages which can respond to lower levels of LPS (< 1 ng/ml). In vivo PMNs
might prove to be a significant source of cytokines, that may influence the direction
and evolution of SIRS.
1.10 CYTOKINE INDUCTION BY GRAM-POSITIVE BACTERIA AND
OTHER BACTERIAL STRUCTURES
Although LPS is the principal trigger of SIRS and the cytokine cascade, there is
increasing evidence to suggest that components of Gram-positive cell walls and other
bacterial products stimulate the release of cytokines from macrophages.
It has been shown that purified cell walls from Gram-positive bacteria, and
peptidoglycan and teichoic acid from Staphylococcus epidermidis sthnulate the
release of IL-6 and TNF-a on a magnitude 100 times less than E. coli. (Heumann et
al 1994, Mattsson et al 1993, Lichtman et al 1993). It is not known what role serum
proteins play in the induction of cytokine release by Gram-positive cell wall
components.
Fimbriae from Porphyromonas gingivalis have also been shown to induce production
of IL-1 (3, IL-6, IL-8 and TNF-a in human blood monocyte/macrophage cultures
(Ogawa et al 1994b). It is also proposed that the CP from B. fragilis may induce
cytokine release (Cross 1994).
1.11 TREATMENT OF SHIS
As previously discussed, SIRS results from the interactions of LPS with the host.
Accordingly, therapies aimed at inhibiting or neutralising endotoxin or the cytokine
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cascade have been extensively explored. As yet no anti-LPS or anti-cytokine
treatment of SIRS and shock have proven any real benefit. What follows is a
discussion of some of the therapies that have been approached.
1.11.1 Anti-Endotoxin Strategies
Table 6 outlines several of the anti-endotoxin approaches to the treatment of SIRS.
Antibodies to endotoxin
Most therapeutic efforts have focused on passive immunotherapy against endotoxin.
Several monoclonal antibodies (mAbs) that bind to the core and lipid A region of LPS
(the region most responsible for the toxicity of LPS and has a highly conserved
structure) have been generated. One of these, HA-1A (Centoxin), a human anti-lipid
A IgM mAb caused a great deal of controversy. The efficacy of this antibody was
reported in 1991 by Ziegler et al. During a controlled trial ofHA-1A in the treatment
of patients with SIRS, no difference in 28 day mortality was seen in the whole group
of 543 patients treated. But in those patients who were subsequently proven to have
Gram-negative bacteraemia there was a significant reduction in 28 day mortality from
49% to 30% in those that received HA-1A. These results prompted the release of
HA-1A on the market in some European countries. Reports of an excess mortality in
treated patients with non-Gram-negative bacteraemia resulted in HA-1A being
withdrawn from sale (Baumgartner 1994, Evan & Cohen 1993).
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Table 6: Anti-endotoxin therapies for treating SIRS (Taken from Corriveau &
Danner 1993).
Non antibody agents that bind endotoxin
Cationic peptides
Colistin, colistin nonapeptide









Analogues of lipid A
Derivatives that induce tolerance
Monophosphorylated lipid A












Non-antibody agents that bind endotoxin
Polymyxin B binds tightly to the lipid A region of LPS and has been shown to
neutralise many of its activities including lethality (Corriveau & Danner 1993, Flynn et
al 1987). Most investigations have concluded that polymyxin B needs to be premixed
with endotoxin ex vivo or given simultaneously to be protective and has never been
evaluated in a clinical trial (Corriveau & Danner 1993).
Theofan and colleagues (1994) cloned and expressed human recombinant LBP
(rLBP) as well as a truncated version rLBP25. Both bound LPS with the same affinity
but whereas rLBP was able to mediate LPS induced TNF secretion by monocytes,
rLBP25 was inactive. This suggests that the LPS binding site resides in a different
region of the protein from the CD 14 stimulatory activity and that rLBP25 may be of
use hi the treatment of endotoxaemia.
BPI has been investigated as a potential anti-endotoxin agent. It binds to Gram-
negative bacteria and LPS via their lipid A moieties. It has been shown to inhibit the
production of TNF in whole human blood and PMN priming. A recombinant amino-
terminal fragment of BPI (rBPI 23) has been shown to retain the properties of the
parent protein and is currently being developed for treatment (Gazzano-Santoro et al
1992).
Analogues of lipid A
Non-toxic derivatives of lipid A that reduce tolerance in animals include
monophosphorylated lipid A (MPL) and Sandoz compound 953 (SDZ MRL 953)
(Corriveau & Danner 1993, Lam et al 1991). Other structural derivatives of lipid A
that have been found to antagonise the actions of LPS in vitro and protect endotoxin-
challenged animals from death include lipid X (a monosaccharide precursor in the
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biosynthetic pathway of lipid A) (Danner et al 1987), lipid IVA (Kovach et aI 1990)
and the diphosphoryl lipid A of Rhodopseudomonas sphaeroides (RsDPLA)
(Takayama et al 1989). Lipid X has been shown to block PMN priming and lipid IVA
and RsDPLA have been shown to block endotoxin induced TNF production.
1.11.2 Blocking The Cytokine Cascade
Since SIRS is characterised by a complex interplay of cytokines it was logical to try
blocking cytokine overproduction. Potential agents for blocking the cytokine cascade
are illustrated in Table 7.
Table 7: Blocking the cytokine cascade (Taken from Darville et al 1993).
Cytokine Potential Blocking Agent
TNF anti-TNF antibodies
soluble TNF receptors
TNF-receptor Tc chimeric proteins
IL-1 IL-1 receptor antagonist
EL-6 anti-IL-6 antibodies
Since IL-1 and TNF-a act synergistically in shock, preventing either cytokine reduces
the effect of the other. No adequate clinical trial addressing the efficacy of an anti-
TNF mAb in human sepsis has yet been published (Darville et al 1993, Mercier
1993).
In addition to antibodies the discovery of natural antagonists of cytokine action has
led to further therapeutic possibilities. These include a soluble form of the TNF
receptor which may act in scavenging circulating TNF resulting in a decrease of an
inflammatory reaction. Recent studies have shown that the human recombinant p55
sTNFr is a better candidate for the development of an anti-inflammatory agent (Hale
et al 1995). The IL-1 receptor antagonist (IL-1 RA) is a naturally-occurring protein
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which binds to the human IL-1 receptor but has no agonist activity. It has been
shown to reduce mortality rates in a rabbit model of sepsis even when it was given
after the onset of shock (Aiura et al 1991). However, the results of a phase III
clinical trial has shown there was no decrease in mortality hi treated patients (Hannum
et al 1990).
A lack of cytokine activity may be detrimental. It has not been determined whether
early intervention in the cytokine cascade would compromise longer term
inflammatory response or tissue repair. Our understanding of SIRS is by no means
complete. The high mortality rate associated with severe sepsis and SIRS will
undoubtedly lead to broad application of immunotherapies if they prove to be
effective.
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AIMS OF THIS THESIS
The objective of this thesis was to re-assess the biological activity of Bacteroides
LPSs and evaluate their possible role hi sepsis. The following main areas of research
were covered:-
1. To investigate the biological activities of Bacteroides LPSs which had been
extracted by three different methods compared to an E. coli 018K" LPS control.
2. To try and relate biological activity to sub-populations, Percoll profiles,
chemotype and chemical composition ofBacteroides LPS and CPs.
3. To examine the capacity of Bacteroides LPS and CP to induce various cytokines
from three different cell populations, with particular emphasis on the role of CD 14 in
cell activation. Inhibition of cytokine production by anti-Bacteroides mAbs will be
attempted.





All reagents were obtained from BDH, Poole, England, UK unless otherwise
indicated.
2.2 BACTERIAL STRAINS
Table 1 overleaf lists all the Gram-negative organisms used. Strains were maintained
as lyophilised cultures. MPRL 1522 could not be distinguished between B. merdae or
B. distasonis due to the insensitivity of the arabinogalactan fermentation test.
2.3 BACTERIAL CULTURE MEDIA
(a) Nutrient broth (Gibco, Paisley, Scotland) (NB) was prepared and filter sterilised
by the Blood Transfusion Service, Protein Fractionation Centre, Edinburgh.
(b) Nutrient agar was Columbia agar base (Oxoid, Basingstoke, England).
(c) Proteose Peptone Yeast extract (PPY) medium pH 7.1 contained per litre:
Proteose peptone (Oxoid) 20 g, yeast extract (Difco, Detroit, USA) 10 g, NaCl 5 g,
cysteine HC1 (3.75% w/v solution) 20 ml, sodium carbonate (2% w/v solution) 20 ml,
haemin/menadione (250 pg/ml: 50 fig/ml solution) 20 ml and 940 ml of pyrogen free
water (PF-EfO).
(d) Van Tassell and Wilkins' (VT) medium was prepared as described in Van Tassell
and Wilkins (1978). It contained per litre: (NH4)2S04 2 g, sodium citrate 0.5 g,
vitamin B12 5 pg, KE^PC^ 7 g, K^HPC^ 8 g, MnCLjAELjO 10 mg, MgCl^AITjO 20
mg, FeCl3.614^0 0.3 mg, CaCL^ELjO 30 mg, NaHC03 4 g, cysteine HC1 0.5 g,
glucose 10 g, haemin 5 mg and resazurin 1 mg.
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Table 1: Bacterial strains
Species Strain Source/origin Used in sub-
population
experiments
B. fragilis NCTC 9343 MPRL 1669 Appendix abscess Yes
B. fragilis GNAB 4 MPRL 1504 Wound Yes
B. fragilis MPRL 1652 Faeces
B. fragilis MPRL 1978 Blood
B. vulgatus NCTC 11154 MPRL 1726 ? Yes
B. vulgatus MPRL 1651 Faeces Yes
B. vulgatus MPRL 1985 Blood Yes
B. thetaiotaomicron
NCTC 10582
MPRL 1720 Faeces Yes
B. thetaiotaomicron MPRL 1959 Blood
B. distasonis ATCC 8503 MPRL 1667 9 Yes
B. caccae ATCC 43185 MPRL 2278 Faeces
B. merdae ATCC 43 184 MPRL 2277 Faeces
B. merdae or distasonis MPRL 1522 Faeces
B. caccae MPRL 1555 Wound Yes
B. ovatus ATCC 8483 MPRL 1709 ?
B. ovatus MPRL 2370 Blood Yes
B. thetaiotaomicron MPRL 1987 Blood
B. uniformis ATCC 8492 MPRL 1721 ? Yes
B. uniformis MPRL 1542 Faeces
B. variabilis VPI 11368 MPRL 1724 ? Yes
B. variabilis MPRL 2244 ?
B. stercoris ATCC 43183 MPRL 2276 Faeces
B. eggerthii NCTC 11155 MPRL 1668 Faeces Yes
B. eggerthii MPRL 1523 Faeces
B. eggerthii MPRL 1216 Appendix





(e) Van Tassell and Wilkins' medium containing 50% heat-inactivated sheep serum
(VT + 50% HISS). Filter-sterilised sheep serum was obtained from the Moredun
Research Institute, Edinburgh, and was heat inactivated by heating at 56°C for 60
min. Sheep serum was stored at -20°C until use.
2.4 BACTERIAL CULTURE
The purity of all cultures was determined by wet film, Gram stain and a 48 h purity
plate.
2.4.1 Anaerobic Growth
(a) On a small scale Bacteroides species were grown in PPY, VT or VT + 50% HISS
in an anaerobic cabinet (Don Whitley, Shipley, UK) at 37°C in an atmosphere of 10%
H^, 80% N2 and 10% C02. E. coli 018K" was grown hi NB and incubated at 37°C in
an atmosphere of 10% Hj, 80% N2 and 10% C02. Cells were either used immediately
or harvested by centrifugation at 10,000 g for 15 min before washing twice in
phosphate buffered saline (PBS) at 10,000 g for 15 min before use.
(b) On a large scale Bacteroides species were grown in PPY or VT, and E. coti
018K" was grown in NB in a 16 1 capacity LH fennenter (LH Engineering, Stoke
Poges, UK) at 37°C hi an atmosphere of 100% N2. Cells were harvested by
centrifugation at 15,000 g using a KSB continuous flow system (Dupont UK Ltd)
before washing twice in PBS at 10,000 g for 15 min. The bacterial pellet was
lyophilised and stored at -20°C for further use.
2.4.2 Aerobic Growth
(a) On a small scale E. coli OI8K" was grown in NB and incubated statically at 37°C
in normal atmospheric air. Cells were used immediately or harvested as described
above.
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(b) On a large scale, E. coli 018K" was grown in NB in a 16 1 capacity LH fermenter
at 37°C in an atmosphere of 50% p02 saturation. Cells were harvested as described
above.
2.5 EXTRACTION OF LIPOPOLYSACCHARIDES
2.5.1 Phenol-Water fPW) Method
LPS was extracted by the method of Westphal & Luderitz (1954) as described in
Hancock & Poxton (1988). A finely divided lyopkilised bacterial mass was
resuspended to a concentration of 5% w/v in PF-H20 and an equal volume of 90%
w/v phenol was heated to 67°C in a water bath. Both solutions were mixed and stirred
at 67°C for 15 min. The mixture was transferred to glass 50 ml centrifuge tubes and
cooled on ice to allow phase separation. The tubes were then centrifuged at 10,000 g
for 15 min to complete separation of the phases. The upper aqueous phase containing
the LPS was carefully removed and transferred to dialysis tubing (Medical
International Ltd, London) (washed and boiled for 10 min in PF-F^O) and dialysed
against running tap water overnight, until the smell of phenol was no longer
detectable. The dialysed extract was then concentrated to approximately one-fifth of
its original volume by rotary evaporation. This was proceeded by ultra centrifugation
(OTD65B, Dupont) of the solution at 100,000 g for 3 h. The resulting pellet was
resuspended in PF-H20 and recentrifuged. The final pellet was suspended in a small
amount of PF-FLjO, lyophilised and weighed. The LPS was stored at -20°C until
required.
2.5.2 Phenol-Chloroform-Petroleum (PCP) Method
LPS was extracted by the method of Galanos et al (1969) as described in Hancock &
Poxton (1988). Tire extraction solvent (PCP) consisted of 90% phenol, chloroform
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and petroleum spirit (40°- 60° b.p.) in the ratio 2:5:8 by volume. Lyophilised bacteria
were resuspended in PCP at approximately 25% w/v, stirred for 2 min below 20°C
and centrifuged at 10,000 g for 15 min. The supernate was filtered through Whatman
No 1 filter paper into a round-bottomed flask. The pellet was re-extracted and the
filtered supemates pooled. Chloroform and petroleum were removed from the
supernate by rotary evaporation. LPS was precipitated by the addition of six volumes
of diethyl ether/acetone (1:5 by volume) to one volume of phenol solution. After
standing for 1 h the LPS was sedimented by centrifugation at 5,000 g for 10 min. The
pellet was washed three times in diethyl ether/acetone and the final pellet dried under
vacuum (by water pump) until the smell of ether/acetone was no longer detectable.
The pellet was resuspended in 5 ml of PF-H20 and LPS recovered by ultra
centrifugation at 100,000 g for 4 h. The resulting LPS was taken up in a small amount
ofPF-H20, lyophilised, weighed and stored at -20°C until required.
2.5.3 Triton-Mg2+ (Triton) Method
LPS was extracted by the method of Uchida & Mizushima (1987). The following
method quotes volumes for 1 g dry cell. Volumes were scaled up accordingly.
To lyophilised bacteria, 22 ml of PF-H20 was added, mixed and followed by
successively adding and mixing 4 ml 100 mM Tris-HCl pH 8, 4 ml 0.5 M MgClj and
10 ml 8% Triton X-100. Finally, 10 ml of ethanol was added, the tube sealed and
boiled at 100°C for 10 min. After cooling, the mixture was centrifuged at 100,000 g
for 90 min at room temperature and the precipitate washed once in 40 ml of 10 mM
Tris-HCl pH 8 containing 10 mM MgCl2. To the washed precipitate, 10 ml of PF-
H20, 10 ml 0.2 M EDTA pH 8, 10 ml 2 M NaCl and 10 ml 8% Triton X-100 was
added, mixed well and incubated for 37°C for 60 min with agitation. The mixture was
centrifuged at 15,000 g for 15 min at room temperature, the supernate collected and
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recentrifuged as before. To the superaate, 4 ml 1 M MgCf was added while stirring
and heated to 37°C for 60 min. The resultant opaque solution was immediately
centrifiiged at 100,000 g for 90 min at 15°C and the resulting clear precipitate
washed once in 40 ml 10 mM Tris-HCl pH 8 containing 10 mM MgCl2. The resultant
precipitate was lyophilised, weighed and stored at -20°C until required.
2.5.4 Proteinase K Digestion Of Bacteria For The Preparation Of LPS
Proteinase K digestion of bacteria was used to prepare LPS for analysis by
polyacrylamide electrophoresis (PAGE). Bacterial cultures were harvested by
centrifugation and washed twice in PBS. The density of washed bacteria was adjusted
to an absorbance at 525 nm ofbetween 0.5 and 0.6. Bacterial suspension (1-5 ml) was
transferred to an Eppendorf tube and the bacteria sedimented by micro-centrifugation
at 10,000 g for 3 min. The pellet was resuspended in 50 pi of single strength PAGE
sample buffer (see section 2.9) and heated at 100°C for 10 min. After cooling, 10 pi
of sample buffer containing 25 pg of proteinase K (Sigma protease Type XI, St
Louis, USA) (2.5 mg/ml in sample buffer) was added followed by incubation in
a 60°C water bath for 60 min. Samples were stored at -20°C until required.
2.6 PURIFICATION OF LIPOPOLYSACCHARIPE FROM PROTEIN
CONTAMINATION
Native LPSs (5 mg/ml) were made free from any protein contamination by treating
with proteinase K (20 pg/ml) by heating at 65°C for 2 h. Proteinase K was removed
by two washes with PF-HjO at 100,00 g.
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2.7 DEIONIZATION OF LIPOPOLYSACCHAR1DES BY
ELECTRODIALYSIS
Deionisation of LPS was based on the method described in Hancock & Poxton
(1988). LPS was suspended in PF-F^O to approximately 5-10 mg/ml and placed in a
three-chambered electrodialysis cell (ISCO, Lincoln, Nebraska, USA), and distilled
water added to the two electrode chambers. A voltage of up to 500 V was maintained
across the cell. The contents of the chambers was replaced several times over 3-4 h
when the pH in the cathodic chamber rose. The precipitated free acid form of the
LPS (deionised) was recovered from the anodic side of the cell and suspended in PF-
HjO. Deionised LPS was solubilised by neutralisation with NaOH.
2.8 PREPARATION OF CAPSULAR POLYSACCHARIDE FROM B.
FRAGILIS NCTC 9343
The method of Pantosti et al (1991) was followed. B. fragilis NCTC 9343 was
grown up in 4 1 of PPY at 37°C, 5% C02. Bacterial cells were suspended in 100 ml
of PF-FLjO and an equal volume of 75% w/v phenol was added. The mixture was
stirred at 68°C for 30 min and cooled on ice. Phases were separated by centrifugation
at 10,000 g for 15 min and the aqueous layer removed. The phenol-water extraction
step was repeated and the aqueous layers pooled. An equal volume of ether was
added to the aqueous layers to remove the phenol and the upper ether layer removed.
The lower layer was concentrated on a rotary evaporator and dialysed against distilled
water and lyophilised.
Volumes of the lyophilised material were suspended in 0.1 M sodium acetate buffer
(pH 4.5) containing 10 mM CaCLj and 10 rnM MgCl2, and treated with 0.5 mg
DNase (DN-25, Sigma) and 2.5 mg RNase (Type 1-A, Sigma) at 37°C for 2 h. This
treatment was then repeated overnight at 37°C. The pH of the solution was adjusted
to pH 7.0 with NaOH and treated with 5 mg of Pronase (Sigma type 70,000 PUK
units per g) at 37°C for 2 h. This treatment was then repeated overnight at 37°C. The
material was brought to a concentration of 80% v/v in ethanol and allowed to stand at
4°C overnight. The alcohol insoluble precipitate was recovered by centrifugation and
dissolved hi a buffer containing 0.5% sodium deoxycholate, 50 mM glycine and 10
rnM EDTA, pH 9.8. A volume of this solution (3 ml) was loaded onto a Sephacryl
column (S-300) (2.5 cm x 30 cm) (Pharmacia, Uppsala, Sweden) which had been
equilibrated in the deoxycholate buffer, pH 9.8. Fractions (1.8 ml) were collected and
examined for capsular polysaccharide by PAGE and staining with silver. Fractions that
contained capsular polysaccharide and low molecular mass LPS were pooled,
precipitated in 80% v/v ethanol and dialysed extensively against distilled H20 before
lyophilising.
The capsular polysaccharide (4.2 mg) was heated at 100°C for 1 h hi 10 ml of 5%
acetic acid. The acetic acid was removed by rotary evaporation and the precipitate
dissolved hi 3 ml of 50 mM Tris-HCl buffer, pH 7.3 and loaded onto a column (1.5
cm x 15 cm) of DEAE-Sephacel (Pharmacia) which had been equilibrated in the 50
mM Tris-HCl buffer. Buffer (100 ml) was washed through the column and 5 ml
fractions collected. The material bound to the column was eluted with a linear
gradient of 0 to 0.5 M NaCl in the 50 mM Tris-HCl buffer collecting 5 ml fractions.
Fractions were examined by PAGE stained with silver. Material obtained after elution
with the 50 mM Tris-HCl buffer was termed polysaccharide A. Material obtained
after elution with low concentrations of NaCl was termed polysaccharide B and
material obtained after elution with high concentrations of NaCl was considered a
mixture of polysaccharide A and B.
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Samples were desalted by running 200 pi samples through disposable polystyrene
columns (Pierce & Warner, Luton, England) that had been packed with Sephadex G-
25 (Pharmacia) and calibrated with Dextran-blue and NaCl. Samples were pooled and
lyophilised.
2.9 PREPARATION OF SAMPLES FOR POLYACRYLAMIDE GEL
ELECTROPHORESIS
Sample buffer (pH 6.8) contained 0.0625 M Tris in which 2% w/v SDS, 10% v/v
glycerol, 1% v/v 2-mercaptoethanol and 0.001% bromophenol blue were present.
Double strength sample buffer (pH 6.8) was made as above with double the
concentration of all constituents.
Proteinase K digests were prepared as described in section 2.5.4 and samples were
loaded onto gels at 10 pi per track for silver staining and Coomassie blue staining.
LPS samples prepared by the PW, PCP and Triton-Mg2+ or capsular polysaccharides
were suspended in PF-H20 to 1 mg/ml and an equal volume of double strength
sample buffer added. Samples were boiled for 10 min and loaded onto gels at 10 pi
per track for silver staining and Coomassie blue staining.
2.10 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE)
PAGE was performed on acrylamide slab gels using the buffer system of Laemmli
(1970) as described in Hancock & Poxton (1988). PAGE of LPS samples were run
on 14% lion-SDS polyacrylamide gels. The following buffers and solution were used:
(a) Separating gel buffer (double strength, pH 8.8) consisted of 0.75 M Tris-HCl.
(b) Stacking gel buffer (double strength, pH 6.8) consisted of 0.25 M Tris-HCl.
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(c) Acry1amide stock solution (40% w/v) contained 100 g acrylamide and 2.7 g
methylene bis acrylamide made up to 250 nil with distilled water.
(d) Electrode buffer (pH 8.3) consisted of 0.025 M Tris, 0.192 M glycine and 0.1%
w/v SDS.
A 14% separating gel consisted of 3.45 ml distilled water, 17.5 ml separating buffer
and 12.25 ml acrylamide solution which was deaerated under vacuum prior to
addition of 0.05 ml TEMED and 1.75 ml ammonium persulphate (15 mg/ml). The
solution was poured between glass plates (160 mm x 125 mm x 1.5 mm) which had
been wiped clean with methanol and sealed with molten Vaseline. The gel was
overlaid with water-saturated butan-2-ol and allowed to set. After removal of the
butan-2-ol, a 4% stacking gel (consisting of 3.5 ml distilled water, 5 ml stacking
buffer and 1 ml acrylamide solution prepared as before prior to addition of 0.02 ml
TEMED and 0.5 ml ammonium persulphate (15 mg/ml)) was poured onto the
separating gel. A comb was inserted and the gel allowed to set. On removing the
comb, the gel was place in an electrophoresis tank and electrode buffer added.
Samples, as described in section 2.9 were loaded into the wells of the stacking gel
and run through the stacking gel at a constant 60 V and through the separating gel at
a constant 150 V until the dye front had run 8 cm. Electrophoresis was followed by
staining.
2.11 STAINING OF POLYACRYLAM1DE GELS
2.11.1 Silver Staining For Lipopolysaccharides
Polyacrylamide gels were stained with silver by the method of Tsai & Frasch (1982),
modified by Hancock & Poxton (1988). The following solutions were used:
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(a) Fixative consisted of 7% w/v acetic acid and 25% propan-2-ol.
(b) Oxidising solution consisted of 1.05 g periodic acid in 150 ml distilled water to
which 4 ml of fixative was added.
(c) Ammonical silver nitrate solution consisted of 1.4 ml ammonia solution (SG
0.88), 21 ml of 0.36% w/v NaOH , 4 ml 19.4% w/v silver nitrate solution made up
to 100 ml with distilled water.
(d) Developing solution consisted of 0.019% v/v formaldehyde solution containing
0.005% citric acid.
The gel was placed in fixative overnight followed by oxidation in freshly prepared
periodic acid for 5 min. After hourly washing over a 4 h period in distilled water, fresh
ammonical silver nitrate solution was added for 15 min Following four 10 min washes
in distilled water, gels were transferred to freshly made developing solution. Once the
gel had developed to the required intensity, it was repeatedly washed in large volumes
of distilled water. The gel was stored in the dark until photographed. (All steps were
with gentle agitation following fixation).
2.11.2 Coomassie Blue Staining For Proteins
The Coomassie blue staining method described in Hancock & Poxton (1988) was
used. Hie following solutions made up in distilled water were used:
Solution 1- 2.5% v/v propan-2-ol, 10% v/v acetic acid and 0.05% w/v Coomassie
brilliant blue R-250.
Solution 2- 10% v/v propan-2-ol, 10% v/v acetic acid and 0.0005% w/v Coomassie
blue.
Solution 3- 10% v/v acetic acid and 0.0025 % w/v Coomassie blue.
Solution 4- 40% w/v methanol and 10% v/v acetic acid.
Solution 5- 10% v/v acetic acid.
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The gel was placed in solution 1 overnight and sequentially placed in solutions 2-5
for 60 min at room temperature with gentle agitation throughout.
2.12 CHEMICAL ANALYSIS OF LIPOPOLYSACCHARIDES AND
CAPSULAR POLYSACCHARIDES
2.12.1 Estimation Of Organic Phosphorus
The phosphorus content was measured by the method of Chen et al (1956).
Solutions (in duplicate) containing up to 10 pg of phosphorus were reduced to
dryness by heating on a micro Kjeldahl rack. To dry samples, 100 pi digestion
mixture (concentrated TLjSO,, and 60% perchloric acid mixed 3:2 v/v) was added and
heated to boiling on the same rack and refluxed for 20 min. After cooling 8 ml of
phosphate reagent (2% w/v ascorbic acid in 0.6 M FLjSC^ containing 0.5% w/v
ammonium molybdate) was added to each tube, mixed and incubated at 37°C for 90
min. The absorbance was read at 820 nm against a reagent blank. Phosphorus content
was calculated relative to a potassium orthophosphate standard.
2.12.2 Estimation Of Carbohydrates
Neutral sugars were quantified using the colourimetric method described by Dubois et
al (1956). Duplicate samples containing between 10-100 pg of carbohydrate were
made up to 500 pi with PF-H^O and 500 pi 5% w/v phenol solution was added.
Concentrated H2S04 (2.5 ml) was pipetted directly onto the samples so that mixing
was instantaneous. After cooling for 30 min, the absorbance was read at 490 nm
against a reagent blank. Carbohydrate content was calculated relative to a glucose
standard.
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2.12.3 Estimation Of KDO
Bacteroides LPSs were dephosphorylated by hydrofluoric acid as described by
Beckmann et al (1989) and the KDO content of all LPSs determined by the use of a
modified thiobarbiturate assay (Hancock & Poxton, 1988).
Approximately 5 mg of dry Bacteroides LPS was suspended in 300 pi of aqueous
50% hydrofluoric acid and sealed in polypropylene tubes at 4°C for 48 h. Volatile
material was removed at room temperature under a stream of N2. The residue was
dissolved in 300 pi PF-H^O and again dried under a stream of N2. The dry residue
was suspended in 1 ml PF-H20 and kept at -20°C until required for further analysis.
Duplicate LPS (40 pi of a 5 mg/ml solution) samples were mixed with 1 ml of 0.125
M H2S04 and heated to 100°C for 8 min. Upon cooling, 0.5 ml of acid hydrolysate
was mixed with 0.25 ml of 25 mM periodic acid in 62.5 mM FLjSC^ and incubated at
37°C for 30 min. After cooling, 0.25 ml of 2% w/v sodium arsenite in 0.5 M HC1 was
added and mixed until the brown iodine colour disappeared. Next, 0.25 ml 0.6% w/v
thiobarbituric acid (adjusted to pH 9 with NaOH) was added and heated to 100°C for
7.5 min. While the reaction mixture was still hot, 1 ml of dimethylsulphoxide was
added to all tubes and then allowed to cool. Tire absorbance was read at 548 nm
against a reagent blank. KDO content was calculated relative to a standard of a
known concentration.
2.12.4 Estimation Of Proteins
Protein was measured by the Folin Assay (Lowry et al 1951). Varying amounts of
duplicate test samples were made up to 0.4 ml with PF-H20 and 1.2 ml 12.5% w/v
Na2C03 and 0.2 ml 0.1% CuSO^FLjO added and mixed. After standing for 1 h at
room temperature, the Folin reagent was diluted 1:3 and 0.2 ml added to each tube.
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After standing at room temperature for 25 min the absorbance was read against a
reagent blank. Protein content was calculated relative to a 2 mg/ml bovine serum
albumin (BSA) standard included in the assay.
2.12.5 Gas Liquid Chromatography For Fatty Acids
Approximately 1 mg of LPS and 1 ml 0.5 M HC1 in methanol were mixed and sealed
in a glass tube before heating for 2 h at 65°C. Upon cooling, 2 ml of PF-H20 and 4 ml
ether were added, mixed and the phases allowed to separate. The upper ether layer
was removed and dried in a rotary evaporator. Dry material was dissolved in 200 pi
chloroform and transferred to a gas liquid chromatography (GLC) vial. Samples were
stored at -20°C until analysis.
Methyl esters of long chain fatty acids were analysed on a Perkin-Elmer 8410 gas
chromatograph fitted with an FID and a split/splitless injector. The split ratio was set
at 100:1 and 1 pi samples were injected onto a BPI fused silica capillary column, 25 m
x 0.22 mm ID and film thickness 0.25 pm (S.G.E.), with the linear velocity of the
helium carrier gas set to 21.9 cm per second. The initial temperature of 150°C was
held for 4 min before rising at 4°C per min to 250°C and held for 2 min. Bacterial
acid methyl esters CP mix (Supelco (Supelchem UK Ltd), Saffron Walden, England)
was used as a standard. Peak identity was confirmed by co-injection of the test
materials and standard. Approximate molar ratios were calculated by comparison of
peak areas.
2.13 LIGHT MICROSCOPY FOR CAPSULES
The presence of capsules was determined by fight microscopy following Indian Ink
staining. Equal volumes of an overnight culture of bacteria was mixed with Indian Ink
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(Windsor & Newton) on a microscope slide, a coverslip added and firm pressure
applied. Slides were viewed under x 40 bright field magnification.
2.14 PERCOLL GRADIENT CENTRIFUGATION
Percoll (Pharmacia) was supplied sterile. A stock solution, iso-osmotic with saline,
was prepared by diluting with 1.5 M NaCl in a ratio of 9:1. The pH of this solution
was adjusted to pH 7 with 1 M HC1. Solutions of 20, 40, 60 and 80% Percoll were
prepared by further dilution with 0.15 M NaCl. A 1 ml volume of each of these
solutions was layered carefully into a test tube to produce a step gradient with 80%
Percoll at the bottom and 20% Percoll at the top. A broth culture of the test organism
(1 ml) was applied to the top of the 20% layer and the gradient centrifiiged at 2,600 g
for 20 min in a bench centrifuge (Heraeus Christ).
2.15 MOUSE LETHALITY - GALACTOSAM1NE fD-GAL N) MODEL
D-gal N (12 mg/mouse) was administered to groups of three, 6-8 week old C57 black
male mice intraperitoneally just prior to administration of varying doses of LPS
intraperitoneally from Bacteroides or E. coli species. Survival was recorded up
to 24 h. Animal experiments were performed in accordance with Home Office
guidelines. All animal manipulations were performed by the staff of the Animal House,
University Medical School, Edinburgh.
2.16 L1MULUS AMOEBOCYTE ASSAY fLALl
Stock LPS samples were diluted in PF-H20 (Blood Transfusion Service, Protein
Fractionation Centre, Edinburgh) to ranges of between 50 ng/ml and 0.5 ng/ml. Each
sample (50 pi) was added in duplicate to wells of flat-bottomed microtitre plates
(Griener, Cam, Dursley, England). Chromogenic LAL reagent (Coatest Endotoxin,
Chromogenix, Sweden) was added to each well through a transfer plate to ensure that
59
each well received the LAL reagent at the same time. To minimise error through
evaporation the outer wells of the plate were omitted. The plate was read kinetically
every 19 s at 405 nm (reference background 650 nm) for 90 rnin in a Thermomax
plate reader (Molecular Devices) at 37°C. The replicate mean onset time for test
samples was standardised against an endotoxin of known potency E. coli Ol 11:B4
(Coatest Kit Endotoxin Standard, Chromogenix).
2.16.1 LAL Assay Characteristics
Detection Level and Sensitivity
A log-log curve (Equation: log (y)= A + B*log (x) ) was fitted to the standard
dilutions and a correlation coefficient of greater than 0.99 was always achieved.
Minimum detectable dose of endotoxin was 0.045 IU/ml (3.125 pg/ml of E. coli
0111.B4 LPS).
Specificity
The LAL gelation cascade is known to be triggered by primarily LPS and (3-( 1,3)-D-
glucans. These glucans are found in the cell walls of fungi, yeast and algae.
Intra-Assav Precision
Samples of known endotoxin concentration were assayed in replicates of 10 to
determine precision within an assay.
Sample 1 Sample 2 Sample 3
Mean IU/ml 10.2 55.6 75.4
Standard Deviation 1.2 4.9 6.3
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Inter-Assay Precision
Samples were assayed 10 times in 5 different assays to determine precision between
assays.
Sample 1 Sample 2 Sample 3
Mean pg/ml 9.5 52.3 77.9
Standard Deviation 1.5 4.6 6.8
2.17 LIPOPOLYSACCHARIDE AND CAPSULAR POLYSACCHARIDE
INDUCED STIMULATION OF CYTOKINES
2.17.1 Stimulation Of Human Peripheral Mononuclear Leukocytes
Mononuclear leukocytes (MNL: approximately 30% monocytes) from freshly
collected human huffy coats (obtained from the Blood Transfusion Service,
Edinburgh) were prepared by sedimentation on lymphocyte separation medium (ICN
Flow, Thame, England, UK). Cells were washed twice in RPMI-1640 and adjusted to
8 x 106 cells/ml and cultured in RPMI-1640 (Blood Transfusion Service, Edinburgh)
supplemented with penicillin (100 U/ml) (Gibco), streptomycin (100 pg/ml) (Gibco),
1 mM L-glutamine (Gibco) and 10% foetal calf serum (FCS) (Gibco) in the absence
and presence ofvarying nanogram concentrations of LPS or capsular polysaccharides
(CP) at 37°C, 5% C02. Culture supemates were collected after 4 h or at one or two
hourly intervals for time course experiments and stored at -20°C for TNF, IL-8, IL-6
or p55 sTNFr content determination.
2.17.2 Stimulation Of THP-1 Cells With And Without Enhancement For CD14
THP-1 cells (a human monocyte-macrophage cell line) were a kind gift from Dr David
Morrison, University of Kansas Medical Centre, Kansas City, USA. Cells were not
screened for mycoplasma as such a checking procedure has yet to be implemented in
the Tissue Culture Laboratory, Medical School, Edinburgh. Cells were
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retrospectively screened for mycoplasma contamination by Ciara Ryan and found to
be clear. Cells were grown routinely in RPMI-1640 supplemented with penicillin
(100 U/ml), streptomycin (100 pg/ml), 1 mM L-glutamine and 10% FCS at 37°C,
5% C02. Cells were subcultured once weekly by splitting 1:20. Cells were not
passaged longer than three months. After this time, stock cultures from liquid nitrogen
stores were used. Culture medium was routinely checked for bacterial contamination
by testing medium on both aerobic and anaerobic blood agar plates.
To induce expression of CD14, cultures were grown in the presence of 0.1 pM 1,25-
dihydroxy vitamin D3 (Sigma) for 72 h. Cells were harvested and washed once in
RPMI-1640. Cells (2 x 106 cells/ml) were cultured in RPMI-1640 supplemented as
before in the absence or presence ofvarying nanogram concentrations of LPS. Culture
supemates were collected after 4 h or at two-hourly intervals for time course
experiments and stored at -20°C for TNF, IL-8, IL-6 or p55 sTNFr content
determination.
2.17.3 Stimulation Of Peritoneal Macrophages From LPS Responder And Non-
Responder Mice
The LPS non-responder mice C3H/HeJ were obtained from Harlan Olac, Germany.
The LPS responder mice C3H/HeN were obtained form Harlan Olac, England, UK.
Sodium thioglycollate (1 ml of 10% w/v in distilled water) was injected
intraperitoneally to each mouse four days prior to collection of peritoneal
macrophages. To collect the macrophages (NB. this cell preparation will contain
neutrophils and lymphocytes as well as macrophages), the mice were killed by cervical
dislocation and the peritoneal cavity washed several times with 5 ml quantities of
RPMI-1640. After washing the cells once in RPMI-1640, cells were resuspended to 2
x 106 cells/ml in RPMI-1640 supplemented as before in the presence or absence of
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varying nanogram concentrations of LPS. Culture supemates were collected after 4 h
or at two-hourly intervals for time course experiments and stored at -20°C for TNF
content determination.
2.18 INHIBITION OF CYTOKINE PRODUCTION
2.18.1 Inhibition By Anti-CD14 Monoclonal Antibody
The anti-CD 14 mouse anti-human IgG monoclonal antibody (mAb) was obtained
from the Scottish Antibody Production Unit (SAPU), Law Hospital, Carluke,
Scotland. The CD14 mAb was serially diluted 1:2 in RPMI-1640 and added to cell
preparations (as described in section 2.17) so that the starting concentration was 75
pg/ml. Cell preparations and mAb were preincubated for 30 min at 37°C, 5% C02
before adding an appropriate dilution of LPS and reincubating as before. Culture
supemates were harvested at 4 h and stored at -20°C for determination of TNF, EL-6
and IL-8 content.
2.18.2 Inhibition By Anti-Bacteroides Monoclonal Antibodies
Cell lines raised against B. fragilis NCTC 9343, producing monoclonal antibodies
were obtained from Dr Sheila Patrick, Queen's University of Belfast and grown
routinely hi RPMI-1640 supplemented with penicillin 100 U/ml,
streptomycin 100 pg/ml, 1 mM glutamine and sodium pyruvate 1.1 g/1 (Gibco). Once
cells bad grown to maximum density, cells were centrifuged and the supemates
collected, abquoted and stored at -20°C until required. See Table 2 below for details.
Supemates were serially diluted 1:2 in RPMI-1640 and added to cell preparations (as
described in section 2.17). Cell preparations and mAb supemates were preincubated
for 30 min at 37°C, 5% C02 before adding an appropriate dilution of LPS and
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reincubating as before. Culture supernates were harvested at 4 h and stored at -20°C
for determination ofTNF and IL-8 content.
Table 2: Monoclonal Antibodies Raised Against B.fragilis NCTC 9343
Cell Line Active Against Isotype
3C8 H mwt, O Ag IgG 2b
3D7 H mwt IgGl
4CS H mwt IgG 1
1A4 H mwt ?
6G3 No H mwt only O Ag IgG 2b
5A12 Complete LPS ladder IgGl
The above table shows information on each cell line obtained from Dr Sheila Patrick,
Queen's University of Belfast. Cell lines had been raised and tested by
immunoblotting against B. fragilis NCTC 9343. Where H mwt = high molecular
weight LPS material, O Ag = O antigen LPS material, ? = not known.
2.18.3 Inhibition By Anti-TNF Monoclonal Antibody
Cell culture supernates derived from human mononuclear leukocytes as described in
section 2.17.1 were incubated with various dilutions of an anti-TNF mAb (Genzyme,
Hartfield, England) in RPMI-1640 for 1 h at 37°C, 5% C02 prior to addition of the
culture supemate to the L929 cells as described in section 2.19 below.
2,19 DETERMINATION OF TNF CONTENT BY L929 BIOASSAY
The L929 mouse fibroblast cell line which is sensitive to TNF, was cultured in growth
medium: MEM (Sigma) containing 5% FCS supplemented with penicillin (100 U/ml),
streptomycin (100 pg/ml) and 1 mM L-glutamine, and maintained by splitting 1:10
twice weekly. Cells were subcultured once weekly by splitting 1:20. Cells were not
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passaged longer than three months. After this time, stock cultures from liquid nitrogen
stores were used. Cells were not screened for mycoplasma as such a checking
procedure has yet to be implemented in the Tissue Culture Laboratory, Medical
School, Edinburgh. Culture medium was routinely checked for bacterial
contamination by testing medium on both aerobic and anaerobic blood agar plates.
Cells were dislodged by 0.005% trypsin/0.02% EDTA to avoid cell clumping, washed
and resuspended in growth medium to 3 x 105 cells/ml. Cells were dispensed in flat-
bottomed microplates (Greiner) at 100 pl/well and incubated at 37°C, 5% C02 for 20
h. The growth medium was then aspirated, discarded and replaced with 100 pl/well of
assay medium: MEM containing 5% FCS supplemented with 1 mM glutamine and 2 p
g/ml actinomycin-D (to stop further cell growth without killing the cells). To
experimental wells, 100 pi of test supemate which had been diluted 1:5 in assay
medium was added. A standard of recombinant TNF (National Institute for Biological
Standards and Control, UK) diluted serially 1:5 at a starting concentration of 1000
IU/ml and wells without TNF were included. Plates were covered and incubated
at 37°C, 5% C02 for 24 h. The medium was then discarded and replaced with
100 pl/well of filtered (0.22 pm) crystal violet solution (0.5% crystal violet in 20%
(v/v) methanol in distilled water) which stains surviving cells. After 2 min the plates
were washed vigorously under tap water and dried. The crystals were dissolved by
addition of 100 pi of 20% (v/v) acetic acid to all wells and the plate read at 585 nm
on a Vmax plate reader (Molecular Devices). The content of TNF was calculated
relative to the standard curve.
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2.19.1 TNF Bioassav Characteristics
Detection Level and Sensitivity
A 4-parameter curve (Equation y=(A-D)/(l+ ( X/C)AB-D) was fitted to the standard
dilutions. This gave a very good fit with correlation coeffecients greater than 0.990.
Using only the linear part of the curve TNF concentrations ranging from 0.5 to 300
IU/ml could be accurately measured.
Specificity
Anti-TNF mAb completely inhibited cytotoxicity to L929 cells in this assay system.
(See section 3.10.4, Table 16 in Results )
Intra-Assav Precision
Samples of known TNF concentration were assayed in replicates of 10 to determine
precision within an assay.
Sample 1 Sample 2 Sample 3
Mean IU/ml 5.6 75.2 150.9
Standard Deviation 0.9 6.9 9.6
Inter-Assay Precision
Samples were assayed 10 times in 5 different assays to determine precision between
assays.
Sample 1 Sample 2 Sample 3
Mean pg/ml 6.3 80.6 153.4
Standard Deviation 2.9 9.2 12.1
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2.20 INTERLEUKIN-8 RADIO IMMUNOASSAY
Test supernates were diluted 1:5 and 1:10 in duplicate in assay buffer (16% w/v
Na2HP04, 4% w/v KH2P04, 0.1% v/v Triton X-100, 0.3% v/v BSA (Boroseral) and
0.05% w/v NaN3 in distilled water pH 7.4) and 100 pi added to each assay tube. A
standard of human recombinant IL-8 (National Institute for Biological Standards and
Control, UK) was diluted serially 1:10 at a starting concentration of 5 mg/ml and
controls of total count and non-specific binding were also included in the assay. The
EL-8 antibody (a rabbit anti-human IgG obtained from Dr R.W. Kelley, Centre for
Reproductive Biology, Edinburgh) was diluted 1:30,000 hi assay buffer and 25 pi
added to each tube except total count and non-specific binding controls. Tubes were
left overnight at 4°C before adding 25 pi of tracer (IL-8 antibody bound to 125I,
obtained from Dr R.W. Kelley) which had been adjusted to 15,000 cpm. Tubes were
left again overnight at 4°C. A second antibody solution consisting of donkey anti-
rabbit IgG (SAPU) diluted 1:20 and normal rabbit serum (SAPU) diluted 1:200 was
made up in assay buffer containing 4% PEG. Second antibody solution (200 pi) was
added to each tube and left for 1 h at 4°C. The tubes were then spun at 3,200 g for 20
min at 4°C, the supernates aspirated and counted in a gamma counter (Packard
Instruments). The IL-8 content of each test sample was calculated relative to the
standard curve.
2.21 IL-8 Radio-Immunoassay Characteristics
Detection Level and Sensitivity
A 4-parameter curve (Equation y=(A-D)/(l+ ( X/C)AB-D) was fitted to the standard
dilutions. This gave a very good fit with correlation coeffeicents greater than 0.990.
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Using only the linear part of the curve IL-8 concentrations ranging from lOpg/ml to
40000pg/ml could be accurately measured.
Specificity
The IL-8 antibody used in this assay is not known to cross react with IL-1, IL-2, IL-6
and EL-10.
Intra-Assav Precision
Intra assay variation of < 5% has been noted.
Enter-Assay Precision
Inter-assay variation of<13% has been noted.
2.21 ENTERLEUKIN-6 ELISA
Interleukin-6 was measured using the commercially available kit Cytoscreen
(Biosource International, Camarillo, CA, USA). All solutions described below were
supplied ready to use in the kit and exact information on each solution was not
available. In brief, to EL-6 antibody-coated wells 100 pi of standard diluent was
added to the blanks, 50 pi of the standard diluent was added to the zero wells, and 50
pi of standards/culture supernates were added. Biotinylated anti-IL-6 antibody (50 pi)
solution was added to each well except the blank wells, the plate covered and
incubated for 2 h at 37°C. Plates were washed thoroughly three times with wash
buffer before adding 100 pi of Streptavidin-HRP working conjugate to all wells.
Plates were covered and incubated at room temperature for 1 h before washing
thoroughly four times in wash buffer. Stabilised Chromogen (100 pi) was added to
each well and incubated in the dark for 20 min before adding 100 pi of Stop Solution
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to each well. The plate was read at 450 nm on a Vmax plate reader (Molecular
Devices) and the content of IL-6 calculated relative to the standard curve.
2.21.1 11 .-6 ELISA Characteristics
Detection Level and Sensitivity
Minimum detectable dose of IL-6 was less than 2 pg/ml.
Specificity
Buffered solutions of a panel of substances were assayed in IL-6 kit at known
concentrations. No cross-reactivity was indicated in any case. Percentage cross-
reactivity is estimated to be less than 0.005% in each case of IL-ip, IL-2, IL-3, IL-7,
IL-8 and TNF-a.
Intra-Assay Precision
Samples of known IL-6 concentration were assayed in replicates of 10 to determine
precision within an assay.
Sample 1 Sample 2 Sample 3
Mean pg/ml 103.3 144.5 228.5
Standard Deviation 6.9 9.9 8.3
Inter-Assay Precision
Samples were assayed 10 times in 5 different assays to determine precision between
assays.
Sample 1 Sample 2 Sample 3
Mean pg/ml 65.9 124.3 250.1
Standard Deviation 3.0 10.4 10.0
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2.22 PROLIFERATION ASSAY
Spleen or lymph nodes were aseptically removed from C3H/HeN mice and placed in
RPMI-1640. Tissues were homogenised gently to make a single cell suspension and
filtered through sterile gauze. Cells were washed twice with RPMI-1640 and
resuspended to 2 x 106 cells/ml hi RPMI-1640 containing 5% FCS for the assay and
2 x 107 cells/ml and treated as described below.
Preparation of T cells: Aliquots of 1 ml of 2 x 107 cells/ml were added to the top of
equilibrated nylon wool columns. The cells were allowed to run into the nylon wool
column before incubating at 37°C, 5% C02 for 45 min. T cells were eluted by
running 10-15 rnl of RPMI-1640 thr ough the column. Cells were washed once in
RPMI-1640 and resuspended to 2 x 106 cells/rnl in RPMI-1640 containing 5% FCS
for the assay.
Preparation of B cells: Aliquots of 2 x 107 cells/ml were incubated in tissue culture
flasks at 37°C, 5% C02 for 1 h to remove the monocytes/macrophages. An anti-CD3
mAb (Cedarlane, VH Bio Ltd, Gosforth, England) was added at a 1:40 dilution and
incubated for 40 min at 4°C. Cells were washed once in RPMI-1640 and resuspended
to the original volume before 0.5 ml of complement (Guinea pig Haemo-10,
Cedarlane) was added. After incubation at 37°C, 5% C02 for 30 min, cells were
centrifuged gently to remove dead cells and the viable cells adjusted to 2 x 106
cells/ml in RPMI-1640 containing 5% FCS for the assay.
Assay: Cell suspension (100 pi) was added to an equal volume of an appropriate
dilution ofphytohaemagglutinin (PHA) (Sigma) or LPS in a 96 well plate in triplicate.
Plates were covered and incubated at 37°C, 5% C02 for 48h, before adding 10 pCi
of 3H-thymidine (Amersham, England,UK) in 20 pi of RPMI-1640 to each well.
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Plates were covered and incubated for a further 24 h at 37°C, 5% C02. Wells were
washed with distilled water using an Automash 2000 washer (Dynatech) and
deposited onto filter paper (Filter Paper for Cell Harvesters, ICN Flow). The filter
paper was allowed to dry overnight before pushing out the filter paper discs and
placing them into Ponyvial polyethylene vials (Packard). Hydrolumac scintillation
fluid (1 ml) (Lumac LSC, Belgium) was added to each vial, capped and the beta
emission measured in a Tricarb Liquid Scintillation Analyser 1900 CA (Packard).
2.23 COLLECTION OF HUMAN SERUM
From a healthy volunteer, 20 ml of blood was collected and decanted into a sterile
universal. Blood was allowed to clot at 37°C for 30 min. Red blood cells were
removed by centrifugation at 3,900 g and the serum removed. Serum was aliquoted
in cryogenic tubes (Nunc, Intermed, Denmark) and stored at -70°C until required.
2.24 CH.„ COMPLEMENT ASSAY
The effect of LPS on the CH50 (haemolytic complement value) of human seium was
examined. Sheep red blood cells (SRBC) were firstly sensitised with an anti-SRBC
antibody. Approximately 1 ml of SRBC (SAPU) were washed twice in PBS and the
cells resuspended in PBS to 1 x 109 cells/ml. An equal volume of this cell suspension
was mixed with a 1:1000 rabbit anti-SRBC antibody (SAPU) in PBS and incubated
at 37°C for 30 min. After washing twice in PBS, the SRBC were resuspended in the
original volume to give 1 x 109 cells/ml for use hi the assay.
Tubes were set out as in the protocol below, with one set for each LPS type. Tubes
were incubated at 37 °C for 45 min before adding 3 ml of ice cold PBS to each tube.
After centrifuging at 200 g for 5 min to remove all cells, the absorbance of each
supernate was measured at 541 nm.
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Protocol: ± Constant concentration of each LPS (ng) in each tube per set. *Human





4 5 6 7
PBS (ml) 1.1 1.05 1.0 0.9 0.8 1.2 1.2 H,0
Serum (ml)* 0.1 0.15 0.2 0.3 0.4 0.0 0.0
Sensitised
SRBC (ml)
0.3 0.3 0.3 0.3 0.3 0.3 0.3
Assuming that tube 7 represents total lysis and tube 6 spontaneous lysis, percentage
lysis was calculated for each tube. Taking y to be percentage lysis and x to be volume
of serum used, a graph of log (y/100-y) against log x was plotted. The straight line
has a slope if 1/n. The abscissa intercept of the line where log(y/100-y)=0 is the log
dilution resulting in 50% lysis i.e. one CH50 unit.
2.25 FLOW CYTOMETRY
2.25.1 Analysis of CD14 Positive Cells
THP-1 cells (with and without enhancement for CD14) and human mononuclear
leukocytes were examined by flow cytometry for CD 14 distribution. Cells were grown
as described in section 2.17 and resuspended in RPMI-1640 to approximately 3 x 106
cells/ml. Cells (100 pi) were added to 25 pi of normal rabbit serum (SAPU) and
incubated at room temperature for 20 min. Cells were washed once in PBS, the
supemate removed and replaced with 100 pi of various dilutions of an anti-CD 14
mAb (SAPU, see section 2.18.1) and incubated at room temperature for 30 min. Cells
were washed twice in PBS, the supemate removed and replaced with 100 pi of a
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1:100 dilution of FITC-conjugated anti-mouse IgG (SAPU). After incubating for 30
min at room temperature, cells were washed twice in PBS, fixed in 200 pi of buffered
paraformaldehyde (10% v/v paraformaldehyde, 10.7% w/v sodium cacodylate, 7.5%
w/v NaCl adjusted to pH 7.2 with HC1) and stored at 4°C until required for analysis.
2.25.2 Analysis of B and T Cells From Mouse Spleens
Cells (spleen mix, B and T cells) prepared as described in section 2.22 were examined
by flow cytometry to ensure homogeneous cell populations. Red blood cells were
firstly lysed by addition of one part distilled ELjO to three parts PBS. Cells (100 pi) at
2 x 106 per ml were added in triplicate to V-bottomed microtitre plates (Griener).
Cells were pelleted out and resuspended in residual buffer before adding 25 pi of
normal rabbit serum. After incubation for 30 min on ice, cells were washed once in
100 pi in PBS before adding 10 pi of an anti-mouse CD3 mAb (SAPU). The
incubation step was repeated and the cells washed three times in 100 pi ofPBS before
adding 100 pi of an anti-mouse FITC IgG (SAPU) that had been diluted 1:20. The
incubation step was repeated and the cells washed four times in 100 pi of PBS.
Buffered paraformaldehyde (100 pi) was added to each well and the sample stored at
4°C until analysis. As a control, cells without the first mAb and without any mAb
treatment were also included.
Samples were analysed in an EPICS "C" (Coulter Electronics) flow cytometer. A total
of 5000 cells were analysed. Background noise and clumps of cells were excluded by
a gate on the forward angle light scatter. The percentage of cells exhibiting positive
fluorescence was calculated with the EPICS "Stat Pack" Program.
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2.26 COATING OF LPSs ONTO MICROTITRE PLATES
All LPSs (1 mg/ml) were mixed with polymyxin B (Sigma) (1 mg/ml) in a ratio of 1:1
in Reactivials (Pierce, Luton, England). Solutions were sonicated in short bursts for
30 s and stirred at room temperature for 1-2 h. The solutions were sonicated for a
further 30 s and then dialysed for 18-20 h at 4°C against PF-H20 in Spectra-Por
dialysis membrane (mwt cut off 2,000) (Spectrum, Houston, USA). Following
dialysis, solutions were diluted 1:50 in coating buffer (0.05 M carbonate/bicarbonate
pH 9.6 containing 0.02% w/v NaN3) and plates (Greiner Removastrip) were coated
at 100 pl/well. Plates were sealed and incubated overnight at room temperature
before washing four times in wash buffer (pyrogen-ffee PBS containing 0.05% Tween
20 and 0.02% w/v NaN3). Plates were post coated (pyrogen free PBS containing 5%
w/v BSA and 0.02% w/v NaN3) at 100 pi/well. Plates were sealed and incubated
overnight at room temperature before washing four times in wash buffer and rinsing
once in PF-FLjO. Plates were stored at -20°C until required.
2.27 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISAi
Bacteroides inAb supernates were diluted appropriately in dilution buffer (PF-PBS
containing 0.05% w/v Tween 20, 0.5% w/v BSA, 4% w/v PEG-6000 and 0.02% w/v
NaN3). A positive human normal serum control was diluted 1:200 in dilution buffer
and 100 pi of each dilution in duplicate added per well. Plates were sealed and
hicubated for 90 min at 37°C before washing four times in wash buffer. An anti-
mouse IgG alkaline phosphatase conjugate (Seralab, Crawley Down, England) was
diluted 1:1000 in dilution buffer and 100 pi added to the Bacteroides mAb supernate
wells. An anti-human IgG alkaline phosphatase conjugate (Sigma) was diluted 1:1000
in dilution buffer and 100 pi added to the positive human normal serum control wells.
Plates were sealed and incubated for a further 90 min at 37°C before washing four
times in wash buffer. Alkaline phosphatase substrate tablets 104 (Sigma) were diluted
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to 1 mg/ml in substrate solvent (0.05 M sodium carbonate buffer pH 9.8 containing 1
mM MgCl2) and 100 pi added to all wells. Plates were incubated for 15-45 min at
room temperature and then read at 405 nm (background 620 nm) in an Anthos reader
2001 (Labtec).
Two negative controls were also included. First was a well for each mAb dilution
which was not coated in antigen but the primary and secondary antibody still applied.
The second was wells coated in antigen but the primary antibody replaced by pure
diluent.
2.28 SANDWICH ELISA FOR QUANTITATION OF p55 SOLUBLE TNF
RECEPTORS
The reagents and method for the sandwich ELISA for the quantitation of p55 soluble
TNF receptors (sTNFr) were kindly donated by Celltech Ltd, Slough, UK.
Anti p55 soluble TNF receptor antibody 5R13 was diluted to 5 pg/ml in coating
buffer (20 mM BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid; 2-(bis(2-
hydroxyethyl) amino) ethanesulfonic acid), pEf 6) and fOO pi dispensed into each well
(Nunc Maxisorb immunostrip flat bottomed plates). Plates were sealed and incubated
overnight at room temperature before washing twice in blocking buffer (Dulbeccos
PBS containing 1% w/v BSA) and then twice in glazing buffer (5% w/v lactose and
0.1% w/v BSA in distilled water). Plates were allowed to dry, sealed in a foil pouches
containing a silica gel sachet and stored at 4°C until required.
Assay diluent (Dulbeccos PBS containing 1% w/v BSA) (100 pi) was dispensed into
each well. Supernates obtained as described in sections 2.17.1 and 2.17.2 were
added (10 pi) in duplicate to appropriate wells. p55 sTNFr standards and interassay
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controls were also added in duplicate (10 pi) to appropriate wells. Plates were sealed
and incubated with agitation for 1 h at room temperature before washing twice with
PBS. 5R5-Biotin solution was diluted in assay diluent to 1 pg/ml and 100 pi
dispensed into each well. Plates were sealed and hicubated with agitation for 30 min at
room temperature before washing twice in PBS. Streptavidin-HRP conjugate (Sigma)
was diluted in assay diluent to 1 pg/ml and 100 pi dispensed into each well. Plates
were sealed and incubated with agitation for 30 min at room temperature before
washing four times with PBS. TMB substrate (tetramethylbenzidine dihydrochloride)
(Sigma) was prepared in 0.05 M phosphate-citrate bulfer pH 5 containing 0.006% v/v
HjOj (added just prior to use) and 100 pi dispensed into each well. Plates were sealed
and incubated with agitation for 10-20 min at room temperature. Plates were read at
650 nm (background reference 405 nra) on a Vmax plate reader (Molecular Devices)
and p55 sTNFr concentration of each sample calculated relative to the standard curve.
2.29 PRECAUTIONS AGAINST ENDOTOXIN CONTAMINATION
As the majority of assays and techniques in this thesis can detect and are sensitive to
picogram amounts of endotoxin it was very important not to introduce any
contaminating endotoxin into test samples and assay systems. The following
precautions were therefore undertaken:
-Use ofPF-I^O where appropriate (Milh-Q pyrogen free unless indicated).
-Use of pyrogen free (PF) pipette tips where appropriate.
-Use ofPF tissue culture plates, plastic wear, tubes, troughs etc.
-All reusable glassware was depyrogenated by heating to 250°C for 3 h.
-All LPS samples aliquoted to avoid freeze/thaw cycle.
-All media, buffers, pipettes and pipette tips supplied sterile.
-Manipulations using tissue culture, LAL assay and LPS samples carried out in a
Class II safety cabinet.
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2.30 STATISTICAL METHODS EMPLOYED
Certain experiments were analysed by statistics (see sections 3.10.6 and 3.10.11). The
student t-test and Mann Whitney test to compare medians were used and in another
instance mean TNF values were normalised to the value for E. coli 018K" LPS which
was given the arbitrary value of 100%. The inter-assay variation between different
buffycoats preparations was high (ranging from 5% to 45%, data not shown) and for
this reason results from MNL experiments were presented as the mean of a least two
experiments. All results depict trends which have confirmed on at least two occasions.
For consistency, other experiments were also presented in this manner. Error bars





Unless otherwise indicated in the results or discussion, LPS samples refer to protein
decontaminated native phenol-water (PW) extracted LPS, which have been prepared
from bacteria grown in PPY medium for Bacteroides species and NB for E. coli
018K". E. coli 018K" was aerobically grown unless otherwise indicated. Serum is
included in all experiments unless indicated. In every stimulation experiment where
used, 8 x 106 cells/ml of human MNL, 2 x 106 cells/ml of THP-1 cells with and
without enhancement for CD 14 and 2 x 106 cells/ml of peritoneal macrophages from
LPS responder and non-responder mice were used. Representation of results is
explained in the Methods section 2.30.
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3.1 THE EFFECT OF GROWTH MEDIUM ON LPS CHEMOTYPE
The effect of growth medium on LPS chemotype was examined in 25 strains of
Bacteroides. Bacteria were grown in PPY medium, VT medium or VT medium
containing 50% HISS and their LPS chemotype compared by proteinase K extracts
on silver stained PAGE (Fig I A-D). The E. coli 018K" LPS control had been
grown in nutrient broth (NB). No clear differences in silver-stained profiles were seen
between bacteria grown in different growth medium. All B. vulgatus strains failed to
grow in VT medium. Several Bacteroides species showed characteristic silver-stain
profiles. A banding pattern typical of smooth LPS was seen for all B. vulgatus
species (Fig 1, gel A tracks 14-19, gel B tracks 2, 4) and the E. coli 018K" control.
Most of the Bacteroides species showed silver-stain profiles of low molecular mass
material only.
3.2 INVESTIGATION INTO SUB-POPULATIONS OF BACTEROIDES
SPECIES
Sub-populations ofBacteroides were examined in 12 strains (see Table 1 Materials &
Methods). Bacteria were grown in VT medium and sub-populations separated on
Percoll density gradients (Fig 2). Bacteria from the bands were removed with a sterile
syringe and stained for capsules with indian ink (Fig 3) or sub-cultured in VT medium
and their LPS chemotype within sub-populations examined by comparing Proteinase
K extracts on silver-stained gels (Fig 4 A, B).
After centrifugation of cultures in defined medium on a Percoll density gradient (Fig
2), cells with large capsules remained on top of the 20% layer and non-capsulate cells
were concentrated at the 80% layer. Most strains tested consisted of mixtures of
small/large/non-capsulate bacteria except for B. fragilis MPRL 1504, which consisted
of 100% large capsulate bacteria. All B. vulgatus strains exhibited the same Percoll
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Fig 1: Silver stain profiles of Proteinase K extracts of 24 Bacteroides species
grown in either PPYa, VT b or VT + 50% HISSC medium
Gel A
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Gel A: Track 1= sample buffer, 2= B. fragilis NCTC 9343a, 3= B. fragilis NCTC
9343b, 4= B. fragilis NCTC 9343c, 5= B. fragilis MPRL 1504a, 6= B. fragilis MPRL
1504b, 7= B. fragilis MPRL 1504°, 8= B. fragilis MPRL 1652a, 9= B. fragilis MPRL
1652b, 10= B. fragilis MPRL 1652c, 11= B. fragilis MPRL 1978a, 12= B. fragilis
MPRL 1978b, 13= B. fragilis MPRL 1978c, 14= B. vulgatus MPRL 1726% 15= B.
vulgatus MPRL 1726bNG , 16= B. vulgatus MPRL 1726c, 17= B. vulgatus MPRL
165 la, 18= B. vulgatus MPRL 1651bNG, 19= B. vulgatus MPRL 1651% 20= E. coli
018K".
Where E. coli 018K" control was grown in NB and NG = no growth.
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Gel B
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Gel B: Track 1= sample buffer, 2= B. vulgatus MPRL 1985a, 3= B. vulgatus MPRL
1985bNG, 4= B. vulgatus MPRL 1985°, 5= B. thetaiotaomicron MPRL 1720a, 6= B.
thetaiotaomicron MPRL 1720b, 7= B. thetaiotaomicron MPRL 1720c, 8= B.
thetaiotaomicron MPRL 1959a, 9= B. thetaiotaomicron MPRL 1959b, 10= B.
thetaiotaomicron MPRL 1959c, 11= B. merdae/distasonis MPRL 1522a, 12= B.
merdae/distasonis MPRL 1522b, 13= B. merdae/distasonis MPRL 1522c, 14= B.
caccae MPRL 1555a, 15=5. caccae MPRL 1555b, 16= B. caccae MPRL 1555c, 17=
B. ovatus MPRL 1709a, 18= B. ovatus MPRL 1709b, 19= B. ovatus MPRL 1709c,
20= E. coli 018K".
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Gel C
Gel C: Track 1= sample buffer, 2= B. uniformis MPRL 1721a, 3= B. uniformis MPRL
172lb, 4= B. uniformis MPRL 1721c, 5= B. uniformis MPRL 1542a, 6= B. uniformis
MPRL 1542b, 7= B. uniformis MPRL 1542°, 8= B. thetaiotaomicron MPRL 1987a,
9= B. thetaiotaomicron MPRL 1987b, 10= B. thetaiotaomicron MPRL 1987°, 11= B.
variabilis MPRL 1742a, 12= B. variabilis MPRL 1724b, 13= B. variabilis MPRL
1724c, 14= B. variabilis MPRL 2244a, 15= B. variabilis MPRL 2244b, 16= B.
variabilis MPRL 2244c, 17= B. eggerthii MPRL 1668a, 18= B. eggerthii MPRL
1668b, 19= B. eggerthii MPRL 1668°, 20= E. coli 018K".
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Gel D
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Gel D: Track 1= sample buffer, 2= B. eggerthii MPRL 1523a, 3= B. eggerthii MPRL
1523b, 4= B. eggerthii MPRL 1523c, 5= B. eggerthii MPRL 1216a, 6= B. eggerthii
MPRL 1216b, 7= B. eggerthii MPRL 1216C, 8= B. caccae MPRL 2278a, 9= B.
caccae MPRL 2278b, 10= B. caccae MPRL 2278c, 11= B. merdae MPRL 2277a, 12=
B. merdae MPRL 2277b, 13= B. merdae MPRL 2277°, 14= B. stercoris MPRL
2276a, 15= B. stercoris MPRL 2276b, 16= B. stercoris MPRL 2276c, 17= B.
distasonis MPRL 1667a, 18= B. distasonis MPRL 1667b, 19= B. distasonis MPRL
1667c
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Fig 3: Typical Indian ink capsule stains from B.fragilis NCTC 9343 after
growth in V I medium
a) Large capsulate bacteria
b) Small capsulate bacteria
c) Non-capsulate bacteria
.j. J®- ^
r W '* • # » -w~ ^ *
. - • =
"
• •• - -- * v#V> t lb!
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profile. No capsules were seen in B. eggerthii MPRL 1668 cultures. A typical indian
ink capsule stain showing small/large/non-capsulate bacteria is shown hi Fig 3 (a-c).
No difference in LPS chernotype within sub-populations of Bacteroides species was
seen in Proteinase K extracts (Fig 4 A, B). Sub-populations of bacteria were
reconfirmed by Percoll gradients and found to consist of homogeneous populations of
cells (data not shown).
3.3 EFFECT OF DIFFERENT ENVIRONMENTAL ATMOSPHERES ON
GROWTH OF BACTEROIDES SPECIES
As a precursor to large scale fermentations in the preparation of a LPS library, the
growth of 10 strains ofBacteroides grown hi PPY or VT medium were examined hi
three different environmental atmospheres: 10% C02 and 90% N2; 10% C02 and
90% 100% N2 (Table 1).
Each strain tested grew well in PPY media in all environmental atmospheres. Most
strains grew poorly in VT medium, especially in an atmosphere of 100% N2. From
these results it was decided to use VT medium in one fermenter run and PPY medium
in the remaining fermenter inns for the preparation of the LPS library (see section 3.4
below). The chosen environmental atmosphere was 100% N2 as it does not require a
catalyst and was easy to administer.
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Fig 4: Silver stain profiles of Proteinase K extracts from sub-populations of
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Gel A: Track 1= sample buffer, 2= B. fragilis NCTC 9343 60%, 3= B. fragilis NCTC
9343 80%, 4= B. fragilis MPRL 1504 20%, 5= B. vulgatus MPRL 1726 20%, 6= B.
vulgatus MPRL 1726 40%, 7= B. vulgatus MPRL 1651 20%, 8= B. vulgatus MPRL
1651 40%, 9= B. vulgatus MPRL 1985 20%, 10= B. vulgatus MPRL 1985 40%, 11=
B. caccae MPRL 1555 20%, 12= B. caccae MPRL 1555 40%, 13= B. uniformis
MPRL 1721 20%, 14= B. uniformis MPRL 1721 40%, 15= B. variabilis MPRL 1724
20%, 16= B. variabilis MPRL 1724 40%, 17= B. ovatus MPRL 2370 20%, 18= B.
ovatus MPRL 2370 60%, 19= B. eggerthii MPRL 1668 80%, 20= E. coli 018K~.
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Gel B
1 2 3 4 5 6
Gel B: Track 1= sample buffer, 2= B. thetaiotaomicron MPRL 1720 40%, 3= B.
thetaiotaomicron MPRL 1720 60%, 4= B. thetaiotaomicron MPRL 1720 80%, 5= B.
distasonis MPRL 1667 60%, 6= B. distasonis MPRL 1667 80%.
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Table 1: Growth of 10 Bacteroides species in three different environmental
atmospheres
Species /Strain number Growth Growth in Environmental Atmospheres
Media
10%CO2 90% H2 10%CO2 90% N2 100% N2
B. fragilis PPY +++ +++ +++
MPRL 1504 VT + + +
B. fragilis PPY +++ +++ +++
NCTC 9343 VT ++ ++ +
B. vulgatus PPY +++ +++ +++
MPRL 1985 VT ++ + +
B. thetaiotaomicron PPY +++ +++ +++
MPRL 1720 VT ++ + -
B. caccae PPY +++ +++ +++
MPRL 1555 VT ++ ++ -
B. uniformis PPY +++ +++ +++
MPRL 1721 VT - ++ -
B. ovatus PPY +++ +++ +++
MPRL 1709 VT ++ ++ +
B. eggerthii PPY +++ ++ +++
MPRL 1668 VT + + -
B. variabilis PPY +++ +++ +++
MPRL 1724 VT + + -
B. distasonis PPY +++ + +
MPRL 1667 VT - - -
Where +++ = good growth to + = poor growth, - = no growth, VT=Van Tassell &
Wilkins medium and PPY= Proteose-peptone yeast extract broth.
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3.4 PREPARATION OF LPS LIBRARY
A library of LPS from 8 Bacteroides species and one E. coli 018K" strain (grown
both aerobically and anaerobically) was prepared from large scale fermenter runs and
the LPS extracted by three different methods.
The yield ofnative LPS obtained for each extraction method is shown in Table 2. The
PCP extraction method gave the highest yield of LPS for each organism, with the PW
method giving the lowest yield for most organisms. Those organisms that gave a high
yield of dry cells were very mucoid and generally gave a poorer yield of LPS. Mucoid
organisms were enriched mainly on the 0-20% interface of the Percoll gradients (Fig
5).
The resulting LPSs were analysed by polyacrylamide gels and stained with silver for
LPS (Fig 6 A-C) and with Coomassie blue for protein (Fig 7 A, B). Contaminating
protein was found in Bacteroides LPSs extracted by all three methods, especially
those extracted by the PCP and Triton methods (Fig 7). See chemical analysis section
3.6 for levels ofprotein prior to Proteinase K treatment.
All LPS preparations were then treated with Proteinase K to remove protein
contamination after which no Coomassie blue-staining material was observed in
PAGE. LPS profiles after silver staining were identical to those before Proteinase K
treatment (data not shown). The results in the following sections are from LPSs
which had been treated with Proteinase Kto remove protein contamination.
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Table 2: Details of LPS library
Strain Growth Culture Vol Yield from different extraction
Medium* (litres) methods
PW PCP Triton
B. fragilis VT 16 1 6.87 6.87 6.87
NCTC 9343 2 41.4 227.5 175.6
3 0.60 3.31 2.56
B. fragilis PPY 15 1 2.34 2.39 2.36
NCTC 9343 2 37.4 99.2 47.2
3 1.60 4.42 2.00
B. fragilis PPY 15 1 2.85 2.57 2.50
MPRL 1504 2 63.7 64.5 47.6
3 2.24 2.51 1.91
B. vulgatus PPY 15 1 2.42 2.47 2.44
MPRL 1985 2 90.7 96.9 53.2
3 3.74 3.92 2.18
B. thetaiotaomicron PPY 15 1 3.23 3.67 3.77
MPRL 1720 2 29.8 103.8 83.0
3 0.92 2.83 2.20
B. caccae PPY 15 1 7.40 7.63 7.50
MPRL 1555 2 20.3 98.6 20.7
3 0.27 1.29 0.28
B. uniformis PPY 15 1 6.75 5.21 5.60
MPRL 1721 2 25.8 213.4 57.7
3 0.38 4.24 1.03
B. ovatus PPY 15 1 3.04 3.00 2.97
MPRL 1709 2 54.9 124.0 73.3
3 0.81 4.14 2.47
E. coli 018K~ NB 15 1 7.63
MPRL 1275 Aerobic 2 169.8
3 2.23
E. coli 018K" NB 16 1 1.18
MPRL 1275 Anaerobic 2 47.5
3 4.04
Where 1= dry weight of cells (g), 2= yield of LPS (mg), 3= % Yield.* VT=Van
Tassell &Wilkins' medium, PPY= Proteose-peptone yeast extract broth, NB= nutrient
broth, PW= phenol-water, PCP= phenol-chloroform-petroleum .
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Where faint band, 7777777"thick band and IIIllll clouding.
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Fig 6: Silver stain profile of LPS library
Gel A
1 2 3 4 5 6 7 8 9 10 11 12
Gel A: Track 1= B. fragilis NCTC 9343 VT PW, 2= B. fragilis NCTC 9343 VT
PCP, 3= NCTC 9343 VT Triton, 4- B. fragilis NCTC 9343 PPY PW, 5= B. fragilis
NCTC 9343 PPY PCP, 6= B. fragilis NCTC 9343 PPY Triton, 7= B. fragilis
MPRL 1504 PPY PW, 8= B. fragilis MPRL 1504 PPY PCP, 9= B. fragilis MPRL
1504 PPY Triton, 10= B. vulgatus MPRL 1985 PPY PW, 11= B. vulgatus MPRL
1985 PPY PCP, 12= B. vulgatus MPRL 1985 PPY Triton.
Where VT= Van Tassell & Wilkins' medium, PPY= Proteose peptone yeast extract
broth, NB= nutrient broth, PW= phenol-water, PCP= phenol-chloroform-petroleum,




Gel B: Track 1= B. thetaiotaomicron MPRL 1720 PPY PW, 2= B. thetaiotaomicron
MPRL 1720 PPY PCP, 3= B. thetaiotaomicron MPRL 1720 PPY Triton, 4= B.
caccae MPRL 1555 PPY PW, 5= B. caccae MPRL 1555 PPY PCP, 6= B. caccae
MPRL 1555 PPY Triton, 7= B. uniformis MPRL 1721 PPY PW, 8= B. uniformis
MPRL 1721 PPY PCP, 9= B. uniformis MPRL 1721 PPY Triton, 10= B. ovatus





Gel C: Track 1= E. coli 018K" PW NB grown aerobically, track 2= E. coli 018K"
PW NB grown anaerobically.
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Fig 7: Coomassie blue profile of LPS library prior to Proteinase K treatment
Gel A
1 2 3 4 5 6 7 8 9 10 11 12
Gel A: Track 1= B. fragilis NCTC 9343 VT PW, 2= B. fragilis NCTC 9343 VT
PCP, 3= NCTC 9343 VT Triton, 4= B. fragilis NCTC 9343 PPY PW, 5= B. fragilis
NCTC 9343 PPY PCP, 6= B. fragilis NCTC 9343 PPY Triton, 7= B. fragilis
MPRL 1504 PPY PW, 8= B. fragilis MPRL 1504 PPY PCP, 9= B. fragilis MPRL
1504 PPY Triton, 10= B. vulgatus MPRL 1985 PPY PW, 11= B. vulgatus MPRL
1985 PPY PCP, 12=5. vulgatus MPRL 1985 PPY Triton.
Where VT= Van Tassell & Wilkins' medium, PPY= Proteose peptone yeast extract
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Gel B: Track 1= B. thetaiotaomicron MPRL 1720 PPY PW, 2= B. thetaiotaomicron
MPRL 1720 PPY PCP, 3= B. thetaiotaomicron MPRL 1720 PPY Triton, 4= B.
caccae MPRL 1555 PPY PW, 5= B. caccae MPRL 1555 PPY PCP, 6= B. caccae
MPRL 1555 PPY Triton, 7= B. uniformis MPRL 1721 PPY PW, 8= B. uniformis
MPRL 1721 PPY PCP, 9= B. uniformis MPRL 1721 PPY Triton, 10= B. ovatus
MPRL 1709 PPY PW, 11= B. ovatus MPRL 1709 PPY PCP, 12= B. ovatus MPRL
1709 PPY Triton.
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Fig 6 shows LPS profiles on PAGE for each strain and extraction method after
separation and silver staining. A banding pattern typical of smooth LPS was seen for
E. coli 018K" (gel C, tracks 1 and 2), B. vulgatus MPRL 1985 (gel A, tracks 10, 11
and 12) and B. thetaiotaomicron MPRL 1720 (gel B, tracks 1, 2 and 3). Material of
high molecular mass was seen in B. fragilis species in both the PW and Triton
extraction methods. Rough/low molecular mass material is seen for all species by each
extraction method, and is "dumbbell shaped" for B. caccae and B. ovatus (gel B,
tracks 4, 5 and 6 and 10, 11 and 12). The PCP extraction method produced a
pronounced band (X) present behind the main front band (R) in all preparations. For
B. fragilis the PCP extraction method did not select for high molecular mass material.
Silver stain profiles for sodium salt form LPS were identical to native forms (data not
shown). LPS profiles for E. coli 018K" grown aerobically and anaerobically were also
identical.
3.5 PREPARATION OF CAPSULAR POLYSACCHARIDE FROM Zk
FRAGILIS NCTC 9343
Capsular polysaccharide was prepared from a 4 litre batch of B. fragilis NCTC 9343
which had been grown in PPY medium. Material was fractionated on a Sephacryl (S-
300) column and Fig 8 shows fractionated material visualised by silver staining on
PAGE. High molecular mass material was seen in fractions 32-40 and low molecular
mass material was seen in fractions 50-54. These fractions were pooled, lyophilised
and stored at -20°C until future use.
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Fig 8: Silver stain profile of fractionated B. fragilis NCTC 9343 capsular
polysaccharide preparation
High rawt Low mwt
i
Fraction number 30 32 34 36 38 40 42 44 46 48 50 52 54
Void volume= 200 ml
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3.6 CHEMICAL ANALYSIS OF LPS LIBRARY
3.6.1 Estimation of Carbohydrate, Phosphorus. KDO and Protein content
Samples of dry extract were resuspended in PF-H20 to a concentration of 5 mg/ml
and assayed for carbohydrate, phosphorus, KDO and protein content. The relative
amounts for native LPS samples are shown in Table 3 and for sodium salt LPS
samples in Table 4. Before Proteinase K treatment, for native LPSs, contaminating
protein was found in PCP extracts from undetectable to > 200 pg/mg dry weight. In
all Triton preparations, with the exception of B. vulgatus MPRL 1985 in which none
was detected, protein contamination was in the range 60-500 pg/mg dry weight and
no protein contamination was detectable in the PW extracts. After Proteinase K
treatment no protein contamination was detectable in any sample. Batches of sodium
salt LPS were prepared after protein decontamination.
Bacteroides species showed a negligible amount or no KDO content before treatment
with hydrofluoric acid. Due to sample size KDO measurement was only carried out
on selected native Bacteroides LPSs (Table 3). Generally the PW extraction method
selected for the greatest amount of carbohydrate and KDO material and the PCP
extraction method for the least. Phosphorus levels were more uniform among all
extraction methods and between native and sodium salt-form LPSs. No difference was
observed between LPS extracts fr om E. coli 018K~ grown in different atmospheres.
3.6.2 Estimation of Fatty Acid content
The fatty acids present in native LPSs from E. coli 018K" and selected Bacteroides
species were analysed by gas liquid chromatography (GLC). Those present and their
relative amounts are shown in Table 5. Each Bacteroides LPS contained different and
varying amounts of fatty acids. In B. fragilis NCTC 9343 VT LPS the Triton
extraction method selected for greater amounts of fatty acids and the PW method the
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Table 3: Estimation of carbohydrate, phosphorus, KDO and protein* content in
native LPS samples
LPS Sample Extraction CHO P KDO Protein*
Method Hg/mg dry wt (rg/rng dry wt (rg/mg dry wt |ig/ml dry wt
B. fragilis PW 415.8 16.4 7.8 -
NCTC 9393 PCP 614.4 33.1 0.8 68.66
VT Triton 229.2 29.3 3.5 477.61
B. fragilis PW 172.2 39.2 3.8 -
NCTC 9343 PCP 90.8 33.6 1.4 59.7
PPY Triton 147.8 49.0 2.1 113.43
B. Jragilis PW 198.2 55.3 6.2 -
MPRL 1504 PCP 120.8 72.4 0.5 -
PPY Triton 130.0 28.5 3.7 447.76
B. vulgatus PW 267.6 78.9 2.7 -
MPRL 1985 PCP 67.4 47.4 0.9 -
PPY Triton 197.2 37.8 2.6 -
B. thetaiotaomicron PW 363.8 54.2 • •• -
MPRL 1720 PCP 43.8 47.4 0.4 179.10
PPY Triton 262.4 79.6 4.0 226.87
B. caccae PW 240.2 54.3 ... -
MPRL 1555 PCP 29.6 33.8 ... 220.9
PPY Triton 148.6 24.9 ... 226.87
B. uniformis PW 221.6 102.0 ... -
MPRL 1721 PCP 53.0 38.2 ... -
PPY Triton 173.4 85.5 ... 113.43
B. ovatus PW 281.0 43.1 5.7 -
MPRL 1709 PCP 110.8 39.6 1.1 -
PPY Triton 178.0 41.6 2.4 268.66
E. coli 018K" PW 254.8 36.5 2.2 -
NB aerobic
E. coli 018K" PW 260.0 34.0 2.4 -
NB anaerobic
Where PW= phenol-water, PCP= phenol-chloroform-petroleum, VT= Van Tassell &
Wilkins' medium, PPY= Proteose peptone yeast extract broth, NB= nutrient broth,
CHO= carbohydrate, P= phosphorus, ... = not done, - = amount not detectable, *=
protein content prior to Proteinase K treatment.
All assays were repeated on at least two occasions and the results presented are the
mean of two experiments. All samples were tested in duplicates for each experiment.
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Table 4: Estimation of carbohydrate and phosphorus content in sodium salt
LPS samples
LPS Sample Extraction CHO P
Method Hg/mg dry wt Hg/mg dry wt
B. Jragilis PW 474.8 18.23
NCTC 9393 PCP 19 31.13
VT Triton 209.4 26.29
B. Jragilis PW 307.2 50.65
NCTC 9343 PCP 30.2 28.87
PPY Triton 175 29.03
B. fragHis PW 235.8 34.65
MPRL 1504 PCP 45.6 32.26
PPY Triton 146.2 34.23
B. vulgatus PW 375.6 76.13
MPRL 1985 PCP 39.4 40.65
PPY Triton 281.4 42.90
B. thetaiotaomicron PW 397.2 51.94
MPRL 1720 PCP 8.0 40.16
PPY Triton 1.38 43.23
B. caccae PW 298.0 52.90
MPRL 1555 PCP 28.6 40.32
PPY Triton 132.0 37.65
B. uniform is PW 234.4 69.03
MPRL 1721 PCP 42.0 38.71
PPY Triton 146.2 46.29
B. ovatus PW 242.0 45.81
MPRL 1709 PCP 85.6 23.84
PPY Triton 210.6 43.23
E. coli 018K" PW 592.4 42.42
NB aerobic
E. coli Ol 8K" PW 589.6 42.26
NB anaerobic
Where PW= phenol-water, PCP= phenol-chloroform-petroleum, VT= Van Tassell &
Wilkins' medium, PPY= Proteose peptone yeast extract broth, NB= nutrient broth,
CHO= carbohydrate, P= phosphorus,... = not done.
All assays were repeated on at least two occasions and the results presented are the
mean of two experiments. All samples were tested in duplicates for each
experiment.
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Where 1= B. fragilis NCTC 9343 VT PW-LPS
2= B. fragilis NCTC 9343 VT PCP-LPS
3= B. fragilis NCTC 9343 VT Triton-LPS
4= B. fragilis NCTC 9343 PPY PW-LPS
5= B. caccae MPRL 1555 PPY PW-LPS
6= B. thetaiotaomicron MPRL 1720 PPY PW-LPS
7= B. vulgatus MPRL 1985 PPY PW-LPS




See Table 3 for other abbreviations.
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least. The Bacteroides LPSs predominately contained larger amounts of
Iso-pentadecanoic, pentadecanoic and dodecanoic fatty acids. Small trace amounts of
3-hydroxytetradecanoic acid, the predominant fatty acid in E. coli 018K" LPS was
found in B.fragilis NCTC 9343 PPY PW-LPS and B. caccae MPRL 1555 PW-LPS.
3.7 CHEMICAL ANALYSIS OF CAPSULE PREPARATION FROM
FRAGIIBS NCTC 9343
Samples of dry high molecular mass and low molecular mass material were
resuspended to 5 mg/ml and assayed for carbohydrate, phosphorus, KDO and protein
content. The relative amounts of each are shown in Table 6. No protein contamination
was found in either the high or low molecular mass material. The low molecular
mass material contained more carbohydrate and phosphorus; and only the low
molecular mass material contained detectable KDO.
Table 6: Estimation of carbohydrate, phosphorus, KDO and protein in capsular











101.4 2.07 - -
Low molecular mass
material
146.34 36.12 6.88 -
Where - = non-detectable. See Table 3 for other abbreviations.
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3.8 LPS INDUCED MOUSE LETHALITY (GALACTOSAMINE MODEL)
E. coli 018K" LPS was lethal for all mice at 50 ng/mouse (Table 7) whereas B.
fragilis NCTC 9343 VT PW-LPS and B. vulgatus MPRL 1985 PW-LPS were only
lethal to mice at 20 jag/mouse. No difference in lethality was seen for native and
sodium salt-form B. fragilis NCTC 9343 VT PW-LPS. Mice were not killed by the
maximum dose of B. fragilis LPS extracted by the Triton or PCP method, nor by B.
uniformis and B. ovatus LPS extracted by the PW method.
Table 7: LPS induced mouse lethality (D-gal N Model)
LPS Sample Survivors after dose of LPS of
5 ng 50 ng 5 pg 10 pg 20 pg
B. fragilis NCTC 9343 VT PW 3/3 1/3 0/3
B. fragilis NCTC 9343 PPY PW 3/3 2/3 1/3
B. fragilis MPRL 1504 PW 3/3 3/3 2/3
B. vulgatus MPRL 1985 PW 3/3 3/3 0/3
B. thetaiotaomicron MPRL 1720 PW 3/3 3/3 1/3
B. caccae MPRL 1555 PW 3/3 3/3 1/3
B. uniformis MPRL 1721 PW 3/3 3/3 3/3
B. ovatus MPRL 1709 PW 3/3 3/3 3/3
B. fragilis NCTC 9343 PPY PCP 3/3 3/3 3/3
B. fragilis NCTC 9343 PPY Triton 3/3 3/3 3/3
*B. fragilis NCTC 9343 PPY PW 3/3 2/3 0/3
*B. fragilis NCTC 9343 PPY PCP 3/3 3/3 3/3
*B. fragilis NCTC 9343 PPY Triton 3/3 3/3 3/3
E. coli 018K aerobic PW 3/3 0/3 0/3 • •• • ••
E. coli 018K anaerobic PW 3/3 0/3 0/3 • •• ...
All LPS are native samples unless indicated. *sodium salt-form LPS, see Table 3 for
other abbreviations.
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3.9 REACTIVITY OF LPS SAMPLES IN LAL ASSAY
3.9.1 Reactivity of Native Bacteroides LPSs Before and After Protein
Decontamination
Endotoxic activities in the LAL assay of native Bacteroides LPSs before and after
protein decontamination are illustrated in Table 8. In the vast majority of cases the
activity of LPS samples increased after protein decontamination. On a weight for
weight basis, the greatest activity was seen in the PW extracts and the least activity in
PCP extracts. The differences in reactivity between protein-decontaminated
Bacteroides LPSs and E. coli 018K" LPS are discussed more fully in section 3.9.2
below.
3.9.2 Reactivity of Native vs Sodium Salt-Form LPS Extracted by Three
Different Methods
Endotoxic activities in the LAL assay of native and sodium salt form LPS are
illustrated in Table 9 (i), (ii) and (iii) for each extraction method. On a weight for
weight basis, the greatest activity was seen in the PW extracts and the least activity
seen in the PCP extracts. All native PW-LPSs were more active than sodium salt PW-
LPSs. Approximately 70% of native PCP-LPSs were more active than sodium salt
PCP-LPSs. No significant difference between native and sodium salt-form Triton
LPSs was seen. Aerobically grown E. coli 018K" LPS was more active than
anaerobically grown E. coli 018K" LPS by a factor of two. Comparing PW LPSs, B.
fragilis MPRL 1504 PW-LPS was more active than E. coli 018K" LPS by a factor of
30, B. fragilis NCTC 9343 VT PW-LPS by a factor of 10, B. fragilis NCTC 9343
PPY PW-LPS by a factor of five and B. caccae MPRL 1555 PW-LPS by a factor of
four. All other Bacteroides species were less active than E. coli 018K". A difference
in activity for B. fragilis NCTC 9343 LPS grown in different media was also seen.
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Table 8: Endotoxic activities in LAL (IU/ml) of native Bacteroides LPSs (5
ng/ml) before and after protein decontamination
LAL activity (IU/ml)
Sample Growth Extraction Before protein After protein
Medium Method decontamination decontamination
B. fragilis VT PW 426.3 617.4
NCTC 9343 PCP 0 0.449
Triton 236.2 480.4
B. fragilis PPY PW 192.72 227.8
NCTC 9343 PCP 0.012 0.608
Triton 58.33 71.75
B. fragilis PPY PW 729.56 1863
MPRL 1504 PCP 0 0.90
Triton 510.11 704
B. vulgatus PPY PW 8.44 15.59
MPRL 1985 PCP 0 0.34
Triton 9.96 11.05
B. thetaiotaomicron PPY PW 3.18 4.11
MPRL 1720 PCP 0 0.80
Triton 15.67 17.38
B. caccae PPY PW 181.04 234.9
MPRL 1555 PCP 0 0.08
Triton 51.26 50.64
B. uniformis PPY PW 10.40 13.72
MPRL 1721 PCP 2.63 20.74
Triton 41.11 42.33
B. ovatus PPY PW 3.85 4.27
MPRL 1709 PCP 0 0.56
Triton 39.90 46.33
All assays were repeated on at least two occasions and the results presented are the
mean of two experiments. All samples were tested in duplicate for all assays. See
Table 3 for other abbreviations.
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LPS Sample Sodium salt form Native form
B. fragilis NCTC 9343 VT 75.4 617.4
B. fragilis NCTC 9343 PPY 48.7 227.8
B. fragilis MPRL 1504 136.2 1863.0
B. vulgatus MPRL 1985 3.3 15.6
B. thetaiotaomicron MPRL 1720 1.0 4.1
B. caccae MPRL 1555 67.4 234.9
B. uniformis MPRL 1721 0.9 13.7
B. ovaIus MPRL 1709 12.5 4.3
E. coli 018K aerobically grown PW 6.8 62.2
E. coli 018K anaerobically grown PW 2.2 31.7
(ii) PCP Extracts
LAL activity (IU/ml)
LPS Sample Sodium salt form Native form
B. fragilis NCTC 9343 VT 1.1 0.5
B. fragilis NCTC 9343 PPY 4.9 0.6
B. fragilis MPRL 1504 0.8 0.9
B. vitlgahts MPRL 1985 4.2 0.4
B. thetaiotaomicron MPRL 1720 0.2 0.8
B. caccae MPRL 1555 0.2 0.1
B. uniformis MPRL 1721 7.9 20.7
B. ovatus MPRL 1709 0.1 0.6
E. coli 018K aerobically grown PW 10.4 45.4
E. coli 018K anaerobically grown PW 6.0 23.9
(iii) Triton Extracts
LAL activity (IU/ml)
LPS Sample Sodium salt form Native form
B. fragilis NCTC 9343 VT 226.2 480.4
B. fragilis NCTC 9343 PPY 455.7 71.7
B. fragilis MPRL 1504 1020.0 704.0
B. vulgatus MPRL 1985 34.6 11.1
B. thetaiotaomicron MPRL 1720 63.5 17.4
B. caccae MPRL 1555 6.0 50.6
B. uniformis MPRL 1721 22.2 42.3
B. ovatus MPRL 1709 124.4 46.3
E. coli 018K aerobically grown PW 9.2 83.6
E. coli 018K anaerobically grown PW 8.8 42.3
All assays were repeated on at least two occasions and the results presented are the
mean of two experiments. All samples were tested in duplicate for all assays. The
above results refer to LPSs which had been protein decontaminated. See Table 3 for
other abbreviations.
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3.10 LPS-EVDUCED TNF SECRETION
3.10.1 Inter- and Intra-Assav Variation
A degree of inter-assay variation in the TNF was unavoidable due to variations
between individual blood donors (this ranged from 5% to 45%, data not shown) and
between cell cultures produced on different occasions. Where the results have not
been analysed statistically, the results presented are the mean of two experiments
performed with the same cell preparations on the same day. All assays were repeated
on at least two occasions with cell supernates derived from different stimulation
experiments. All results presented depict trends which have been confirmed on at least
two occasions. Due to the heterogeneity in molecular mass of the E. coli LPS (ladder
pattern) and the complexity of the appearance on SDS-PAGE (Fig 6) and unknown
chemical structure and molecular composition of the Bacteroides LPS complex, the
following results are compared on a weight for weight basis, rather than a molar basis.
3.10.2 TNF Production by Protein-Contaminated and -Decontaminated LPSs
The effect of protein contamination of native Bacteroides PW-LPSs on TNF
production was examined in human mononuclear leukocytes (MNL) (Table 10). In all
cases the amount of TNF produced increased after protein decontamination. Trends
between species remained the same. B. fragilis NCTC 9343 VT PW-LPS induced the
most TNF and B. vulgatus MPRL 1985 the least. The differences between the
amount of TNF induced by different LPSs is discussed more fully in section 3.10.5.
The following results in section 3.10 are obtained from protein decontaminated
samples only.
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3.10.3 Effect of Different Sera and Different Experimental Volumes on TNF
Production
The effect of different sera in the culture medium on TNF production was examined
in human MNL after stimulation with various LPSs (Table 11). The amount of TNF
produced by all LPSs tested did not alter when FCS was replaced with human serum.
The amount of TNF produced by all Bacteroides LPSs was not affected by the lack
of serum in the culture medium, however the amount of TNF produced by E. coli
018K" LPS was approximately halved when serum was absent from the culture
medium.
The effect of different experimental volumes on TNF production was examined in
human MNL after stimulation with various LPSs (Table 12). Tire largest amount of
TNF was produced when the experiment was conducted in the wells of 96 well
microtitre plates which had an experimental volume size of 200 pi. The amount of
TNF produced decreased as the experimental volume size increased. All experiments
in results conducted in 96 well plates unless otherwise indicated.
3.10.4 Effect of Amount of LPS on TNF Production
The effect of varying ng amounts of native PW-LPS on TNF production was
examined for E. coli 018K" and B. fragilis NCTC 9343 (Fig 9). In all cell populations
tested, more TNF was produced as LPS levels increased. For human MNL (Fig 9 a)
E. coli 018K" LPS produced more TNF than B. fragilis NCTC 9343 LPS for all
amounts tested. No difference in TNF production by B. fragilis NCTC 9343 LPS was
seen for THP-1 cells with and without enhancement for CD 14 (Fig 9 b). The level of
TNF production by E. coli 018K" LPS in THP-1 cells without enhancement for
CD 14 was comparable to that produced by B. fragilis NCTC 9343 LPS. However,
the level of TNF production by E. coli 018K" LPS was greatly increased in THP-1
cells with enhancement for CD 14 compared to B. fragilis NCTC 9343. No major
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Table 10: Measured TNF concentration (IU/ml) from human MNL after
stimulation for 4 h with native PW-LPS (50 ng/ml) from Bacteroides species
before and after protein decontamination
LPS TNF concentration IU/ml TNF concentration IU/ml
+ protein contamination - protein contamination
B. fragilis NCTC 9343 VT 19.15 23.16
B. fragilis NCTC 9343 17.7 18.82
B. fragilis MPRL 1504 3.99 4.93
B. vulgatus MPRL 1985 2.41 2.58
B. thetaiotaomicron MPRL 1720 5.88 6.4
B. caccae MPRL 1555 11.27 13.89
B. uniformis MPRL 1721 9.832 10.1
B. ovatus MPRL 1709 6.21 8.66
Table 11: Measured TNF concentration (ITJ/ml) from human MNL after
stimulation for 4 h with various native PW-LPSs (50 ng/ml) from Bacteroides








B. fragilis NCTC 9343 48.97 42.66 45.92
B. vulgatus MPRL 1985 9.26 10.18 11.54
B. thetaiotaomicron MPRL 1720 7.28 9.23 8.77
B. caccae MPRL 1555 29.04 27.78 26.10
E. coli 018K" 48.97 101.01 104.19
Each value in Tables 10 and 11 are the mean of duplicate experiments performed with
the same cell preparations.
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Table 12: Measured TNF concentration (IU/ml) from human MNL after
stimulation for 4 h with various native PW-LPSs (50 ng/ml) from Bacteroides
species and E. coli 018K" in different experimental volumes*
TNF concentration (IU/ml)
LPS 96 well plate 24 well plate tube
(200 pi)* (1 ml)* (2 ml)*
B. fragilis NCTC 9343 27.88 15.04 14.87
B. vulgatus MPRL 1985 4.98 2.86 0
B. thetaiotaomicron MPRL 1720 4.55 2.83 1.32
B. caccae MPRL 1555 14.74 8.78 7.87
E. coli 018K" 103.04 83.27 78.75
Each value is the mean of duplicate experiments performed with the same cell
preparation.
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Fig 9: TNF production (IU/ml) after 4 h by: a) human MNL, b) THP-1 cells
with (—) and without (—) enhancement for CD14, and c) peritoneal
macrophages from C3H/HeJ (—) and C3H/HeN (—) mice after stimulation
with native PW-LPS from E. coli 018K" (•) and B. fragilis NCTC 9343 (A).
Each point is the mean of duplicate experiments performed with the same cell





difference in TNF production by B. fragilis NCTC 9343 LPS was seen between
peritoneal macrophages from C3H/HeJ (LPS non-responder) and C3H/HeN (LPS
responder) mice (Fig 9 c), but consistently there was slightly more TNF produced by
the C3H/HeN cells. Note the different scales of the y axes. There was no TNF
production observed in C3H/HeJ peritoneal macrophages stimulated by E. coli 018K~
LPS. However, in peritoneal macrophages from C3H/HeN mice, the level of TNF
production was greatly increased after stimulation by E. coli Ol 8K~ LPS. The amount
of TNF produced by peritoneal macrophages after stimulation by all LPSs tested was
considerably lower than that produced by the other cell populations.
3.10.5 TNF Production by Bacteroides LPSs Extracted by Three Different
Methods
Based on the data from Fig 9, a LPS concentration of 50 ng/ml was selected to
compare a larger panel of LPSs from other Bacteroides species and enterobacteria
(Table 13). This value was chosen as it was in the middle of the linear part ofboth the
dose response curve and the standard curve of the assay system employed. This would
not show the maximum induction capacity of the LPSs but was a compromise for
comparing a large number of LPS samples. It is recognised that this level of LPS is
high and may not reflect the situation in vivo in the bloodstream but may mimic the
situation in abscesses where the local concentration of LPS is presumed to be higher.
E. coli 018K" stimulated the most TNF production with no difference hi TNF
production between E. coli 018K" LPS grown aerobically or anaerobically. On a
weight for weight basis, PW-LPS stimulated the greatest TNF production. Comparing
PW-LPS, Bacteroides LPS induced TNF on a magnitude much less than E. coli
018K", with the most active (B. fragilis NCTC 9343 VT) being four times less active
than E. coli 018K" and the least active (B. vulgatus MPRL 1985) being 37 times less
active than E. coli 018K". TNF production of other enterobacterial LPSs tested was
of the same level or less than E. coli 018K", all being more active than Bacteroides
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Table 13: Measured TNF concentration (IU/ml) from human MNL after 4 h
stimulation with native and sodium salt-form LPS (50 ng/ml) from E. coli





Native LPS Sodium Salt LPS
B. fragilis NCTC 9343 VT PW 23.16 11.92
PCP 0.30 0.71
Triton 2.99 1.07
B. fragilis NCTC 9343 PPY PW 18.81 4.60
PCP 2.53 1.78
Triton 0.51 0.31
B. fragilis MPRL 1504 PW 4.93 2.51
PCP 0.42 0.25
Triton 0.99 0.47
B. vulgatus MPRL 1985 PW 2.58 0.72
PCP 0.15 0.51
Triton 0.39 0.31
B. thetaiotaomicron MPRL 1720 PW 6.40 6.47
PCP 0.03 0.43
Triton 0.17 0.49
B. caccae MPRL 1555 PW 13.89 15.25
PCP 0.22 0.74
Triton 2.48 2.44
B. uniformis MPRL 1721 PW 10.10 35.34
PCP 4.81 4.81
Triton 10.87 5.09
B. ova/wsMPRL 1709 PW 8.66 13.89
PCP 1.44 5.37
Triton 1.25 2.32
E. coli Ol 8 K aerobically grown PW 94.61 43.21
E. coli 018K anaerobically grown PW 99.00 43.21
E. coli 06 PW 59.00 • ••
E. coli 012 PW 58.20 • ••
E. coli 015 PW 68.96 ...
K. pneumoniaeMl OB PW 48.21 ...
E. coli J5 PCP 36.63 • ••
E. coli K12 PCP 49.90 ...
S. minnesota Ra PCP 31.68 ...
S. minnesota Rb PCP 96.70 ...
S. minnesota Rc PCP 49.90 ...
S. minnesota Rd PCP 78.45 ...
S. minnesota Re PCP 50.48 ...
All assays were carried out on at least two occasions and the results presented are the
mean of two experiments. All samples were tested in duplicate for each assay. See
Table 3 for other abbreviations.
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LPS. Sodium salt-form E. coli 018K" LPS had half the activity of native form E.
coli 018K" LPS. Generally for Bacteroides LPS there is no clear distinction in
activity between native and sodium salt-form LPS.
3.10.6 Time course of TNF Production
Levels of TNF production by human MNL were measured at hourly intervals after
stimulation with LPS (50 ng/ml) from E. coli 018K" and B. fragilis NCTC 9343 (Fig
10 a). The response produced by the E. coli LPS showed a complex periodic rise and
fall with major peaks at between three and five hours and eight hours. The B. fragilis
NCTC 9343 LPS showed one major peak between three and six hours with a minor
rise at eight hours. This type of response for E. coli 018K" LPS has been seen by
other workers in other laboratories (Gardiner et al 1991 and Dr Isla Halliday, Queen's
University of Belfast, personal communication) and a second peak at eight hours has
been a consistent finding and has been reproduced on numerous occasions in our
laboratories by several different workers. To confirm the periodicity of the TNF
response to E. coli 018K" LPS the experiment was repeated on four occasions with
MNLs from different donors, sampling at two-hourly intervals until eight hours and
then at 20 hours (Fig 10 b, c). All the mean TNF values in IU/ml from duplicate
estimations were normalised to the value for E. coli 018K" LPS at 4 h which was
given the arbitrary value of 100%. Statistical analysis by the students t test for paired
means showed that the differences between peaks and troughs for the response to E.
coli 018K" LPS were highly significant: between 2 h and 4 h p=0.0027, between 4 h
and 6 h p=0.0032 and between 6 h and 8 h p=0.0312 where p< 0.05 is significant.
TNF induction by LPSs from other Bacteroides species and E. coli Ol 8K~ were also
followed by sampling at two hourly intervals in other cell populations (Fig 11 a-d).
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Fig 10: Time course of TNF production after stimulation of human MNL with
LPS (50 ng/ml) from E. coli 018K" (•) or B. fragilis NCTC 9343 (A), a)
Samples taken hourly over 24 h from a single experiment where TNF values in
HJ/ml are the means of duplicate TNF estimations (vertical bars indicate the
difference between duplicate estimations), b) and c) Results from four separate
experiments performed on different occasions with different cell preparations.
Each point is the mean of two TNF estimations and all values have been
normalised relative to the 4 h value for E. coli LPS which has been defined as
100%.
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Fig 11: Time course of TNF production (IU/ml) by: a) THP-1 cells without
enhancement for CD14, b) THP-1 cells with enhancement for CD14, c)
peritoneal macrophages from C3H/HeJ mice and d) peritoneal macrophages
from C3H/HeN mice after stimulation with LPS (50 ng/ml) from E. coli
018K" (•), B. fragilis NCTC 9343 (A), B. caccae MPRL 1555 (♦), B. uniformis
MPRL 1721 (■), and B. vulgatus MPRL 1985 ( I ). Each point is the mean of
duplicate experiments performed with the same cell preparations. Note different
scales on y axes.
Time (h) Timc (h)
Time (h) Time (h)
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For THP-1 cells without enhancement for CD 14, only one peak of TNF was
stimulated at 4 h for all LPSs tested. LPSs from E. coli 018K" and B. uniformis
MPRL 1721 were the most active and LPS from B. vulgatus being the least active
(Fig 11 a), hi THP-1 cells with enhancement for CD 14 a peak of TNF production was
seen at 4 h for all LPSs tested. However, a second peak of TNF production, larger
than the first was seen at 8 h for E. coli 018K" only. LPS from E. coli 018K" was
approximately three- to five-fold more active than the most active Bacteroides LPS
(Fig 11 b). In peritoneal macrophages from both C3H/HeJ (LPS non-responder) and
C3H/HeN (LPS responder) mice a peak of TNF production was seen at 4 h for the
LPSs tested (Fig 11c, d), with the exception of is. coli 018K" in C3H/HeJ peritoneal
macrophages where no TNF was produced. In peritoneal macrophages from
C3H/HeN mice, E. coli 018K" LPS was only 2-fold more active than B. fragilis
NCTC 9343 LPS. The difference in activity between B. fragilis NCTC 9343 and B.
vulgatus MPRL 1985 LPS was not as marked as previously seen. In most cell
populations the amount of TNF production fell to zero more quickly for Bacteroides
LPS than E. coli 018K" LPS. B. fragilis NCTC 9343 LPS which had been extracted
by the PCP and Triton methods also produced a single peak of TNF at 4 h from
human MNL but on a magnitude much less than that seen for the PW-LPS (data not
shown).
3.10.7 Effect of TNF Production by E. coli Q18K"LPS With B. frasilis NCTC
9343 LPS Present in Excess
When LPS from B. fragilis NCTC 9343 was in excess of a constant amount of E.
coli 018K" LPS (40 ng/ml) in human MNL and THP-1 cells with and without
enhancement for CD 14, TNF production was comparable to that of B. fragilis NCTC
9343 LPS alone and not that ofE. coli 018K" alone (Fig 12 a, b, c). There appeared
to be a lowering and masking effect of TNF production from E. coli 018K" LPS
when LPS from B. fragilis NCTC 9343 was present in excess. This trend was also
120
Fig 12: TNF production (IU/ml) after 4 h by a) human MNL b) THP-1 cells
without enhancement for CD14, c) THP-1 cells with enhancement for CD14, d)
peritoneal macrophages from C3H/HeJ mice and e) peritoneal macrophages
from C3H/HeN mice after stimulation with varying amounts of LPS from B.
fragilis NCTC 9343 (A), varying amounts of B. fragilis NCTC 9343 LPS
together with a constant amount of E. coli 018K" (40 ng/ml) (A). Maximum
amount of TNF produced by E. coli 018K" alone shown by (—). Each point is
the mean of duplicate experiments performed with the same cell preparations.
Note different scales on y axes.
B. fragilis NCTC 9343 LPS cone ng/ml
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seen for B. vulgatus MPRL 1985 and B. caccae MPRL 1555 PW-LPS (data not
shown). A masking effect was still observed for B. fragilis NCTC 9343 LPS which
had been extracted by the PCP and Triton methods. In this case TNF production was
approximately half the normal level of that induced by E. coli 018K" LPS (not
comparable to B. fragilis NCTC 9343 LPS alone) when B. fragilis NCTC 9343 LPS
was in excess. For peritoneal macrophages from C3H/HeJ mice TNF production for
B. fragilis NCTC 9343 LPS alone and B. fragilis NCTC 9343 LPS together with E.
coli 018K" LPS were identical: E. coli 018K" LPS alone does not cause TNF
stimulation (Fig 12 d). The trend seen in the other cell populations was not clear for
peritoneal macrophages from C3H/HeN mice as the amount of TNF produced by E.
coli 018K" LPS alone is lower than that of the highest concentration of B. fragilis
NCTC 9343 LPS (Fig 12 e).
3.10.8 Time course of TNF Production by E. coli Q18K" LPS With B. frasilis
NCTC 9343 LPS Present in Excess
When LPS from B. fragilis NCTC 9343 was present in excess of a constant amount
of E. coli 018K" LPS (40 ng/ml) in human MNL and THP-1 cells with enhancement
for CD 14, TNF production was greatly reduced and produced only one peak of TNF
at 4 h (Fig 13 a, c). The second peak of TNF production at 8 h returned as the
amount of B. fragilis NCTC 9343 LPS present with E. coli 018K" LPS decreased
until it is was no longer present in excess. There was no effect on the kinetics of TNF
production when LPS from B. fragilis NCTC 9343 was present in excess of a
constant amount of E. coli 018K" LPS (40 ng/ml) in THP-1 cells without
enhancement for CD 14 (Fig 13 b). In this cell population TNF production was greatly
reduced when B. fragilis NCTC 9343 LPS was present in excess and a peak of TNF
at 4 h was observed hi all cases.
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Fig 13: Time course of TNF production (IU/ml) by a) human MNL, b) THP-1
cells without enhancement for CD14 and c) THP-1 cells with enhancement for
CD14 after stimulation with 10 ng/ml (I), 20 ng/ml (■), 40 ng/ml (♦), 80 ng/ml
(•) and 160 ng/ml (A) of LPS from B. fragilis NCTC 9343 together with a
constant amount of E. coli 018K" (40 ng/ml). TNF produced by E. coli 018K"
alone shown by (X). Each point is the mean of duplicate experiments performed
with the same cell preparations. Note different scales on y axes.
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3.10.9 TNF Production by E. coli Q18K' LPS With B. fraeilis NCTC 9343 LPS
Present in Excess at Various Time Intervals
The effect of delaying the addition of an excess amount of B. fragilis NCTC 9343
LPS (160 ng/ml) to E. coli 018K" LPS (40 ng/ml) in stimulating TNF production
after 4 h from human MNL and THP-1 cell populations was examined (Table 14).
TNF production was most greatly reduced in all cell populations when an excess ofB.
fragilis NCTC 9343 LPS was added at the same time as E. coli 018K" LPS. A
masking effect was still observed in all cell populations but slightly reduced when B.
fragilis NCTC 9343 LPS was added 2-3 h after the addition of E. coli 018K" LPS
to cell populations.
3.10.10 Inhibition of TNF Production by an Anti-CD14 mAb
The effect of a CD 14 mAb in inhibiting TNF production was examined. In all cell
populations tested, the presence of a CD 14 mAb did not affect the production of TNF
stimulated by B. fragilis NCTC 9343 LPS (Fig 14). However, the production of TNF
stimulated by E. coli 018K" was inhibited as the concentration of CD 14 mAb
increased. This inhibition of TNT production was more marked in human MNL and
THP-1 cells with enhancement for CD 14 (Fig 14 a, c). A small amount of
background TNF was produced by the CD 14 mAb alone.
3.10.11 Time course of TNF Production After Inhibition by an Anti-CD14 mAb
In the presence of high levels of anti-CD14 mAb, the 8 h peak of TNF production
after stimulation with E. coli 018K" LPS seen in human MNL and THP-1 cells with
enhancement for CD 14 was absent (Fig 15 a, c). The 4 h peak of TNF after
stimulation with E. coli 018K" LPS was greatly diminished at high levels of anti-
CD 14 mAb for both the human MNL and THP-1 cells with enhancement for CD14.
Statistical analysis by a one sided students t test showed that the difference between
the response of TNF at 4 h by E. coli at low and high levels of anti-CD 14 mAb was
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Table 14: TNF production (lU/ml) after 4 h from human MNL and THP-1 cells
with and without enhancement for CD14 after stimulation by E. coli 018K"
LPS (40 ng/ml), with B. fragilis NCTC 9343 LPS (160 ng/ml) present in excess
at various time intervals. Each value is the mean of duplicate experiments
performed with the same cell preparations.
TNF production (IU/ml)
Time (h) after start of Human THP-1 cells THP-1 cells
experiment in which MNL with without
B. fragilis NCTC 9343 LPS enhancement for enhancement for
added to E. coli 018K" LPS CD14 CD 14
0 52.98 75.65 89.3
1 51.48 46.21 91.55
2 62.42 85.95 108.21
3 87.63 90.21 120.39
E. coli 018K" alone 140.66 102.7 170.02
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Fig 14: Inhibition of TNF production after 4 h by a CD14 mAb from a) human
mononuclear leukocytes, b) THP-1 cells without enhancement for CD14 and c)
THP-1 cells with enhancement for CD14 after stimulation with LPS (50 ng/ml)
from E. coli 018K" ( • ), B. fragilis NCTC 9343 ( ▲ ) and CD14 monoclonal
antibody alone (—). Each point is the mean of duplicate experiments performed
with the same cell preparations. Note different scales on y axes.
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Fig 15: Time course of TNF (IU/ml) production after inhibition by (•) 75 pg/ml,
(♦) 2.34 pg/ml and (A) no anti-CD14 mAb following stimulation of a) human
MNL, b) THP-1 cells without enhancement for CD14 and c) THP-1 cells with
enhancement for CD14 with E. coli 018 K~ (—) LPS and B. fragilis NCTC
9343 (—) LPS (50 ng/ml). Each point is the mean of duplicate experiments













significant for MNL where p=0.021. The same results analysed by the Mann Whitney
test to compare medians also showed that the reduction in TNF for MNL was
significant with p=0.04, where p<0.05 is significant. Results for the THP-1 cells with
enhancement for CD14 were approaching significance where p=0.054 with the
student t test and p=0.095 with the MannWhitney test. The CD 14 mAb had no effect
on the kinetics ofBacteroides LPS induced TNF release in all cell populations or on
the kinetics ofTNF release in THP-1 cells without enhancement for CD14 (Fig 15 b).
3.10.12 Inhibition of TNF Production by Anti-Bacteroides mAbs
The effect of mti-Bacteroides rnAbs hi inhibiting TNF production was examined. In
all cell populations, the presence of mAb 6g3 did not effect the production of TNF
stimulated by any of the LPSs tested (Table 15). The mAb 4CS only slightly inhibited
the production of TNF by E. coli 018K" LPS in human MNL but not in other cell
populations. In all cell populations the presence of 3C8 inhibited the production of
TNF stimulated by B. fragilis NCTC 9343 and B. caccae MPRL 1555 LPS but not
that of E. coli 018K" LPS. The presence of 5A12, 3D7 and 1A4 inhibited the
production of TNF stimulated by E. coli 018K" and B. fragilis NCTC 9343 LPS.
The presence 5A12 caused the most marked inhibition of TNF production stimulated
by B. fragilis NCTC 9343 LPS. There was low level background stimulation of TNF
for each mAb. Inhibition of TNF production stimulated by B. vulgatus MPRL 1985
LPS was not seen due the low amount of TNF produced by this LPS and the
background level of TNF produced by the mAbs alone.
3.10.13 Effect of TNF Production by E. coli Q18K- LPS with B. frasilis NCTC
9343 LPS Present in Excess Together With an Anti-Bacteroides mAb
In the absence of an anti-Bacteroides mAb, there was a lowering and masking effect
of TNF production from E. coli 018K" LPS when B. fragilis NCTC 9343 LPS was
present in excess (Fig 16 b) as previously seen in Fig 12. In the presence of a 1:20
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Table 15: Inhibition of TNF production (IU/ml) after 4 h by a 1:20 dilution of
anti-Bacteroides mAbs from human MNL, THP-1 cells with and without
enhancement for CD14 after stimulation with LPS (50 ng/ml) from E. coli
018K", B. fragilis NCTC 9343, B. caccae MPRL 1555 and B. vulgatus MPRL
1985. Each value is the mean of duplicate experiments performed with the same
cell population.
TNF induced by mAb at 1:20 dilution
Sample Cell
population no mAb 5A12 1A4 4CS 3D7 6G3 3C8
E. coli 018K" MNL 87.76 41.59 44.10 61.78 50.36 84.21 87.52
THP-1 - 86.3 73.21 70.27 80.13 77.31 82.47 82.73
THP-1 + 187.5 161.0 160.32 170.01 151.5 187.32 186.3
B. fragilis MNL 37.63 10.46 10.36 35.21 10.15 34.65 18.47
NCTC 9343 THP-1 - 52.58 23.13 33.37 49.08 30.94 52.0 41.06
THP-1 + 50.61 25.93 40.84 48.92 32.85 50.06 39.74
B. caccae MNL 24.94 20.85 23.92 18.85 16.69 18.57 16.70
MPRL 1555 THP-1 - 30.52 • •• ... ... ... ... 22.77
THP-1 + 26.87 ... ... ... ... ... 18.77
B. vulgatus MNL 2.76 1.89 3.31 2.09 2.18 2.94 2.97
MPRL 1985 THP-1 - 17.4 • •• • •• • •• ... ... 16.52
THP-1 + 22.21 ... ... ... ... ... 21.64
mAb only MNL 0 0.37 0.641 0.92 1.71 1.07 0.98
THP-1 - 0 0.2 1.33 0.53 0.0 0.21 0.90
THP-1 + 0 0.01 0.02 0.14 0.57 0.98 1.80
Where MNL= human MNL, THP-1 - = THP-1 cells without enhancement for CD 14,
THP-1 + = THP-1 cells with enhancement for CD 14 and ... = not done.
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Fig 16: TNF production (IU/ml) after 4 h by human MNL after stimulation
with varying amounts of B. fragilis NCTC 9343 LPS (A) and varying amounts
of B. fragilis NCTC 9343 LPS together with a constant amount of E. coli 018K"
(40 ng/ml) (A) LPS in the a) presence or b) absence of a 1:20 dilution of 5A12
anti-Bacteroides mAb. The maximal amount of TNF produced by E. coli 018K"
LPS alone shown by (—). Each point is the mean of duplicate experiments
performed with the same cell preparations.
B. fragilis NCTC 9343 LPS cone ng/ml B. fragilis NCTC 9343 LPS cone ng/ml
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dilution of 5A12 mAb, the amount of TNF produced was lowered and the same
pattern of results seen (Fig 16 a).
3.10.14 Inhibition of TNF Production by an Anti-TNF mAb
To ensure killing of L929 cells was due to TNF and not other factors, a dilution of
anti-TNF mAb was incubated with cell culture supernates (derived after 4 h from
human MNL after stimulation with LPS (50 ng/ml) from E. coh 018K" and
B. fragilis NCTC 9343) prior to addition to L929 cells. The inhibition of TNF
activity for both LPSs was nearly 100% for dilutions of anti-TNF mAb tested (Table
16).
Table 16: Inhibition of TNF production (IU/ml) after 4 h by an anti-TNF mAb
from human MNL after stimulation with LPS (50 ng/ml) from E. coli 018K"
and B. fragilis NCTC 9343.
TNF production IU/ml








3.11 REACTIVITY OF LPS ON THE BASIS OF KDO CONCENTRATION
All the assays in sections 3.9 and 3.10 have been done on a weight for weight basis.
However, as endotoxicity is likely to be dependent on lipid A concentration it was
decided to re-evaluate some of the results of TNF induction and LAL activity relative
to KDO concentration hi an attempt to compare lipid A levels - making the
assumption, which could well be false, that lipid A concentration is proportional to
KDO concentration hi all species.
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Measured TNF concentration IU/ng KDO from human MNL and endotoxic activity in
LAL IU/ng KDO after stimulation with selected Bacteroides and E. coli 018K" LPS
is presented in Table 17. For measured TNF concentrations, this shows that
previously low activities seen on a weight for weight basis (Table 13) were due in part
to less KDO being present. However, LAL activity for PCP extracted LPS is still
low when the results are represented per ng KDO.
Table 17: Measured TNF concentration IU/ng KDO from human MNL and
endotoxic activity in LAL IU/ng KDO after stimulation with selected
Bacteroides and E. coli 018K" LPS
LPS Sample Extraction TNT Stimulation LAL Activity
Method IU/ng KDO EU/ng KDO
B.fragilis NCTC 9343 VT PW 59.38 1583.08
PCP 7.16 10.69
Triton 17.3 2784.93
B. fragilis NCTC 9343 PPY PW 46.11 1191.11
PCP 35.11 8.44
Triton 4.90 693.24
B. frcigilis MPRL 1504 PW 15.85 5985.54
PCP 17.42 37.38
Triton 5.38 3846.99
B. vulgatus MPRL 1985 PW 19.11 115.48
PCP 3.41 7.93
Triton 3.00 84.67
B. thetaiotaomicron MPRL 1720 PW • •• • ••
PCP 1.55 42.61
Triton 8.64 867.91
B. ovatus MPRL 1709 PW 30.37 14.98
PCP 25.89 4.68
Triton 10.43 385.5
E. coli 018K" PW 502.16 572.32
aerobically grown
E. coli 018K" PW 485.60 261.15
anaerobically grown
See Table 3 for abbreviations.
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3.12 CAPSULAR POLYSACCHARIDE INDUCED TNF PRODUCTION
3.12.1 Effect of Amount of Capsular Polysaccharide on TNF Production
The effect of varying amounts of high and low molecular weight (mwt) capsular
polysaccharide (CP) from B. fragilis NCTC 9343 in inducing TNF production from
human MNL was examined compared to LPS controls (Table 18). Comparing TNF
production at a sample size of 50 ng/ml, E. coli 018K" LPS induced the most TNF,
with B. fragilis NCTC 9343 LPS inducing four-fold less TNF and low mwt CP
inducing approximately fifty three-fold less TNF than E. coli 018K" LPS. At this
level high mwt CP failed to induce any TNF production. TNF production by 500-
5000 ng/ml of low mwt CP was comparable to that produced by 50 ng/ml of B.
fragilis NCTC 9343 LPS.
Table 18: Measured TNF concentration (IU/ml) from human MNL after
stimulation for 4 h with varying amounts of high and low molecular weight
capsular polysaccharide from B. fragilis NCTC 9343 and LPS from B. fragilis
NCTC 9343 and E. coli 018K". Each value is the mean of duplicate experiments
performed with the same cell preparations.
TNF Production IU/ml




50000 1.421 36.72 ... ...
5000 0 34.49 ... ...
500 0 14.64 ... ...
50 0 1.69 21.44 90.17
5 0 0.06 7.21 45.25
0.5 0 0 ... ...
0.05 0 0 ... ...
Where mwt = molecular weight, CP= capsular polysaccharide and ... = not done. See
Table 3 for other abbreviations.
133
3.12.2 Time course of TNF Production
Levels of TNF production by human MNL were measured every 2 h after stimulation
with LPS (50 ng/ml) from E. coli 018K" and B. fragilis NCTC 9343, and with
high/low mwt CP (500 ng/ml) from B. fragilis NCTC 9343 (Fig 17). As previously
seen in Fig 10 a peak of TNF production at 4 h was seen after stimulation with all
LPSs tested, with a second peak at 8 h seen for E. coli 018K" LPS only. A peak of
TNF production at 6 h was seen after stimulation with both high and low mwt CP
from B. fragilis NCTC 9343.
Fig 17: Time course of TNF production (IU/ml) from human MNL after
stimulation with LPS (50 ng/ml) from E. coli 018K" (A), B. fragilis NCTC 9343
(•) and B. vulgatus MPRL 1985 (♦); and 500 ng/ml of high mwt CP (•) and
low mwt CP (+) from B. fragilis NCTC 9343. Each point is the mean of





3.12.3 Effect of TNF Production by E. coli Q18K- LPS With B. frasilis NCTC
9343 Capsular Polysaccharide Present in Excess
When LPS from B. fragilis NCTC 9343 was in excess of a constant amount of E.
coli 018K" LPS (50 ng/ml) in human MNL, TNF production was comparable to that
ofB. fragilis NCTC 9343 LPS alone and not that of E. coli Ol 8K" LPS alone (Table
19). This lowering and masking effect of TNF production from E. coli 018K" LPS
previously described in section 3.10.7 was enhanced when an excess of low mwt CP
from B. fragilis NCTC 9343 was present, and reduced when an excess of high mwt
CP from B. fragilis NCTC 9343 was present (Table 19).
Table 19: Effect of TNF production (IXJ/ml) from human MNL by E. coli
018K" LPS with B. fragilis NCTC 9343 LPS and capsular polysaccharide
present in excess. Each value is the mean of duplicate experiments performed
with same cell preparations.
Sample TNF production
(IU/ml)
E. coh 018K" LPS (50 ng/ml) 151.4
B. fragilis NCTC 9343 LPS (160 ng/ml) 58.72
B. fragilis NCTC 9343 high mwt CP (500 ng/ml) 3.10
B. fragilis NCTC 9343 low mwt CP (500 ng/ml) 27.6
E. coli Ol 8K" LPS (50 ng/ml) +
B. fragilis NCTC 9343 LPS (160 ng/ml)
62.76
E. coli Ol 8K" LPS (50 ng/ml) +
B. fragilis NCTC 9343 high mwt CP (500 ng/ml)
111.5
E. coli 018K" LPS (50 ng/ml)+
B. fragilis NCTC 9343 low mwt CP (500 ng/ml)
57.28
Where mwt = molecular weight and CP= capsular polysaccharide. See Table 3 for
other abbreviations.
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3.13 LPS INDUCED SECRETION OF INTERLEUK1N-8
3.13.1 IL-8 Production by Bacteroides LPSs Extracted by Three Different
Methods
E. coli 018K" LPS stimulated the most IL-8 production with no difference in IL-8
production between E. coli OI8K" LPS grown aerobically or anaerobically (Table
20). On a weight for weight basis, PW-LPS from Bacteroides species stimulated the
most IL-8 production and PCP-LPS the least. Comparing PW-LPS, Bacteroides LPS
induced IL-8 at a magnitude much less than E. coli 018K", with the most active (B.
fragilis NCTC 9343 VT) being approximately three times less active than E. coli
018K" and the least active B. thetaiotaomicron MPRL 1720 being 13 times less
active than E. coli 018K". Matched TNF production results are shown in Table 13.
3.13.2 Time course of IL-8 Production
Levels of IL-8 by human MNL were measured at hourly intervals after stimulation
with LPS (50 ng/ml) from E. coli 018K" and B. fragilis NCTC 9343 (Fig 18 a). The
response produced by the E. coli 018K" LPS showed a uniform rise and fall, peaking
at 6-7 hours. Tire B. fragilis NCTC 9343 LPS showed peaks of EL-8 production at
6, 9 and 12 hours. Matched TNF production results are shown in Fig 10 a.
IL-8 production by sampling every two hours in THP-1 cells with and without
enhancement for CD 14 was followed (Fig 18 b, c). hi THP-1 cells without
enhancement for CD 14 (Fig 18 b) IL-8 production occurred on a much smaller
magnitude. E. coli 018K" LPS was the least active producing one peak of IL-8 at 4
hours and B. vulgatus MPRL 1985 LPS the most active. Both Bacteroides LPS
produced peaks of IL-8 at both 4 and 8 hours. In THP-1 cells with enhancement for
CD 14 (Fig 18 c) IL-8 production occurred on a greater magnitude with levels of IL-8
produced comparable to those found in human MNL. E. coli 018K" LPS produced
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Table 20: Measured IL-8 concentration pg/ml from human MNL after 4 h
stimulation with native form LPS (50 ng/ml) from E. coli 018K" and
Bacteroides species extracted by three different methods. Each value is the mean
of duplicates from one experiment.
Native LPS Sample Extraction IL-8 Production
Method pg/ml
B. fragilis NCTC 9343 VT PW 9320
PCP 3006
Triton 1629
B. fragilis NCTC 9343 PPY PW 4695
PCP 1541
Triton 2189
B. fragilis MPRL 1504 PW 5102
PCP 2294
Triton 4401
B. vulgatus MPRL 1985 PW 3027
PCP 1552
Triton 3216
B. thetaiotaomicrcm MPRL 1720 PW 2034
PCP 1383
Triton 1592
B. caccae MPRL 1555 PW 5084
PCP 1212
Triton 2764
B. uniformis MPRL 1721 PW 5343
PCP 2339
Triton 3863
B. ovatus MPRL 1709 PW 7088
PCP 1522
Triton 3122
E. coli 018 K aerobically grown PW 29784
E. coli 018K anaerobically grown PW 26360
See Table 13 for matched TNF production results. See Table 3 for abbreviations.
137
Fig 18: Time course of IL-8 production (pg/ml) by a) human MNL, b) THP-1
cells without enhancement for CD14 and c) THP-1 cells with enhancement for
CD14 after stimulation with LPS (50 ng/ml) from E. coli 018K" (•), B. fragilis
NCTC 9343 (A) and B. vulgatus MPRL 1985 (♦). Each point is the mean of
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one peak of EL-8 at 8 hours and both Bacteroides LPSs produced peaks of IL-8 at
both 4 and 8 hours.
3.13.3 Effect of IL-8 Production by E. coli Q18K" LPS with B. fragilis NCTC
9343 LPS Present in Excess
When LPS from B. fragilis NCTC 9343 was in excess of a constant amount of E.
coli 018K" LPS (40 ng/ml) in human MNL, IL-8 production was comparable to that
of B. fragilis NCTC 9343 LPS alone and not that of E. coli 018K" alone (Fig 19).
There appeared to be a lowering and masking effect of IL-8 production from E. coli
018K" LPS when LPS from B. fragilis NCTC 9343 was present in excess. Matched
TNF production results are shown in Fig 12 a.
3.13.4 Inhibition of IL-8 Production by An Anti-CD14 mAh
The effect of an anti-CD 14 mAb in inhibiting IL-8 production was examined (Fig 20).
In all cell populations tested, the production of IL-8 stimulated by both E. coli 018K"
and B. fragilis NCTC 9343 LPS was slightly inhibited as the concentration of CD 14
mAb increased. Matched TNF production results are shown in Fig 14.
3.13.5 Inhibition of IL-8 Production by Anti-Bacteroides mAbs
All anti-Bacteroides mAb had no effect in inhibiting IL-8 production from human
MNL after stimulation with all LPSs tested (Table 21). Matched TNF production
results are shown in Table 15.
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Fig 19: IL-8 production (pg/ml) after 4 h by human MNL after stimulation
with varying amounts of LPS from B. fragilis NCTC 9343 (A), varying amounts
of B. fragilis NCTC 9343 LPS together with a constant amount of E. coli 018K"
(40 ng/ml) (A). Maximum amount of IL-8 produced by E. coli 018K" alone
shown by (—). Each point is the mean of duplicate experiments performed with
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Fig 20: Inhibition of IL-8 production (pg/ml) after 4 h by an anti-CD14 mAb
from a) human mononuclear leukocytes, b) THP-1 cells without enhancement
for CD14, and c) THP-1 cells with enhancement for CD14, after stimulation
with LPS (50 ng/ml) from E. coli 018K" ( • ), B. fragilis NCTC 9343 ( A ) and
CD14 monoclonal antibody alone (—). Each point is the mean of duplicate
experiments performed with the same cell preparations. Note different scales on
y axes.




0 20 40 60 80
Cone of CD14 mAb pg/ml
Cone of CD 14 mAb pg/ml
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Table 21: Inhibition of IL-8 production (pg/ml) after 4 h by a 1:20 dilution of
anti-Bacteroides mAbs from human MNL after stimulation with LPS (50 ng/ml)
from E. coli 018K", B. fragUis NCTC 9343, B. caccae MPRL 1555 and B.
vulgatus MPRL 1985. Each value is the mean of duplicate experiments
performed with the same cell population.
IL-8 induced by mAb at 1:20 dilution
Sample
no mAb 5A12 1A4 4CS 3D7 6G3 3C8
E. coli
018K-
25684 24920 25650 24539 28228 26312 27851
B. fragilis
NCTC 9343
9306 9495 9082 8848 9719 9063 9333
B. caccae
MPRL 1555
8178 8655 8363 8577 8898 7898 8504
B. vulgatus
MPRL 1985
4314 4325 4598 4804 4578 4892 4801
mAb only 0 202 314 250 302 119 344
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3.14 CAPSULAR POLYSACCHARIDE INDUCTION OF EVTERLEUKIN-8
Levels of IL-8 by human MNL were measured every 2 h after stimulation with LPS
(50 ng/ml) from E. coli 018K" and B. fragilis NCTC 9343; and low mwt CP (500
ng/ml) and high mwt CP (500 ng/ml) from B. fragilis NCTC 9343 (Fig 21). As seen
in Fig 18, E. coli 018K" LPS induced one peak of IL-8 at 6 h whereas B. fragilis
NCTC 9343 LPS induced two peaks of IL-8 at 6 and 10 h. Low mwt CP induced one
peak of EL-8 at 10 h and high mwt CP induced increasing quantities of IL-8 over time
with maximum levels observed after 24 h stimulation. Maximum levels of IL-8
produced by CPs and LPSs are comparable.
3.15 LPS INDUCTION OF 1NTERLEUK1N-6
3.15.1 Effect of Amount of LPS on IL-6 Production
The effect ofvarying ng amounts of LPS on IL-6 production from human MNL was
examined for E. coli 018K", B. fragilis NCTC 9343, B. vulgatus MPRL 1985, B.
caccae MPRL 1555 and B. thetaiotaomicron MPRL 1720 (Fig 22). E. coli 018K"
LPS produced more EL-6 than all Bacteroides LPSs for all amounts tested. The most
active Bacteroides LPS (B. fragilis NCTC 9343) was approximately two-fold less
active than E. coli 018K" LPS and the least active (B. vulgatus MPRL 1985) being
approximately seven-fold less active.
3.15.2 Time course of IL-6 Production
IL-6 induction by LPSs from Bacteroides species and E. coli 018K" by sampling
every two hours was examined in human MNL and in THP-1 cells with and without
enhancement for CD 14 (Fig 23). In all cell populations, all LPSs produced a single
peak of IL-6 production at 6-8 hours. There was little, if any, difference in IL-6
produced between THP-1 cells with and without enhancement, for CD 14 for both E.
coli 018K" LPS and B. fragilis NCTC 9343 LPS.
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Fig 21: Time course of EL-8 production (pg/ml) by human MNL after
stimulation with LPS (50 ng/ml) from E. coli 018K" (A), B.fragilis NCTC 9343
(•) and 500 ng/ml of low mwt CP (♦) and high mwt CP (■) from B. fragilis
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Fig 22: EL-6 production (pg/ml) from human MNL after stimulation for 4 h
with LPS from E. coli 018K" (A), B.fragilis NCTC 9343 (•), B. caccae MPRL
1555 (♦), B. vulgatus MPRL 1985 (•) and B. thetaiotaomicron MPRL 1720 (+).











Fig 23: Time course of IL-6 production (pg/ml) by a) human MNL, b) THP-1
cells without enhancement for CD14 and c) THP-1 cells with enhancement for
CD14 after stimulation with LPS (50 ng/ml) from E. coli 018K~ (A), B. fragilis
NCTC 9343 (•), B. caccae MPRL 1555 (♦), B. vulgatus MPRL 1985 (•) and B.
thetaiotaomicron MPRL 1720 (+). Each point is the mean of duplicates from one
experiment. Note different scales on y axes.
Time (h)
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3.15.3 Effect of 11 -6 Production by E. coli Q18K" LPS with B. fragilis NCTC
9343 LPS Present in Excess
When LPS from B. fragilis NCTC 9343 was in excess of a constant amount of E.
coli 018K" LPS (40 ng/ml) in human MNL. IL-6 production was comparable to that
of B. fragilis NCTC 9343 LPS alone and not that of E. coli 018K" alone (Fig 24).
There appeared to be a lowering and masking effect of EL-6 production from E. coli
018K" LPS when LPS from B. fragilis NCTC 9343 was present in excess.
3.15.4 Inhibition of 11-6 Production by an Anti-CD14 mAb
The anti-CD 14 mAb did not inhibit IL-6 production in all cell populations tested after
stimulation with both E. coli 018K" and B. fragilis NCTC 9343 LPS (Fig 25).
3.16 LPS INDUCTION OF SOLUBLE p55 TNF RECEPTOR
Levels of soluble p55 TNF receptor (sTNFr) from human MNL was measured at two
hourly intervals after stimulation with LPS (50 ng/ml) from E. coli 018K" and
various Bacteroides species (Fig 26). Levels of p55 TNF receptor fell to zero at 4 h
for all LPSs tested except B. vulgatus MPRL 1985 which fell to a minimum value at 6
h. The production of p55 sTNFr steadily rose for all LPSs (including that of the
control which contained no LPS), to maximum levels observed by 24 h at the end of
the experiment. At 24 h E. coli 018K" LPS had induced the most p55 sTNFr and B.
vulgatus the least.
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Fig 24: EL-6 production (pg/ml) after LPS stimulation for 4 h by human MNL
after stimulation with varying amounts of LPS from B. fragilis NCTC
9343 (A), varying amounts of B. fragilis NCTC 9343 LPS together with a
constant amount of E. coli 018K" (40 ng/ml) ( A ). Maximum amount of IL-6
produced by E. coli 018K" alone shown by (—). Each point is the mean of
duplicates from one experiment.
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Fig 25: Inhibition of IL-6 production after 4 h by a CD14 mAb from a) human
MNL, b) THP-1 cells without enhancement for CD14, and c) THP-1 cells with
enhancement for CD14, after stimulation with LPS (50 ng/ml) from E. coli
018K" ( • ) , B. fragilis NCTC 9343 ( A ) and CD14 monoclonal antibody
alone (—). Each point is the mean of duplicates from one experiment. Note
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Fig 26: Time course of p55 soluble TNF receptor production (ng/ml) from
human MNL after stimulation with LPS (50 ng/ml) from E. coli 018K" (▲), B.
fragilis NCTC 9343 (•), B. caccae MPRL 1555 (♦) and B. vulgatus MPRL 1985
Amount produced by culture medium control shown by (—). Each point is
the mean of duplicate experiments performed with the same cell preparations.
Time (h)
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3.17 MITOGENICITY OF BACTEROIDES LPSs
3.17.1 Mitogenicity of Bacteroides LPSs to Mouse Spleen and Lymph Nodes
The mitogenicity of Bacteroides LPSs to mixed cell populations from mouse spleen
and lymph nodes is shown in Table 22. Those LPSs which induced a value greater
than the PF-FLjO negative control were considered to be mitogenic. By comparing the
results obtained by 25 pg/ml of LPS, most mitogenicity was seen towards the spleen
cell population. B. vulgatus MPRL 1985 LPS induced the most mitogenicity followed
by E. coli 018K" LPS and B. caccae MPRL 1555 LPS, with B. fragilis NCTC 9343
LPS inducing the least effect.
3.17.2 Mitogenicitv of Bacteroides LPSs and Capsular Polysaccharides to
Mouse B Cells, T Cells and Mixed Spleen Cell Populations
In another experiment the mitogenicity of Bacteroides LPS and CPs from B. fragilis
NCTC 9343 to mouse B cells, T cells as well as mixed cell populations of mouse
spleen cells, is shown in Table 23. Control values were high in this instance but those
LPSs or CPs which induced a value greater than the PF-HjO negative control were
considered to be mitogenic. To all cell populations E. coli 018K" LPS induced the
most mitogenicity while B. vulgatus MPRL 1985 LPS induced more mitogenicity than
B. fragilis NCTC 9343 LPS in all cell populations apart fr om the T cell population
where B. fragilis NCTC 9343 LPS was more active than B. vulgatus MPRL 1985
LPS. In all cell populations high mwt CP was more mitogenic than low mwt CP. In
mixed spleen cells and T cells the level ofmitogenicity by high CP was comparable to
that found by E. coli Ol 8K" LPS.
151
Table 22 : Mitogenicity of Bacteroides LPSs to mouse spleen and lymph nodes
Sample pg/ml Counts per minute Counts per minute
per 2 x 106 cells/ml per 2 x 106 cells/ml
Spleen Lymph nodes
Control (PF-H70) - 3700 3400
PHA 5 11,100 11,633
















Where PHA= phytohaemagglutinin. Each value is mean of triplicates from a single
experiment. Results repeated on at least two occasions.
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Table 23: Mitogenicity of Bacteroides LPSs and capsular polysaccharide from
B. fragilis NCTC 9343 to mouse B cell, T cell and mixed spleen cell populations
Sample (5 pg/ml) Counts per min








per 2 x 106
cells/ml
T Cells
Control (PF-H,0) 18,799 8817 17,662
PHA 31,397 14,747 35,681
E. coli 018K" LPS 34,734 24,641 31,156
B. fragilis NCTC 9343 LPS 24,090 19,863 14,446
B. vulgatus MPRL 1985 LPS 25,213 21,917 22,962
High mwt CP 33,852 18,082 25,170
Low mwt CP 27,987 15,195 28,453
Where High mwt CP= High molecular weight capsular polysaccharide from B.
fragilis NCTC 9343, Low mwt CP= Low molecular weight capsular polysaccharide
from B. fragilis NCTC 9343 and PHA= phytohaemagglutinin. Each value is the mean
of triplicates from a single experiment.
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3.18 FLOW CYTOMETRIC ANALYSIS
3.18.1 Analysis of CD14 Positive Cells
To confirm the results shown in sections 3.10 and 3.11, the binding of an anti-CD14
mAb to human MNL and THP-1 cells with/without enhancement for CD 14 was
examined and the results illustrated in Table 24. The binding of the anti-CD 14 mAb to
THP-1 cells without enhancement for CD14 was low and increased three to four-fold
in THP-1 cells with enhancement for CD 14. The percentage of cells exhibiting binding
of an anti-CD14 mAb to human MNL was at approximately the same level as THP-1
cells with enhancement for CD14.
3.18.2 Analysis of Mouse B Cell, T Cell and Mixed Spleen Cell Populations
In order to ensure homogeneous cell populations had been prepared for mitogenicity
experiments (section 3.17.2) the binding of an anti-CD3 mAb to cells was examined
and the results illustrated in Table 25. CD3 is a cell surface antigen present on T cells
only. Those cells excluded and termed lymphocytes and macrophages are shown in
Fig 27. No significant difference in percentage fluorescence with and without the
presence of the CD3 mAb was seen and the binding to the macrophage population
was also high, suggesting that non-specific binding of the FITC labelled mAb had
occurred.
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Table 24: Binding of an anti-CD14 mAb to human MNL and THP-1 cells with
/without enhancement for CD14
Cell population CD 14 mAb % of 5000 cells
pg/ml exhibiting fluorescence
THP-1 cells without 0 0.95
enhancement for CD 14 750 5.3
375 4.5
THP-1 cells with 0 0.13
enhancement for CD 14 750 17.5
375 16.8




Table 25: Binding of an anti-CD3 inAb to mouse mixed spleen cell, B cell and T
cell populations
Cell population Anti-CD3 mAb % fluorescence % fluorescence
Lymphocytes Macrophages
Spleen mix + 45 74
- 42 72
B cells + 85 79
- 85 85
T cells + 50 85
- 52 42
Fig 27: A representation of lymphocyte1 and macrophage2 cell populations from
mixed mouse spleen cells
Granularity
(Log forward light scatter)
Size
(Log 90° light scatter)
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3.19 THE EFFECT ON THE CEU OF HUMAN SERUM IN THE PRESENCE
OF BACTEROIDES LPSs
The effect oil the CH50 (units/ml) of human serum by LPSs from Bacteroides species
and E. coli 018K" extracted by different methods was examined and the results
illustrated in Table 26. Comparing the different types of LPSs extracted from B.
fragilis NCTC 9343, PW-LPS induced the greatest increase in CH50 and PCP-LPS
the least. Comparing the PW-LPSs, E. coli 018K" LPS induced the greatest increase
in CH50 of human serum by approximately two-fold. LPS from B. vulgatus MPRL
1985 and B. thetaiotaomicron MPRL 1720 did not alter the CH50 ofhuman serum.
When B. fragilis NCTC 9343 LPS was present together and in excess of E. coli
018K" LPS, the CH50 value of the serum was closer to that produced by B. fragilis
NCTC 9343 LPS alone and not E. coli 018K" LPS alone (Table 27).
3.20 BINDING ACTIVITY OF BACTEROIDES mAbs TO LPSs
The binding activities in ELISA of anti-Bacteroides mAbs to various Bacteroides
LPSs and E. coli 018K" LPS are shown in Table 28. The anti-Bacteroides LPSs did
not bind well to the Bacteroides LPSs and E. coli 018K" LPS. The mAbs 4CS, 3C8
1A4 and 3D7 bound with the greatest affinity to B. fragilis NCTC 9343 LPS. The
mAb 5A12 bound with greatest affinity to E. coli 018K" LPS and the mAb 6G3 did
not bind significantly to any LPS tested. There was no non-specific binding to the
uncoated plastic wells for any ofthe raAbs tested.
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Table 26: Effect on CH50 (units/ml) of human serum by LPSs (100 ng/ml) from
Bacteroides species and E. coli 018K" extracted by different methods
LPS Extraction CH50 units/ml
method of serum
Control (serum only) - 60.25
E. coli 018K" PW 127.33
B. fragilis NCTC 9343 PW 91.98
B. fragilis NCTC 9343 PCP 65.86
B. fragilis NCTC 9343 Triton 82.04
B. caccae MPRL 1555 PW 89.81
B. vulgatus MPRL 1985 PW 58.43
B. thetaiotaomicron MPRL 1720 PW 62.73
Table 27: Effect on CHS0 (units/ml) of human serum by E. coli 018K" LPS with
B. fragilis NCTC 9343 LPS present in excess
Sample CH50 units/ml
of serum
Control (serum only) 63.24
E. coli 018K" LPS (100 ng/ml) 118.2
B. fragilis NCTC 9343 LPS (100 ng/ml) 59.04
B. fragilis NCTC 9343 LPS (200 ng/ml) 108.79
E. coli 018K" LPS (100 ng/ml) +
B. fragilis NCTC 9343 LPS (100 ng/ml)
100.00
E. coli 018K" LPS (100 ng/ml) +
B. fragilis NCTC 9343 LPS (200 ng/rnl)
72.32
For Tables 26 and 27, each value is the mean of triplicates from a single experiment.
Results repeated on two occasions. See Table 3 for other abbreviations.
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Table 28: Binding activities in ELISA of anti-Bacteroides mAbs (1:5 dilutions)
to various Bacteroides LPSs and E. coli 018K" LPS
Mean OD 405 nrn
LPS 4CS 3C8 1A4 5A12 3D7 6G3
E. coli 018K" 0.124 0.133 0.123 0.130 0.011 0.031
B. fragilis NCTC 9343 0.385 0.227 0.267 0.109 0.110 0.011
B. vulgatus MPRL 1985 0.108 0.026 0.137 0.096 0.007 0.018
B. caccae MPRL 1555 0.086 0.023 0.106 0.104 0.004 0.024
B. thetaiotaomicron MPRL 1720 0.114 0.022 0.148 0.120 0.005 0.016
Control (uncoated ) 0.021 0.022 0.019 0.024 0.006 0.021





4.1 DIFFERENCES IN BIOLOGICAL ACTIVITY BETWEEN
EXTRACTION METHODS
Bacteroides LPS has been disregarded by many authors as being much less endotoxic
than enterobacterial LPS (Lindberg et al 1990, Weintraub et al 1985), but this study
has shown that the biological activity of Bacteroides LPS was dependent on the
extraction method employed. The three methods were selected in an attempt to
produce products of different chemical composition. The classical PW method was
hkely to select for higher molecular mass, less hydrophobic material; the PCP method
for rough-form, more hydrophobic material; while the Triton-Mg2+ method was
chosen as a milder, less selective method. The PW method produced LPS with the
highest biological activity and the PCP and the Triton methods producing LPS with
low biological activities. Which extracted LPS type, if any, reflects that in vivo
remains to be defined.
In a mouse lethality model, the results obtained (Table 7) agree with previous studies
(Lindberg et al 1990) that Bacteroides LPS is approximately 5000-fold less active
than LPS from E. coli. In past studies (Lindberg et al 1990, Loppnow et al 1989,
Fujiwara et al 1988) Bacteroides LPS has been quoted as being 100 to 1000-fold less
biologically active in vitro, depending on the assay, than LPS from
Enterobacteriaceae. Our results for Bacteroides LPS extracted by the PCP or Triton
methods agree with this. However, our results for LPS extracted by the PW method
disagree with the accepted view. In the TNT induction assay, E. coli Ol8K" LPS was
only 4-fold more active than B. fragilis NCTC 9343 LPS and 7-fold more than B.
caccae MPRL 1555 LPS but up to 50-fold more than the other Bacteroides LPSs.
In the LAL assay, (a standard in vitro method for detection of endotoxin), which has
questionable value to the situation in vivo, the same LPSs which were most active in
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the TNF-induction assay (from B. fragilis and B. caccae) were 30-40 fold more active
than E. coli 018K" LPS, with E. coli 018K" LPS being approximately 10-fold more
active than the rest of the Bacteroides LPS tested. In a study by Laude-Sharp et al
(1990) no relationship between IL-1 inducing capacity and LAL reactivity was found
for various LPSs from Enterobacteriaccae. They describe how biologically active
LPS species can escape recognition in the LAL assay which only detects LPS of
molecular mass above 8,000 Da.
The biological activity of enterobacterial LPS is thought to be dependent on its
solubility (Galanos & Luderitz 1984), and for this reason the native and soluble
sodium salt forms were prepared from electrodialysed material. Results found that
solubility (native vs. sodium salt form LPS) does not play an important role in
biological activity as has been previously described for enterobacterial LPS (Galanos
& Luderitz 1984). In most cases the sodium salt form was of lower activity.
It must be stressed at this stage that the term "Bacteroides LPS" is probably not a
single molecular species, of even heterogeneous chain length, but is much more likely
to be a complex of surface lipopolysaccharides, both rough and smooth, as well as
possibly lipid-linked CP. In SDS-PAGE the Bacteroides LPS appears as a series of
several different molecules of high and low molecular mass (Fig 6). To add to the
complexity, some of the molecules can only be detected by immunostaining as they
are not sensitive to staining by silver (Allan et al 1995). From the work of Patrick and
colleagues (Patrick 1993, Patrick & Reid 1983) we know that a pure laboratory
culture of B. fragilis exists as a collection of sub-populations expressing a range of
surface antigens. These sub-populations can be separated on Percoll density gradients,
and the different antigens identified with a series of mAbs (Lutton et a! 1991). The
degree of different molecular species of LPS and other co-purifying carbohydrate, due
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to the probable sub-populations of cultures in this study, is by no means certain.
Because of this complexity of the different molecular species, the comparison of
activity with E. coli 018K" LPS on a weight-for-weight basis is preferred to a
comparison on a molar basis.
4.2 DIFFERENCES IN BIOLOGICAL ACTIVITY BETWEEN
BACTEROIDES SPECIES
Some PW preparations of Bacteroides LPSs are clearly more active than others. For
example in the LAL, TNF, IL-8 and complement CH50 assays B. fragilis NCTC 9343
VT/PPY and B. caccae MPRL 1555 were consistently the most active Bacteroides
LPSs. In the same assays, B. vulgatus MPRL 1985 and B. thetaiotaomicron MPRL
1720 were consistently the least active LPSs. However, in the rnitogenicity assays, B.
vulgatus MPRL 1985 LPS was more active than B. fragilis NCTC 9343 LPS (see
section 4.8 for further discussion).
Growth in the defined VT medium was included because a recent study in our
laboratory found that growth in this medium converts several B. fragilis strains,
including NCTC 9343, from being sensitive to the lytic action ofnormal human serum
to resistant. This may be due to a change in expression of certain surface polymers
such as LPS (Allan & Poxton 1994). Results found in this study show that LPS from
B. fragilis NCTC 9343 grown in VT is more active in the LAL and TNF assays and
less active in the mouse lethality model compared to B. fragilis NCTC 9343 LPS
grown in PPY.
Due to anaerobic conditions in the gut, E. coli 018K" LPS was grown anaerobically
as well as aerobically. There was no difference in activity between E. coli 018K" LPS
grown aerobically and anaerobically apart from in the LAL assay. In this assay, the
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two-fold difference in activity for E. coli 018K" LPS grown aerobically and
anaerobically is unclear.
4.3 REASONS FOR DIFFERENCES IN BIOLOGICAL ACTIVITY
BETWEEN EXTRACTION METHODS AND BACTEROIDES SPECIES
Chemical analysis does not explain clearly why the LPS from some species are more
active than others. It does show that more carbohydrate and KDO is present in the
PW preparations. The amount ofKDO destroyed or not released by hydrofluoric acid
treatment is not known. B. fragilis NCTC 9343 VT LPS had more carbohydrate and
KDO than B. fragilis NCTC 9343 PPY LPS. Fatty acid analysis was not conclusive
and its reliability debatable when we consider that results found do not relate to those
previously accepted. Lindberg and colleagues (1990), found that CI4, the most
common enterobacterial fatty acid was absent in Bacteroides. However, in this study
(see Table 5) a small quantity of this fatty acid was found in B. fragilis NCTC 9343
PPY PW-LPS. It has previously been found that B. fragilis LPS contains fatty acids
C15-C17 and E. coli LPS C12-C16, but in this study fatty acids C12-C13 were
present in B. fragilis NCTC 9343, B. thetaiotaomicron MPRL 1720 and B. vulgatus
MPRL 1985 LPS. Differences in detected fatty acids may be due to different sub-
populations present in cultures used and the extraction method employed. Clearly,
further analysis is required to clarify results.
Those species that had a low reactivity in the LAL assay, TNF and IL-8 bioassays,
and mouse lethality model (B. vulgatus MPRL 1985 and B. thetaiotaomicron MPRL
1720) had a smooth LPS profile on PAGE for all extraction methods (Fig 6). This is
in apparent contradiction to the view that aqueous phenol preferentially extracts
smooth-form LPS of higher activity, while those strains which are obviously smooth
(e.g. B. vulgatus) are less endotoxic. However, even the highest molecular band is
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much lower than the highest enterobacterial LPS bands. Background information into
sub-populations, Percoll profiles and Proteinase K profiles failed to account for any
differences in activity between Bacteroides species as well.
The possibility that some contaminant may be present in the LPS preparations from
Bacteroides must be considered. In this connection, no contaminating organisms were
found when culturing the organisms for extraction and the identity of each strain of
Bacteroides was confirmed prior to the start of the study. Furthermore, PW-LPS
samples from several Bacteroides species prepared by different individuals at different
times in our laboratory were tested alongside our own samples hi the LAL and TNF
mduction assay. They were found to produce near identical results (data not shown).
Higher biological activity in the PW preparations cannot be due to a biologically
active protein as protein levels were negligible after purification. LPS samples with
protein contamination had lower activity in the TNF and LAL assays (Tables 8 and
10). Biological activity also cannot be due to any contaminating Proteinase K as all
Bacteroides LPSs had been treated similarly with Proteinase K.
4.4 INDUCTION OF CYTOKINES BY BACTEROIDES LPS
4.4.1 General Comments
Several points must be kept in mind when drawing conclusions from this area of
work. As mycoplasma screening had not been carried out on tissue culture cells, the
effect of contaminating mycoplasma cannot be ruled out. Cell lines were not thought
to be contaminated as retrospective testing showed no presence of mycoplasmas
(Ciara Ryan, personal communication).
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Choice of LPS level
As previously discussed in section 3.10.5, the amount of LPS used to stimulate
secretion of cytokines was chosen as it fell in the middle of the linear part of the
standard curve of the assay employed in this thesis. This amount of LPS (50 ng/ml)
may be felt to be particularly high compared to the situation in vivo in the
bloodstream, but this amount of LPS may resemble the situation in abscesses and
other sites of infection where the local concentration of LPS may be higher.
Circulating levels of LPS in vivo are measured by the LAL assay and represent
"excess" LPS. LPS bound or masked by serum proteins may not trigger the LAL
assay and therefore circulating levels of endotoxin may be higher than measured.
LPS is only thought to interact with CD14/LBP when circulating levels of LPS are
low (< 1 ng/ml) and the level of LPS employed during the functional studies may be
deemed too high to refer any conclusions from the interactions of LPS with CD 14.
Since levels of 1 ng/ml of LPS only gave baseline levels of cytokines in the assay
systems employed hi this thesis, a larger quantity (i.e. 50 ng/ml) of LPS was used.
Clearly the situation in vivo cannot be reproduced in vitro.
Choice of CD14 m \b
The binding characteristics of the CD 14 mAb employed in this thesis are not known.
It was chosen due to its abundant, free availability. At this stage it was deemed
important to find out if neutralisation occurred. If it did, then the study could be
extended to employ a mAb ofknown binding site.
Sodium azide is commonly found in many commercial mAb preparations. The
presence of sodium azide may kill tissue culture cells and therefore affect results in the
assay systems employed in this thesis. The presence or absence of sodium azide in
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the CD14 preparation used in this thesis cannot be confirmed. If the killing of L929
cells was due to sodium azide alone we would not have seen a differential effect as
was seen with the different LPSs. These studies would have benefited from a
matched isotype mAb control. Antibody preparation available in our laboratory had
significant endotoxin levels present as determined by the LAL assay and the best
control was therefore thought to be no antibody.
4.4.2 Induction of Tumour Necrosis Factor
Bacteroides LPS is capable of inducing mononuclear cells to produce TNF, which is
considered the pivotal cytokine in the host response to endotoxin. This induction
seems to be independent of CD14 expression, the 55 kD glycosyl
phospkatidylinositol-linked protein expressed on the surface of monocytes,
macrophages and PMNs (Haziot et al 1988), which has been found to serve as a
specific binding site for complexes of LPS and LBP in serum (Lynn & Golenbock
1992, Wright 1991, Wright et al 1990). Although CD 14 has been shown to play a
very important role in LPS activation events, its functional role has yet to be fully
defined.
It is well documented that immature THP-1 cells are lacking in CD 14 and do not
respond as well to LPS as THP-1 cells that have been matured with vitamin D3
(Martin et al 1994, Kitchens et al 1992). Flow cytometric analysis determined that
THP-1 cells without enhancement for CD14 were lacking in CD14 (Table 24). In this
cell population, E. coli 018K" LPS could only induce one peak of TNF release at 4 h,
compared to peaks at 4 h and 8 h in CD14-rich populations (human MNL and THP-1
cells with enhancement for CD14 (Table 24, Figs 10 and 11). The peak of TNF
release at 8 h was inhibited by high concentrations of the anti-CD14 mAb (Fig 15).
Bacteroides LPS could only induce one peak of TNF release at 4 h regardless of the
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cell population, suggesting that it stimulates cells to produce TNF via a pathway
independent ofCD 14 and that the periodic response may be related to CD 14. The fact
that TNF release stimulated by Bacteroides LPS could not be inhibited by an anti-
CD14 mAb (compared to E. coli 018K" LPS which could be inhibited), is further
evidence to support this concept. These results can be contrasted to those found in a
study by Shapira et al (1994), where TNF production by human MNL by E. coli
LPS and Porphyromonas gingivalis LPS (once a member of the Bacteroides genus)
was inhibited by an anti-CD14 mAb. Of note is that only in human cell populations
rich in CD 14 is there a significant difference in TNF inducing capability by LPS from
Bacteroides and E. coli 018K".
The presence or absence of serum does not effect TNF production by Bacteroides
LPS, whereas the absence of serum greatly reduces the ability of E. coli 018K" LPS
to induce TNF (Table 11). This suggests that Bacteroides LPS does not require the
presence of serum proteins to activate cells to produce TNF, and that E. coli 018K~
LPS can activate cells without the presence of serum proteins which is greatly
enhanced by the presence of serum proteins. Serum proteins derived from both FCS
and human serum produce the same effects (Table 11), suggesting a degree of
homology between the species. It is not known what amount ofLBP, if any, is present
in the serum used. The addition of LBP to the culture medium could not be earned
out due to its lack of commercial availability and to its complex purification from
serum.
hi a recent paper by Lynn et al (1993) neither CD14 or seium were shown to be
absolutely necessary for the activation ofmononuclear phagocytes by bacterial LPS.
They suggested that a CD14-independent pathway may be of importance in local sites
of infection where the concentration of LPS may be high: for example, faecal soiling
168
of the peritoneum. Local concentrations of LPS may be high in abscesses which may
be reason why Bacteroides has evolved to trigger cells to produce cytokines without
the need for CD 14. Peritoneal macrophages may differ in their ability to respond to
LPS compared to circulating macrophages. It has been reported that different
macrophage populations differ in their TNF response to LPS: alveolar macrophages
for example, produce a much higher level of TNF with a faster response than Kuppfer
cells (Callery et al 1991). It must be remembered that the peritoneal macrophage
preparation used in this thesis contained contaminating neutrophils and lymphocytes.
It is not known at this stage what amount of cytokines is produced by each of these
cell types.
In peritoneal macrophages from C3H/HeJ mice the B. fragilis NCTC 9343 LPS
stimulates a low level of TNF whereas E. coli 018K" LPS stimulates no TNF
production. It is well documented that peritoneal macrophages from C3H/HeJ mice
are unable to respond to LPS from Enterobacteriaceae due to a genetic deficiency
(Sultzer 1976). However, a pathway open to B. fragilis LPS is capable of stimulating
TNF production. The component of B. fragilis NCTC 9343 LPS complex which is
inducing this effect and through which pathway is not yet known. Other Bacteroides
species have yet to be investigated.
It appears that the amount of TNF produced is also directly related to the
experimental volume. When the experimental volume was small, cells had a greater
tendency to pellet out on the bottom of the microtitre plates. This suggests that the
LPS has a greater probability to interact with cell surface receptors, which could
explain greater amounts of TNF produced. This effect has also been observed by
other workers (J. Pitts, Personal Communication).
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4.4.3 Induction of Interleukin-8
IL-8 is a powerful chemoattractant for PMNs, recruiting them to a site of infection
such as intra-abdominal abscesses (Janeway & Travers 1994, Neilson et a1 1994).
Abscesses consist primarily ofPMNs, some macrophages, bacteria and cellular debris.
Since B. fragilis is the predominant organism found in such abscesses, it was logical
to determine the abihty ofB. fragilis LPS to induce this cytokine.
In contrast to the production of TNF by human MNL, where E. coli 018K" LPS
induced a periodical TNF response with major peaks at 4 and 8 h and B. fragilis
NCTC 9343 LPS induced one peak (if somewhat complex-shaped) of TNF at 4 h, the
kinetics of IL-8 induction by these LPSs was different. In this cell population, E.
coli 018K" LPS induced a single peak of IL-8 at 6 h and B. fragilis NCTC 9343 LPS
induced three peaks of IL-8 at 6, 9 and 12 h (Fig 18).
Similarly the kinetics of IL-8 production from THP-1 cells with and without
enhancement for CD14 differed from those found for TNF production. In THP-1
without enhancement for CD 14, E. coli 018K" LPS induced a single peak of IL-8 at
4 h and B. fragilis NCTC 9343 LPS induced two peaks of IL-8 at 4 and 10 h. The
amount of IL-8 produced in THP-1 cells with enhancement for CD14 was much
larger and produced a single peak of EL-8 at 8 h by E. coli 018K" LPS and two
peaks at 4 and 8 h by B. fragilis NCTC 9343 LPS (Fig 18). Ofnote is the fact that B.
vulgatus MPRL 1985 LPS induced more IL-8 than E. coli 018K" and B. fragilis
NCTC 9343 LPS. However, since these results are the means of duplicates from a
single experiment, their reliability could be debated.
The kinetics of IL-8 production found in this study differ from those previously
described (DeForge et al 1992). In that study a single peak of TNF/DL-6 and a
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second peak of both mRNA and protein IL-8 was described following stimulation
with E. coli. It is not known if this effect is due to stimulation in whole blood rather
than purified MNL as in this study, or to the type ofLPS preparation used.
The production of IL-8 by both E. coli 018K" LPS and B. fragilis NCTC 9343 LPS
could be slightly inhibited by an anti-CD 14 mAb (Fig 20). The amount of inhibition is
not significant enough to conclude that both these LPSs activate cells to produce IL-
8 through a pathway involving CD14. Although IL-8 production is greatly increased
in THP-1 cells which have been enhanced for CD 14, it is not known at this stage if
the slight inhibition seen is due to the presence of antibody in the assay system. This
is where the presence of a matched isotype mAb control would have been beneficial.
The fact that B. fragilis NCTC 9343 LPS can induce multiple peaks of IL-8 in all cell
populations tested may have some significance in the abscess model.
4.4.4 Induction of lnterleukin-6
One of the most important multi-functional activities of IL-6 is the initiation of the
acute phase response. IL-6 acts on hepatocytes in the liver to induce the production of
acute phase proteins such as C-reactive protein.
In all cell populations tested, both E. coli 018K" LPS and B. fragilis NCTC 9343
LPS induced a single comparable peak of IL-6 at between 6-8 h (Fig 23). The
production of IL-6 by both LPSs could not be inhibited by an anti-CD 14 mAb (Fig
25) suggesting that they induce cells to produce DL-6 through a pathway independent
of CD 14. Further evidence to support this concept is the fact that the amount of IL-6
produced by both LPSs is nearly identical in THP-1 cells with and without
enhancement for CD 14.
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Clearly from the results found in this study, TNF at 4 h is the first cytokine to be
induced from all cell populations tested by both E. coli 018K" LPS and Bacteroides
LPS. The production of IL-6 and IL-8 follows a little while later at between 6-8 h.
The influence of TNF in the production of IL-6 and IL-8 in the cell models used in
this study is not known at this stage, but has been reported to influence their
production by many other workers (DeForge et al 1992, Matsushima & Oppenheim
1989, Janeway & Travers 1994). Why both E. coli 018K" LPS and B. fragilis NCTC
9343 LPS should utilise CD14 to induce some cytokines and not others is not known.
This phenomenon has been observed by other workers. In a study by Le Dur et al
(1994), they observed that CD 14 induced the signal for TNF but not IL-1 from
human MNL stimulated with LPS. The activation pathway independent of CD14 is
not known at present.
The ability of LPS to induce TNF and interact with CD14 has been reported to be
connected with the chain length of the LPS (Jahr et al 1994), where the longer the
chain length of the LPS, the more able it is to interact with CD 14. If Bacteroides
LPS is more of a rough form than E. coli 018K~ LPS then this may explain results
found for TNF hiduction assays. However, this theory would contradict those results
found for IL-8 and IL-6 assays.
4.5 INDUCTION OF CYTOKINES BY CAPSULAR POLYSACCHARIDES
FROM B. FRAGILIS NCTC 9343
The CP of B. fragilis has been seen to consist of at least two different molecules
(Patrick 1993, Tzianabos et al 1993, Tzianabos et al 1992). An intriguing observation
was made several years ago by Onderdonk and colleagues (Onderdonk et al 1977)
that the CP of B. fragilis could induce sterile abscesses. This has recently been re-
addressed (Tzianabos et al 1993), and Cross (Cross 1994) has suggested that CP may
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induce proinflammatory mediators such as IL-1. It has previously been reported that
some preparations of CP are contaminated with high molecular mass LPS (Poxton &
Brown 1986) and as mentioned before in section 4.1, Bacteroides LPS preparations
used in this study may not be pure but heterogeneous with lipid-linked CP. For this
reason, the ability of CP from B. fragilis NCTC 9343 to induce cytokines was
examined.
Due to the very small quantity of CP prepared, a fully comprehensive study was not
possible. Although purification of polysaccharide A and B was attempted, not enough
material to cany out extensive studies with these fractions was obtained. Most
cytokine-induction capacity was seen in the low molecular weight CP fraction. This
fraction contained KDO whereas the high molecular weight CP fraction contained no
KDO. The low mwt CP fraction is most likely to be pure LPS and the high mwt CP is
most likely to be pure CP. Both the low and high molecular weight CP induced TNF
from human MNL on a scale much less than B. fragilis NCTC 9343 LPS. Both
induced a single peak of TNF like Bacteroides LPSs but later at 6 h (Fig 17). The
low mwt CP induced a single peak of IL-8 at 10 h and in contrast the high mwt CP
induced increasing levels ofEL-8 with a maximal level at 24 h comparable to the levels
seen for the LPSs (Fig 21). The significance of the amount of IL-8 produced by the
high mwt CP hi abscess formation is not known at this stage. The kinetics of IL-8
production following stimulation with high mwt CP resembles that by E. coli in a
study by DeForge et al 1992. The role of CD 14 in CP cell activation is also not
known at this stage. Further biological activities of CP are discussed in sections 4.6
and 4.8.
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4.6 EFFECT ON CYTOKINE INDUCTION BY E. COLI Q18K' LPS WHEN
B. FRAGILIS NCTC 9343 LPS OR CAPSULAR POLYSACCHARIDE
PRESENT IN EXCESS
An excess of Bacteroides LPS (by all three extraction methods) or CP (particularly
low molecular weight CP) blocked the effects of E. coli 018K" LPS on human MNL
and THP-1 cells (with and without enhancement for CD14) in producing the
cytokines TNF, EL-8 and IL-6 (Figs 12, 19, 24 and Table 19). This effect was also
seen in the complement CH50 assay (Table 27). In TNF induction, an excess of B.
fragilis NCTC 9343 LPS inhibited the second peak of TNF production at 8 h
previously seen by E. coli 018K" LPS (Fig 13). Most inhibition was seen when both
LPSs were added to cell populations at the same time (Table 14). Whether this was
purely due to the configuration of LPS in solution or due to an effect at the cellular
level is not known.
A similar phenomenon has been reported by Ogawa et al (1994a) where they report
that the production of IL-1 (3 by E. coli is inhibited by Porphyromonas gingivalis
(once a member of the B. fragilis group) LPS and its lipid A. Their results also mimic
those found in this study where the difference in IL-6 and IL-8 production by both E.
coli and P. gingivalis LPS was less marked.
A well documented synergistic relationship exists between E. coli and B. fragilis,
where B. fragilis inhibits the phagocytic killing of E. coli (Onderdonk et al 1976,
Rotstein et al 1989). Magnuson et al (1989) also found that B. fragilis NCTC 9343
LPS inhibits E. coli LPS-induced human endothelial cell adhesiveness for neutrophils.
However, in that study it was not found that B. fragilis LPS inhibited TNF
production, but the B. fragilis LPS was extracted sequentially by the phenol-water
method followed by the phenol-chloroform-petroleum method. This contradicts
174
findings in this study where B. fragilis NCTC 9343 LPS by all three extraction
methods inhibited TNF production by E. coli 018K" LPS.
These observations in this study may be of some importance when we consider that
Bacteroides outnumber E. coli in the gut by at least 1000-fold. It is not yet known if
the situation observed in vitro will occur in vivo. However, it may be significant in
terms of immunotherapy ifbacteria or their products translocate from the gut into the
bloodstream. If Bacteroides LPS is the major inducer of cytokine responses we
should be targeting them with antibody therapy instead of E. coli (Baumgartner
1994). However, if the inhibition of the E. coli LPS response occurs in vivo then
perhaps the Bacteroides LPS might serve a protective role.
4.7 INHIBITION OF CYTOKINE PRODUCTION BY ANTI-BACTEROIDES
MONOCLONAL ANTIBODIES
Some anh-Bacteroides mAbs could inhibit TNF production from human MNL (Table
15) but not IL-8 production (Table 21). Although these rnAbs were raised against B.
fragilis NCTC 9343 they displayed a degree of cross-reactivity. At this stage it is not
known to which epitopes they are cross-reactive. The mAbs 5A12, 1A4 and 3D7
were cross-reactive with E. coli 018K" LPS and B. fragilis NCTC 9343 LPS. The
mAbs 5A12, 3D7 and 3C8 cross-reacted slightly with B. caccae MPRL 1555. The
mAb 6g3 and 4CS had little or no activity in inhibiting TNF production and did not
bind in ELISA suggesting that little or no antibody was present in the culture
supemates. The rnAb 5A12, which was against the complete LPS ladder pattern on
PAGE was the most successful in inhibiting TNF production. The mAbs 1A4 and
3D7 were the next most successful in inhibiting TNF production. These mAbs were
against the high molecular material on PAGE, however, other mAbs to the high
molecular material such as 4CS and 3C8 were less successful. In general the binding
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of these mAbs to various LPSs in ELISA was poor due to the probable low
concentration of mAbs in the culture supemates (Table 28). Interestingly, 5A12
bound most strongly to E. coli 018K" LPS hi ELISA, with the rest of the mAbs
binding most strongly to B. fragilis NCTC 9343 LPS. The mAbs 3D7 and 6G3
showed no binding hi ELISA.
As discussed in section 4.5 most TNF-induction capacity lies in the low molecular
weight material and not the high molecular weight material. How mAbs directed
against the high molecular weight material can therefore prevent TNF production is
unclear. This may be due to the configuration of LPS in solution. It is not known if
the reduction of TNF production due to the action of the anti-Bacteroides mAbs
would in turn reduce the amount of other cytokines produced such as IL-6 or IL-1.
Of note is the fact that when B. fragilis NCTC 9343 LPS is present in excess of E.
coli 018K" LPS together with the mAb 5A12 (Fig 16), the re-emergence of TNF
levels by E. coli 018K" LPS alone is not seen, but the amount of TNF produced is
further reduced. If Bacteroides LPS were to prove as an important factor in the
development of sepsis then a mAb against the whole LPS ladder for use in
immunotherapy such as 5A12 would be preferred.
4.8 MITOGENIC1TY OF BACTEROIDES LPSs AND CAPSULAR
POLYSACCHARIDES
LPS has been well described as a potent activator ofB cells (Chaby & Girard 1993).
B cells can bind LPS without macrophage activation and can also be activated by
cytokines released from mononuclear cells stimulated by LPS. Some authors have
reported binding of LPS to T cells, others concluded that LPS cannot bind to T cells
(Haeffher-Cavaillon et al 1985).
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It was first recognised by Joiner and colleagues in 1982 that LPS from B. fragilis
23745 showed potent mitogenic activity for spleen cells from both responder and
non-responder mice. Williamson et al (1984) corroborated these findings and
recognised that the polysaccharide and lipid A fractions of B. fragilis LPS (prepared
by aqueous phenol extraction) had different effects on macrophages of C3H/HeJ
(non-responder) mice. The mitogenic response was only to the polysaccharide
fraction. Fujiwara et al (1988) further demonstrated that LPS extracted by aqueous
phenol from oral Bacteroides species (now reclassified as Porphyromonas and
Prevotella) were highly mitogenic for peritoneal macrophages from C3H/HeJ mice.
LPSs from Enterobacteriacae are not mitogenic for C3H/HeJ mice. However when
the LPS is extracted with hot trichloroacetic acid or aqueous butanol, it contains a
lipid A associated protein which is mitogenic for both LPS responder and LPS non-
responder mouse spleen cells (Morrison 1976).
It has also been observed that T cells (phenotypically T helper or precursor cells) are
required for the induction of abscesses caused by B. fragilis. Protection against
abscess formation has been found to be a consequence of suppressor T cell activity
(Shapiro et al 1986). No literature on mitogenic responses for E. coli LPS to T
cells has been found.
Studies on mitogenicity of LPS in this thesis were not successful. Flow cytometric
analysis could not demonstrate that homogeneous cell populations were obtained.
Fluorescence was seen on macrophage populations and there was no difference in
fluorescence between those cells treated with and without an anti-CD3 mAb (Table
25). This suggests non-specific binding of the FITC-labelled mAb. Attempts to repeat
these experiments using a different FITC-labelled mAb were made, but due to
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repeated failure of the T cell columns, this was not possible. Because of these
problems, these studies were not extended to non-responder mice.
Although firm conclusions from the mitogenic studies cannot be made, several
observations are of note. Generally, the high mwt CP was more active than the low
mwt CP. This ties in with findings previously described by Williamson et al (1984)
who found that only the polysaccharide fraction was mitogenic. LPS from B. vulgatus
MPRL 1985 was more active than B. fragilis NCTC 9343 LPS in all cell populations
apart from in the T cell population where B. fragilis NCTC 9343 LPS was more
active (Tables 22 and 23). This is in contrast to results found in the cytokine assays
where LPS from B. vulgatus MPRL 1985 was consistently of lower activity. B.
vulgatus LPS appears smooth on PAGE (Fig 6) which could indicate that more
polysaccharide is present. The fact that a mitogenic response was seen in the T cell
population for all samples is further evidence to suggest that homogeneous cell
populations were not achieved.
It has been described that inhibition of LPS intemalisation by neuraminadase
treatment prevents mitogenic responses ofB cells to LPS (Chaby & Girard 1993). B.
fragilis is known to secrete neuraminadases (Imai et al 1991). It is not known at this
stage whether viable B. fragilis bacteria would activate B cells in comparison to LPS
and CP in vivo.
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4.9 UNANSWERED QUESTIONS FROM THIS STUDY
There are still many questions that remain to be answered.
i) Since chemical analysis in this study has been non-conclusive, what are the reasons
behind the differences in biological activity between Bacteroides species? What type
of extracted LPS mimics that in vivo?
ii) Why are there several peaks of TNF production after stimulation with E. coli LPS
in CD14-rich cell populations? What causes the "troughs" in the periodic TNF
response? It is acknowledged that there may be heterogeneity in the cell population or
different stages present in the cell cycle which may cause this response. Also TNF
may be present during the "trough" but in a bound form which would not be
detectable in the bioassay. The possibility that TNF is neutralised during the "trough"
by the p55 sTNFr appears unlikely (Fig 26). The role of the p75 sTNFr (which has a
greater affinity for TNF) in this regard is unknown at this stage.
iii) What is the activation pathway which is independent ofCD 14 in the production of
TNF by Bacteroides LPS and by both E. coli 018K~ LPS and Bacteroides LPS in
the production of IL-6, and how does Bacteroides LPS stimulate peritoneal
macrophages from C3H/HeJ mice to produce TNF?
iv) Does Bacteroides LPS utilise CD 14 in the production of IL-8, and does
Bacteroides LPS bind to LBP? If Bacteroides LPS does bind to LBP in vivo, could
its lower biological activity be due to its preferential neutralisation by HDL? Studies
should be extended to include a CD 14 mAb of known binding site to assist in finding
these answers.
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v) How does an excess of Bacteroides LPS mask the effects of E. co/i LPS? Does
this effect observed in vitro occur in vivol Is it the physical state of the LPS mixture
or is there competition or masking ofbinding sites?
vi) What species of LPS is circulating in the septic patient and in what form is it
predominant?
vii) Neutrophils are a characteristic of intra-abdominal abscesses and are the most
common leukocyte in the bloodstream. Since B. fragilis is the predominant organism
in intra-abdominal abscesses and are capable of inducing IL-8 (a powerful
chemoattractant for neutrophils), what role does the neutrophil play in Bacteroides
LPS-induced cytokine response?
viii) Only a fraction of the cytokines produced in vivo have been examined, does
Bacteroides LPS induce other cytokines in a significant amount compared to E. coli
LPS?
There is still therefore much to be learnt about Bacteroides LPS
monocyte/macrophage activation pathways and its role in the cytokine cascade.
4.10 CONCLUSIONS
Despite many unanswered questions, many points can be concluded from this study,
i) PW extracted Bacteroides LPS is more active than PCP or Triton extracted LPS.
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ii) B.fragilis NCTC 9343 and B. caccae MPRL 1555 LPSs are consistently the most
active Bacteroides LPSs, with B. vulgatus MPRL 1985 and B. thetaiotaomicron
MPRL 1720 LPSs consistently the least active LPSs.
hi) In TNF production, E. coli 018K" LPS can produce multiple peaks through a
CD14-dependent pathway while B. fragilis NCTC 9343 LPS can only produce one
peak through a pathway hidependent of CD14. Both low and high mwt CPs induce
one peak of TNF. Low mwt CP induces more TNF than high mwt CP but on a scale
much lower than both E. coli 018K" and B. fragilis NCTC 9343 LPS.
iv) In IL-8 production, E. coli 018K" LPS can produce one peak while B. fragilis
NCTC 9343 LPS can produce two peaks. Low mwt CP induced one peak of IL-8
whereas high mwt CP induces an increasing level ofEL-8 over 24 h.
v) In DL-6 production, both E. coli 018K" LPS and B. fragilis NCTC 9343 LPS
produce one peak through a pathway independent ofCD 14.
vi) An excess of B. fragilis NCTC 9343 LPS and CP can mask the effects of E. coli
018K" LPS.
vii) Firm conclusions from the autogenic studies cannot be drawn, but a trend towards
high mwt CP being more autogenic than low mwt CP and B. vulgatus MPRL 1985
LPS being more autogenic than B. fragilis NCTC 9343 LPS was seen.
B. fragilis has a history of debate and some confusion as to the structure/function
relationships of its polysaccharide surface structures (Lindberg et al 1990, Poxton &
Brown 1986). It is perhaps too early at this stage to suggest that individual molecules
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can induce specific mediators. However, until we can finally fractionate, or clone, the
various other constituent molecules, little further progress can be made in determining
their individual and combined functions in pathogenesis. The role ofBacteroides LPS
in shock remains to be defined, but by taking the results of this study, Bacteroides
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BACTERIAL PATHOGENICITY
A re-appraisal of the biological activity of bacteroides LPS
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Summary. Lipopolysaccharides (LPS) were extracted from seven Bacteroides strains by three
different techniques: the phenol-water (PW), phenol-chloroform-petroleum (PCP) and
Triton-Mg2+ methods. The strains selected included two different B. fragilis strains, one of
which was grown in two different media. Yields varied between the strains, growth media and
extraction technique, but generally the highest yield by weight was from the PCP method and
the lowest from the PW method. The PW method was selected for the greatest amounts of
carbohydrate and KDO, and the PCP method for the least. Phosphorus levels were more
uniform among all extraction methods. Protein contamination was found in all Bacteroides
LPS extracts, with extremely low levels in PW-LPS and the highest levels in material extracted
by the PCP and Triton-Mg2+ techniques. No protein contamination could be detected after
proteinase K treatment. After silver staining LPS PAGE profiles showed ladder patterns
characteristic of smooth LPS for B. vulgatus, B. thetaiotaomicron and the control Escherichia
coli 018: K~ strains, whereas the other Bacteroides strains showed mainly rough and low Mr
material only. The PCP method did not select for high Mr material in the B. fragilis strains;
otherwise the LPS profiles for all extraction methods were identical. The biological activities
of native and sodium salt form LPS were investigated on a weight for weight basis and
compared to that of E. coli 018 :K~ PW-LPS. Amongst the LPS from Bacteroides strains,
those prepared by the PW method were found to have a significantly higher activity in a
galactosamine mouse lethality model, in induction of TNF and the Limulus amoebocyte
lysate (LAL) assay, than LPS extracted by the PCP or Triton-Mg2+ methods. LPS from
Bacteroides strains extracted by the PCP method had consistently low activity in all assays.
Comparing PW-LPS from Bacteroides strains with that from E. coli 018:K in the
galactosamine mouse model, the E. coli 018:K~ LPS was c. 5000-fold more active than the
most active bacteroides LPS. However, in the LAL assay native PW-LPS from both the B.
fragilis strains, and B. caccae had higher activities (up to 30-fold) than E. coli 018:Kr LPS,
with the PW-LPS from the other Bacteroides spp. being up to 15-fold less active than the E.
coli 018:K~ PW-LPS. In the TNF induction assay, E. coli 018:Kr PW-LPS was 4-50-fold
more active than bacteroides PW-LPS. In the LAL assay and galactosamine mouse model,
native LPS had more activity (c. two-fold) than sodium salt form LPS. There was no clear
difference in activity between native and sodium salt form LPS in the TNF induction assay.
The results for the LAL and TNF induction assay were re-evaluated relative to KDO
concentration. In the TNF induction assay, previously low activities seen on a weight for
weight basis were due in part to less KDO being present. However, LAL activity for PCP-LPS
was still low after re-evaluation relative to KDO concentration. The molecular basis for the
differences in biological activity of bacteroides LPS in relation to extraction methods and
chemical composition is not yet understood.
Introduction
The gram-negative bacillus Bacteroidesfragilis is the
anaerobe most frequently isolated from human infec-
Received 9 Feb. 1994; revised version accepted 16 Aug. 1994.
t Correspondence should be sent to Dr I. R. Poxton.
tions including intra-abdominal, vaginal, brain and
lung abscesses and peritonitis. The source is usually
the faecal flora. Faeces contain 10u-1012 bacteria/g
and anaerobes constitute c. 99-9 % of the faecal bac¬
terial mass. Of this, the species belonging to the genus
Bacteroides sensu stricto (formerly members of the B.
fragilis group of Bacteroides) account for 20-30 % of
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the species isolated.1 The genus Bacteroides constitutes
B.fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron,
B. vulgatus, with B. eggerthii, B. uniformis, B. caccae,
B. merdae and B. stercoris being more recently added
to the group due to changes in classification. Other
species formerly classified as Bacteroides have been
reclassified into the genera Porphyromonas and Prevo-
te/laA3
In the past 25 years, the lipopolysaccharide (LPS) of
B. fragilis has been studied by many groups and has
yielded many controversial results regarding its rough
or smooth structure, and presence ofKDO or not, but
it is generally agreed that it is weakly endotoxic.4-7 It
was thought initially that B.fragilis LPS contained no
repeating long chains of polysaccharide linked to lipid
A core. This was due in part to the use of the phenol-
chloroform-petroleum extraction method which tends
to select for rough type LPS5 and it was not recognised
that subpopulations existed that expressed different
surface molecules.3 In 19918 Masked investigated
by polyacrylamide gel electrophoresis LPS from 10
species of Bacteroides prepared by the non-selective
proteinase K method. He showed that some Bac¬
teroides spp. produced predominantly rough LPS
whereas others such as B. vulgatus and B. caccae
produced smooth LPS similar to that of facultative
enterobacteria. Other species such as B. fragilis pro¬
duced poorly resolved high molecular mass (Mr)
material as well as rough LPS. It is nowwell established
that B. fragilis LPS does contain KDO, but only in a
phosphorylated form which renders it undetectable in
the standard thiobarbituric acid assay. Prior dephos-
phorylation by hydrofluoric acid treatment is required
for its detection.9 It is well documented that the lipid A
of B. fragilis LPS contains different fatty acids from
the lipid A of enterobacterial LPS and is mono-
phosphorylated, and this is one reason why it is less
endotoxic than enterobacterial LPS.7
Endotoxaemia can occur as a primary event, for
example in patients with intra-abdominal or urinary
tract sepsis. However, in critically ill patients without
a confirmed bacteraemia, it is thought that the gut is
themajor source of " endotoxin "10 which subsequently
leads to the systemic inflammatory response syndrome
(SIRS),11 a consequence of which can be multiple
organ failure and death in up to 80% of patients.
Although it has been shown that the LPS ofB.fragilis
has lower activity than enterobacterial endotoxin,7
Bacteroides spp. are numerically far more predomi¬
nant (c. 1000-fold) in the gut than enterobacteria such
as E. coli, thus representing a vast pool of potentially
biologically active LPS.
In this paper, the biological activity of LPS from
seven species of Bacteroides is re-examined by com¬
paring the activity of LPS extracted by three different
methods in mouse lethality and TNF induction
models, and an attempt is made to relate activity to
chemical composition. The Limulus amoebocyte lysate
(LAL) assay was included in the study as the standard
in-vitro method for detection of endotoxin.
Materials and methods
Bacterial strains
A list of strains used and their origin is shown in
table I.
Culture methods
Bacteria were grown in 15-16-L batches in a 20-L
capacity fermenter (LH Engineering, Stoke Poges).
Bacteroides spp. were grown in defined broth12 or
proteose-peptone yeast extract (PPY) broth, anaer-
obically, in N2100 % at 37°C. Escherichia coli 018: K"
was grown in nutrient broth (NB) anaerobically, in N2
100% at 37°C, or aerobically (pO, 50%) at 37°C.
Strict purity checks were made for each organism at
the end of each fermentation run.
Extraction ofLPS
LPS was extracted by the phenol water (PW) method
as described by Westphal and Luderitz;13 by the
phenol-chloroform-petroleum (PCP) method as de¬
scribed by Galanos et u/.,14 and by the Triton-Mg2+
method described by Uchida and Mizushima.15 All
native LPS (5 mg/ml) were freed from protein con¬
tamination by treating with proteinase K 20 pg/rcA at
65°C for 2 h. Proteinase K was removed by two washes
with pyrogen-free water (PFH^O) at 100000 g. Batches
ofde-ionised and sodium salt form LPS were prepared
by the method of Galanos as described by Hancock
and Poxton.16 Further native enterobacterial LPS used
in the TNF induction assays were obtained from PW
or PCP extracts prepared by F. McLoughlin, De¬
partment of Medical Microbiology, Edinburgh Uni¬
versity Medical School.
Polyacrylamide gel electrophoresis
Polyacrylamide gels (14% without SDS) were pre¬
pared with the buffer system of Laemmli.17 Each
extract was dissolved to a concentration of LPS
1 mg/ml in the SDS-2-mercaptoethanol solubilisation
buffer of Laemmli17 and heated at 100°C for 3 min.
Samples (20 pX) were applied to a non-SDS poly¬
acrylamide 14% gel. To visualise LPS, gels were
oxidised with periodate and stained with silver by a
method modified from that of Tsai and Frasch.16,18
Gels were stained for protein by the Coomassie Blue
method as described by Hancock and Poxton.16
Chemical analysis of LPS
Neutral sugars were quantified by the colorimetric
method ofDubois et al.19 The phosphorus content was
measured by the method of Chen et al.20 Bacteroides
LPS were dephosphorylated by hydrofluoric acid as
described by Beckmann et al.9 and the KDO content of
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Table I. Bacterial strains
Species Strain no. Origin or source
B. fragilis MPRL 1669 Appendix, NCTC 9343
B. fragilis MPRL 1504 Wound
B. vulgatus MPRL 1985 Blood
B. thetaiotaomicron MPRL 1720 Faeces
B. caccae MPRL 1555 Wound
B. uniformis MPRL 1721 ?, ATCC 8492
B. ovatus MPRL 1709 ?, ATCC 8483
E. coti 018: KT (bort) MPRL 1274 Dr A. S. Cross, Walter Reed
Army Institute for Research,
Washington DC, USA
NCTC, National Collection of Type Cultures, PHLS, Colindale Avenue, London; ATCC,
American Type Culture Collection, Rockville, MD, USA; MPRL, departmental stock culture.
Table II. Details of LPS library
r , Yield from different extraction
c Growth u. ure methods*Strain ,. volume
medium .
1 ; PW PCP Triton
B. fragilis VT 16 1 6-87 6-87 6-87
NCTC 9343 2 41-4 227-5 175-6
3 0-60 3-31 2-56
B. fragilis PPY 15 1 2-34 2-39 2-36
NCTC 9343 2 37-4 99-2 47-2
3 1-60 4-42 2-00
B. fragilis PPY 15 1 2-85 2-57 2-50
MPRL 1504 2 63-7 64-5 47-6
3 2-24 2-51 1-91
B. vulgatus PPY 15 1 2-42 2-47 2-44
MPRL 1985 2 90-7 96-9 53-2
3 3-74 3-92 2-18
B. thetaiotaomicron PPY 15 1 3-23 3-67 3-77
MPRL 1720 2 29-8 103-8 83-0
3 0-92 2-83 2-20
B. caccae PPY 15 1 7-40 7-63 7-50
MPRL 1555 2 20-3 98-6 20-7
3 0-27 1-29 0-28
B. uniformis PPY 15 1 6-75 5-21 5-60
MPRL 1721 2 25-8 213-4 57-7
3 0-38 4-24 1-03
B. ovatus PPY 15 1 3-04 300 2-97
MPRL 1709 2 54-9 124-0 73-3
3 0-81 4-14 2-47
E. coli 018:K" NB 15 1 7-63 — —
MPRL 1275 Aerobic 2 169-8 — —
3 2-23 — —
E. coli 018:Kr NB 16 1 118 — —
MPRL 1275 Anaerobic 2 47-5 — —
3 404 — —
VT, Van Tassell and Wilkins' medium; PPY, proteose-peptone yeast extract broth; NB,
nutrient broth; PW, phenol-water; PCP, phenol-chloroform-petroleum.
* 1, dry weight of cells (g); 2, yield of LPS (mg); 3, % yield.
all LPS was determined by a modified thiobarbiturate
assay.16 Protein was measured by the Folin assay.21
Mouse lethality: galactosamine model
D-Galactosamine (12 mg/mouse) was administered
intraperitoneally to groups of three 6-8-week-old male
C57 black mice just before intraperitoneal admin¬
istration of LPS in the range 5 ng-5 /tg. Survival was
recorded up to 24 h. Animal experiments were per¬
formed in accordance with Home Office guidelines.
Limulus amoebocyte lysate (LAL) assay
LPS samples were diluted to ranges of 50-0-5 ng/ml
in PFH,0. Each sample (50 /A) was added in duplicate
to wells of microtitration plates (Greiner). Chromo-
genic LAL reagent (Coatest Endotoxin, Chromogenix,
Sweden) was added to each well through a transfer
plate to ensure that each well received the LAL reagent
at the same time. To minimise error through tempera¬
ture gradients the outer wells of the plate were left
unfilled. The plate was read kinetically every 19 s at
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Fig. 1. Silver stain profile of LPS library. R, position of rough LPS; X, band present in PCP preparations, a: track 1, NCTC 9343 VT PW;
2, NCTC 9343 VT PCP; 3, NCTC 9343 VT TRITON; 4, NCTC 9343 PPY PW; 5, NCTC 9343 PPY PCP; 6. NCTC 9343 PPY TRITON;
7, MPRL 1504 PPY PW; 8, MPRL 1504 PPY PCP; 9. MPRL 1504 PPY TRITON; 10, MPRL 1985 PPY PW; II. MPRL 1985 PPY PCP;
12, MPRL 1985 PPY TRITON, b: track l.MPRL 1720 PPY PW;2, MPRL 1720 PPY PCP; 3, MPRL 1720 PPY TRITON; 4, MPRL 1555
PPY PW; 5, MPRL 1555 PPY PCP; 6, MPRL 1555 PPY TRITON; 7, MPRL 1721 PPY PW;8, MPRL 1721 PPY PCP; 9, MPRL 1721 PPY
TRITON; 10. MPRL 1709 PPY PW; 11, MPRL 1709 PPY PCP; 12. MPRL 1709 PPY TRITON, c: track 1, E. coli 018:Kr LPS grown
aerobically; 2, E. coli 018:K~ LPS grown anaerobically.
405 nm (reference background 650 nm) for 90 min in a
Thermomax plate reader (Molecular Devices) at 37°C.
The replicate mean onset time for test samples was
standardised against an endotoxin of known potency
(E. coli 0111: B4, Coatest Kit endotoxin standard,
Chromogenix).
LPS-induced TNF secretion
Mononuclear leucocytes (MNL: c. 30% mono¬
cytes) from freshly collected human buffy coats (ob¬
tained from the Blood Transfusion Service, Edin¬
burgh) were prepared by sedimentation on lymphocyte
separation medium (ICN Flow). Cells (SxlO^/ml)
were cultured in RPMI 1640 (Blood Transfusion
Service, Edinburgh) supplemented with penicillin
100 U/ml, streptomycin 100 /ig/ml, 1 mM L-glutamine
and fetal calf serum (FCS) 10% in the presence or
absence ofvarying (ng) concentrations of LPS. Culture
supernates were collected after 4 h and stored at
— 20°C for TNF determination.
Determination of TNF content
The L929 mouse fibroblast cell line, which is
sensitive to TNF, was cultured in growth medium—
MEM (Sigma) containing FCS 5% supplemented
with penicillin 100 U/ml, streptomycin 100 /(g/ml and
1 mM L-glutamine, and maintained by splitting 1 in 10
twice weekly. Cells were dislodged by a solution of
trypsin 0-05%, EDTA 0-02% to avoid cell clumping,
washed and resuspended in a growth medium to
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Table III. Estimation ofcarbohydrate, phosphorus and KDO content in native LPS
samples
pc, . . Extraction CHO P KDOsamp e/me mm meth0d (/tg/mg dry wt) (/tg/mg dry wt) (jrg/mg dry wt)
B. fragilis PW 415-8 16-4 7-8
NCTC 9393/VT PCP 614-4 33-1 0-8
Triton 229-2 29-3 3-5
B. fragilis PW 172-2 39-2 3-8
NCTC 9343/PPY PCP 90-8 33-6 1-4
Triton 147-8 49-0 2-1
B. fragilis PW 198-2 55-3 6-2
MPRL 1504/PPY PCP 120-8 72-4 0-5
Triton 130-0 28-5 3-7
B. vulgatus PW 267-6 78-9 2-7
MPRL 1985/PPY PCP 67-4 47-4 0-9
Triton 197-2 37-8 2-6
B. thetaiotaomicron PW 363-8 54-2 —
MPRL 1720/PPY PCP 43-8 47-4 0-4
Triton 262-4 79-6 4-0
B. caccae PW 240-2 54-3 —
MPRL 1555/PPY PCP 29-6 33-8 —
Triton 148-6 24-9 —
B. uniformis PW 221-6 102-0 —
MPRL 1721/PPY PCP 53-0 38-2 —
Triton 173-4 85-5 —
B. ovatus PW 281-0 43-1 5-7
MPRL 1709/PPY PCP 110-8 39-6 1-1
Triton 178-0 41-6 2-4
E. coli 018:K7 PW 254-8 36-5 2-2
NB aerobic
E. coli 018:K7 PW 260-0 34-0 2-4
NB anaerobic
PW, phenol-water; PCP, phenol-chloroform-petroleum; VT, Van Tassell and Wilkins'
medium; PPY, proteose-peptone yeast extract broth; NB, nutrient broth; CHO, carbohydrate;
P, phosphorus; —, not done. All assays were repeated on at least two occasions and the
results presented are the mean of two experiments. All samples were tested in duplicate for
each experiment.
3x10° cells/ml. Cells were dispensed in flat-bottomed
microtitration plates (Greiner) at 100 /d/well and
incubated in C02 5 % at 37°C for 20 h. The growth
medium was then aspirated, discarded and replaced
with 100 /d/well of assay medium—MEM containing
FCS 5% supplemented with 1 mM glutamine and
actinomycin-D (to stop further cell growth without
killing the cells) 2 /tg/ml. To experimental wells, 100 p\
of test supernate diluted 1 in 5 in assay medium was
added. A standard of recombinant TNF (National
Institute for Biological Standards and Controls) di¬
luted serially 1 in 5 from a starting concentration of
1000 IU/ml and wells without TNF were included.
Plates were sealed and incubated in C02 5 % at 37°C
for 24 h. The medium was then discarded and replaced
with filtered (0-22 /im) crystal violet solution (crystal
violet 0-5% in methanol 20% v/v in distilled water)
100/d/well which stains surviving cells. After 2 min,
the plates were washed vigorously under tap water and
dried. The crystals were dissolved by addition of 100 //I
of acetic acid 20% v/v to all wells and the plate was
read at 585 nm on a Vmax plate reader (Molecular
Devices). The content of TNF was calculated relative
to the standard curve.
Results
Comparison of different extraction methods
The yield of native LPS obtained with each ex¬
traction method is shown in table II. The PCP
extraction method gave the highest yield of LPS for
each organism, whereas the PW method gave the
lowest yield for most organisms. Those organisms that
gave a high yield of dry cells were very mucoid and the
yield of LPS was generally poorer.
Polyacrylamide gels were run and stained for LPS
and protein. Contaminating protein was found in
bacteroides LPS extracted by all three methods,
especially those extracted by the PCP and Triton
methods (data not shown). LPS extracts were assayed
for protein content:21 in PCP extracts protein content
ranged from undetectable to > 200 /tg/mg dry weight;
in all Triton preparations, with the exception of that
from B. vulgatus MPRL 1985 in which none was
detected, protein contamination was in the range
60-500 /tg/mg dry weight; and none was detectable in
the PW extracts.
All LPS preparations were then treated with pro¬
teinase K. On repeating the protein assays, none was
detected and no Coomassie Blue-stainingmaterial was
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Table IV. LPS-induced mouse lethality (galactosamine model)
Number of survivors after
i—ii ij aaiiipiv^
5 ng 50 ng 5^g 10 fig 20 fig
B.fragilis NCTC 9343 VT PW — — 3/3 1/3 0/3
B.fragilis NCTC 9343 PPY PW — — 3/3 2/3 1/3
B.fragilis MPRL 1504 PW — — 3/3 3/3 2/3
B. vulgatus MPRL 1985 PW — — 3/3 3/3 0/3
B. thetaiotaomicron MPRL 1720 PW — — 3/3 3/3 1/3
B. caccae MPRL 1555 PW — — 3/3 3/3 1/3
B. uniformis MPRL 1721 PW — — 3/3 3/3 3/3
B. ovatus MPRL 1709 PW — — 3/3 3/3 3/3
B.fragilis NCTC 9343 PPY PCP — — 3/3 3/3 3/3
B.fragilis NCTC 9343 PPY Triton — — 3/3 3/3 3/3
* B.fragilis NCTC 9343 PPY PW — — 3/3 2/3 0/3
* B. fragilis NCTC 9343 PPY PCP — — 3/3 3/3 3/3
* B.fragilis NCTC 9343 PPY Triton — — 3/3 3/3 3/3
E. coli 018: K~ aerobic PW 3/3 0/3 0/3 — —
E. coli 018: KC anaerobic PW 3/3 0/3 0/3 — —
All LPS are native samples unless indicated.
* Sodium salt form LPS; see table III for other abbreviations.
Table V. Endotoxic activities of sodium salt and native LPS (5 ng/ml) samples
LALIU/ml
LPS sample
Sodium salt form Native form
(i) PW extracts
B.fragilis NCTC 9343 VT 75-4 617-4
B.fragilis NCTC 9343 PPY 48-7 227-8
B.fragilis MPRL 1504 136-2 1863
B. vulgatus MPRL 1985 3-3 15-6
B. thetaiotaomicron MPRL 1720 1-0 4-1
B. caccae MPRL 1555 67-4 234-9
B. uniformis MPRL 1721 0-9 13-7
B. ovatus MPRL 1709 12-5 4-3
E. coli 018:K~ aerobically grown PW 6-8 62-2
E. coli 018:K~ anaerobically grown PW 2-2 31-7
(ii) PCP extracts
B.fragilis NCTC 9343 VT 1-1 0-5
B.fragilis NCTC 9343 PPY 4-9 0-6
B.fragilis MPRL 1504 0-8 0-9
B. vulgatus MPRL 1985 4-2 0-4
B. thetaiotaomicron MPRL 1720 0-2 0-8
B. caccae MPRL 1555 0-2 0-1
B. uniformis MPRL 1721 7-9 20-7
B. ovatus MPRL 1709 0-1 0-6
E. coli 018 :K aerobically grown PW 10-4 45-4
E. coli 018:K~ anaerobically grown PW 6-0 23-9
(iii) Triton extracts
B.fragilis NCTC 9343 VT 226-2 480-4
B.fragilis NCTC 9343 PPY 455-7 71-7
B.fragilis MPRL 1504 1020 704
B. vulgatus MPRL 1985 34-6 111
B. thetaiotaomicron MPRL 1720 63-5 17-4
B. caccae MPRL 1555 6-0 50-6
B. uniformis MPRL 1721 22-2 42-3
B. ovatus MPRL 1709 124-4 46-3
E. coli 018:Kr aerobically grown PW 9-2 83-6
E. coli 018: K anaerobically grown PW 8-8 42-3
All assays were repeated on at least two occasions and the results presented are the mean of two
experiments. All samples were tested in duplicate for all assays. See table III for abbreviations.
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Fig. 2. TNF concentration (IU/ml) from human mononuclear leucocytes (8 x 106 cells/ml) after stimulation for 4 h with B. fragilis NCTC
9343 PPY (■),£. vulgatus MPRL 1985 (•) and aerobically grown E. coli018: K" (♦) native LPS samples extracted by the PW method. Each
point is the mean of two readings.
observed in PAGE. LPS profiles after silver staining
were identical to those before proteinase K treatment
(data not shown). The following results are from LPS
preparations which had been treated with proteinase
K to remove protein contamination.
Pig. 1 shows LPS profiles on PAGE for each strain
and extraction method after separation and silver
staining. A banding pattern typical of smooth LPS was
seen for E. coli 018:K (gel c, tracks 1 and 2), B.
vulgatus MPRL 1985 (gel a, tracks 10, 11 and 12) and
B. thetaiotaomicron MPRL 1720 (gel b, tracks 1, 2 and
3). Material of high Mr was seen in B. fragilis LPS
extracted by both the PW and Triton methods. Rough,
low Mr material was seen in extracts prepared for all
species by each method, and was "dumbbell shaped"
for B. caccae and B. ovatus (gel b, tracks 4, 5 and 6,
and 10, 11 and 12). The PCP extraction method
produced a pronounced band (X) present behind the
main front band (R) in all preparations. Lor B. fragilis,
the PCP extraction method did not select for high Mr
material. Silver stain profiles for sodium salt form LPS
were identical to profiles of native forms (data not
shown). LPS profiles for E. coli 018:K grown
aerobically and anaerobically were identical.
Chemical analysis ofLPS samples
Samples of dry extract were resuspended in PLH20
to a concentration of 5 mg/ml and assayed for
carbohydrate, phosphorus and KDO content. The
relative amounts of carbohydrate, phosphorus and
KDO are shown in table III. Bacteroides spp. showed
a negligible amount or no KDO content before
treatment with hydrofluoric acid. The PW extraction
method selected for the greatest amount of carbo¬
hydrate and KDO material and the PCP extraction
method for the least. Phosphorus levels were more
uniform among all extraction methods. No difference
was observed between LPS extracts from E. coli
018 :K grown in different atmospheres.
LPS induced mouse lethality (galactosamine model)
E. coli 018:K~ LPS was lethal to all mice at
50 ng/mouse (table IV) whereas B. fragilis NCTC
9343 VT PW-LPS and B. vulgatus MPRL 1985 PW-
LPS were only lethal to mice at 20 //g/mouse. No
difference in lethality was seen for native and sodium
salt form B. fragilis NCTC 9343 VT PW-LPS. Mice
were not killed by the maximum dose ofB. fragilis LPS
extracted by PCP or Triton, nor by B. uniformis and B.
ovatus LPS extracted by PW.
Reactivity of LPS samples in LAL assay
Endotoxic activities in the LAL assay of native and
sodium salt form LPS are illustrated in table V (i), (ii)
and (iii) for each extraction method. On a weight for
weight basis, the greatest activity was seen in the PW
extracts and the least activity seen in the PCP extracts.
Most native PW-LPS were more active than sodium
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Table VI. Measured TNF concentration from human MNL (8 x 106 cells/ml) after
stimulation for 4 h with native and sodium salt form LPS (50 ng/ml) from E. coli
018:K~ and Bacteroides spp. extracted by three different methods
c . .. TNF concentration (IU/ml)
. nc , Extraction 'LPS sample . ,method
Native LPS Sodium salt LPS
B.fragilis NCTC 9343 VT PW 23-16 11-92
PCP 0-30 0-71
Triton 2-99 1-07
B.fragilis NCTC 9343 PPY PW 18-81 4-60
PCP 2-53 1-78
Triton 0-51 0 31
B.fragilis MPRL 1504 PW 4-93 2-51
PCP 0-42 0-25
Triton 0-99 0-47
B. vulgatus MPRL 1985 PW 2-58 0-72
PCP 015 0-51
Triton 0-39 0-31
B. thetaiotaomicron MPRL 1720 PW 6-40 6-47
PCP 003 0-43
Triton 0-17 0-49
B. caccae MPRL 1555 PW 13-89 15-25
PCP 0-22 0-74
Triton 2-48 2-44
B. uniformis MPRL 1721 PW 10-10 35-34
PCP 4-81 4-81
Triton 10-87 5-09
B. ovatus MPRL 1709 PW 8-66 13-89
PCP 1-44 5-37
Triton 1-25 2-32
E. coli 018:K~ aerobically grown PW 94-61 43-21
E. coli 018:K~ anaerobically grown PW 99-00 43-21
E. coli 06 PW 59-00 —
E. coli 012 PW 58-20 —
E. coli 015 PW 68-96 —
K. pneumoniae M10B PW 48-21 —
E. coli J5 PCP 36-63 —
E. coli K.12 PCP 49-90 —
S. Minnesota Ra PCP 31-68 —
S. Minnesota Rb PCP 96-70 —
S. Minnesota Rc PCP 49-90 —
S. Minnesota Rd PCP 78-45 —
S. Minnesota Re PCP 50-48 —
All assays were carried out on at least two occasions and the results presented are the mean of
two experiments. All samples were tested in duplicate for each assay. See table III for
abbreviations.
salt PW-LPS. Approximately 70% ofnative PCP-LPS
are more active than sodium salt PCP-LPS. No
significant difference was seen between the native and
sodium salt form LPS extracted by Triton. LPS from
E. coli 018:K~ grown aerobically was more active
than LPS from E. coli 018: K grown anaerobically by
a factor of two. B.fragilis MPRL 1504 PW-LPS was
more active than E. coli 018:K" LPS by a factor of
30, B. fragilis NCTC 9343 VT PW-LPS by a factor of
10, B. fragilis NCTC 9343 PPY PW-LPS by a factor of
four and B. caccae MPRL 1555 PW-LPS by a factor
of four. LPS from all other Bacteroides spp. were less
active than that from E. coli 018:K". A difference in
activity for B. fragilis NCTC 9343 LPS grown in
different media was also seen.
LPS-induced TNF secretion from human buffy coats
The amount ofTNF induced by different LPS from
human MNL (8 x 10" cells/ml) at several different
concentrations is shown in fig. 2. TNF appears to
reach a maximal level at c. 160 ng of LPS for all those
tested. Based on the data from fig. 2, an LPS
concentration of 50 ng/ml was selected to compare a
larger panel of LPS from other Bacteroides spp. and
enterobacteria (table VI). This value was chosen as it
was in the middle of the linear part of both the dose
response curve and the standard curve of the assay.
This would not show the maximum induction capacity
of the LPS but was a compromise for comparing a
large number of LPS samples. E. coli 018:K~ LPS
stimulated the most TNF production with no dif¬
ference in TNF production between LPS from E. coli
018:Kr grown aerobically or anaerobically. On a
weight for weight basis, PW-LPS stimulated the
greatest TNF production. Comparing PW-LPS, bac¬
teroides LPS induced TNF much less than did E. coli
018:Kr LPS, with the most active (B.fragilis NCTC
9343 VT) being four times less active than E. coli
018: K and the least active (B. vulgatus MPRL 1985)
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Table VII. TNF concentration from human MNL and endotoxic activity after
stimulation with LPS from selected Bacteroides spp. and E. coli 018:K~ LPS
relation to KDO content
Extraction TNF stimulation LAL activity
method (IU/ng of K.DO) (EU/ngofKDO)
B.fragilis NCTC 9343 VT PW 59-38 1583-08
PCP 7-16 10-69
Triton 17-3 2784-93
B.fragilis NCTC 9343 PPY PW 46-11 1191-11
PCP 35-11 8-44
Triton 4-90 693-24
B.fragilis MPRL 1504 PW 15-85 5985-54
PCP 17-42 37-38
Triton 5-38 3846-99
B. vulgatus MPRL 1985 PW 19-11 115-48
PCP 3-41 7-93
Triton 3-00 84-67
B. thetaiotaomicron MPRL 1720 PW — —
PCP 1-55 42-61
Triton 8-64 867-91
B. ovatus MPRL 1709 PW 30-37 14-98
PCP 25-89 4-68
Triton 10-43 385-5
E. coli 018:K PW 502-16 572-32
aerobic
E. coli 018:K~ PW 485-60 261-15
anaerobic
See table 111 for abbreviations.
being 37 times less active than E. coli 018:K~. TNF
production with other enterobacterial LPS tested was
of the same level or less than that with E. coli 018: K~
LPS, all being more active than bacteroides LPS.
Sodium salt form E. coli 018:K~ LPS had half the
activity of native form E. co//018:K~ LPS. Generally
for bacteroides LPS there was no clear distinction in
activity between sodium salt and native form LPS.
Reactivity ofLPS samples on the basis ofKDO
concentration
All the above assays were done on a weight for
weight basis. However, because endotoxicity is likely
to depend on lipid A concentration, it was decided to
re-evaluate some of the results of TNF induction and
LAL activity relative to KDO concentration in an
attempt to compare lipid A levels—on the assumption
(which could well be false) that lipid A is proportional
to KDO in all species.
The TNF concentration from human buffy coats
expressed as IU/ng of KDO and endotoxic activity in
LAL expressed as EU/ng of KDO after stimulation
with selected bacteroides and E. coli 018:K~ LPS is
presented in table VII. For the TNF concentrations
measured, this shows that the low activities seen
previously on a weight for weight basis (table VI) were
due in part to less KDO being present. However, LAL
activity for PCP-extracted LPS was still low when the
results were represented/ng of KDO.
Discussion
This study has shown that an aqueous phenol (PW)
extract of bacteroides LPS is significantly different
both in terms of chemical composition and biological
activity from the PCP or Triton products. The three
methods were selected in an attempt to produce
products of different composition. The classical PW
method was likely to select for higher Mr, less
hydrophobic material, the PCP method for rough-
form, more hydrophobic material, and the Triton-
Mg2+ method was chosen as a milder, less selective
method. It is well accepted that enterobacterial LPS is
heterogeneous in M,. even when pure. We acknowledge
that the bacteroides "LPS" used in this study may be
heterogeneous both in Mr and in molecular com¬
position. The degree of different molecular species of
LPS and other co-purifying carbohydrate, due to the
probable subpopulation structure of our cultures,3 is
by no means certain. The biological activity of entero¬
bacterial LPS is thought to depend on its solubility22
and, for this reason, the native and the standardised,
soluble sodium salt forms were prepared from electro-
dialysed material.
Our results agree with previous studies7 that in a
mouse lethality model bacteroides LPS is c. 5000-fold
less active than LPS from E. coli. In past studies,7,23'24
bacteroides LPS has been quoted as being 100-1000-
fold less biologically active in vitro, depending on the
assay, than LPS from enterobacteria. Our results for
bacteroides LPS extracted by the PCP or Triton
method agree with this. However, our results for LPS
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extracted by the PW method disagreewith the accepted
view.
Tumour necrosis factor-alpha (TNF) is considered
to be the pivotal cytokine in the host response to
endotoxin. In the TNF induction assay, E. coli
018:K~ LPS was only four-fold more active than B.
fragilis LPS, seven-fold more than B. caccae LPS and
up to 50-fold more than the other bacteroides LPS. In
the LAL assay, which has questionable value for the
in-vivo situation, the same LPS that were the most
active in the TNF-induction assay (from B. fragilis and
B. caccae) were 30-40-fold more active than E. coli
018:K" LPS, with E. coli 018:K" LPS being c. 10-
fold more active than the rest of the bacteroides LPS
tested. The two-fold difference in activity in the LAL
assay for LPS from E. coli 018: K grown aerobically
and anaerobically is unclear. Our results also show
that solubility (native versus sodium salt form LPS)
does not play an important role in biological activity
as has been described previously for enterobacterial
LPS;22 in most cases the sodium salt form was of lower
activity. Growth in the defined van Tassell and
Wilkins' medium was included because we have found
recently that growth in this medium converts several
B. fragilis strains, including NCTC 9343, from being
sensitive to the lytic action of normal human serum to
being resistant. This may be due to a change in
expression of certain surface polymers such as LPS.25
The results show some differences between the two
growth media in respect to both chemical composition
and biological activities.
The possibility that some contaminant may be
present in the LPS preparations from Bacteroides spp.
must be considered. In this connection we found no
contaminating organisms when culturing the organ¬
isms for extraction and the identity of each strain of
Bacteroides was confirmed before the start of the
study. Furthermore, PW-LPS samples from several
Bacteroides spp. prepared by different individuals at
different times in our laboratory were tested alongside
our own samples in the LAL and TNF induction
assay. They were found to produce nearly identical
results (data not shown). Higher biological activity in
the PW preparations cannot be due to a biologically
active protein as protein levels were negligible after
purification (table III). Biological activity also cannot
be due to any contaminating proteinase K as all
bacteroides LPS had been treated similarly with
proteinase K.
Some PW preparations of bacteroides LPS are
clearly more active than others, e.g., B. fragilis NCTC
9343 VT/PPY and B. caccae MPRL 1555. Chemical
analysis does not explain why the LPS from some
species are more active than from others. It does show
that more carbohydrate and KDO is present in the PW
preparations. The amount of KDO destroyed or not
released by hydrofluoric acid treatment is not known.
Those species that had a low reactivity in the LAL and
TNF bioassays (B. vulgatus MPRL 1985 and B.
thetaiotaomicron MPRL 1720) had a smooth LPS
profile on PAGE (fig. 1). This is in apparent con¬
tradiction to the view that aqueous phenol preferen¬
tially extracts smooth-form LPS. Moreover it is
surprising that those strains which are obviously
smooth (e.g., B. vulgatus) are less endotoxic.
In the light of the great variation found in the
chemical analyses, PAGE profiles and biological ac¬
tivities of the various preparations, and the knowledge
that several different LPS-like molecules have been
identified by monoclonal antibodies,26 the suggestion
that different extraction methods selectively produce
different populations of LPS or perhaps lipid-linked
capsular polysaccharides is strong. In nature all of
these different molecular species, if expressed, might
contribute towards a range of "endotoxic" phenom¬
ena. Therefore, it is essential to be able to purify the
various components of this heterogeneous "LPS"
population and relate them to biological function.
The role of bacteroides LPS in endotoxic shock
remains to be defined. We have shown that PW-
extracted LPS has a higher biological activity than
previously reported.7'24 How these chemically ex¬
tracted "LPS" relate to what is found in vivo also
needs to be defined. When we consider that Bacteroides
spp. are in vast excess of E. coli in the gut and may
have higher biological activity than previously
thought, the bacteroides LPS may play an important
but neglected role in endotoxic shock.
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The stimulation of macrophages and monocytes by lipopolysaccharide (LPS) results in the secretion of
tumor necrosis factor (TNF), a cytokine which is thought to play a pivotal role in subsequent host responses.
Its induction is thought to be facilitated by the binding of complexes of LPS and LPS-binding protein to CD14.
The LPS of Bacteroides species was considered a weak endotoxin; however, in a recent study we have shown that
the biological activity and chemical composition of the LPS from Bacteroides species are dependent on the
extraction method. The present study determines the capacity of LPS extracted by aqueous phenol (the method
for producing an LPS of high endotoxic activity) from four species of Bacteroides to induce TNF. Induction was
investigated from human mononuclear leukocytes (MNL), THP-1 cells (with and without enhancement by
vitamin D, for CD14), and peritoneal macrophages from C3H/HeJ (LPS nonresponder) and C3H/HeN (LPS
responder) mice. Escherichia coli 018K- LPS, a typical smooth LPS of heterogeneous molecular mass, was
used as a control throughout. The stimulation of TNF production by E. coli LPS was between two- and fourfold
more than that by Bacteroides LPS in MNL, in THP-1 cells (with enhancement for CD14), and in peritoneal
macrophages from C3H/HeN mice. In THP-1 cells (without enhancement for CD14), there was no significant
difference in TNF production between E. coli and Bacteroides LPSs. In peritoneal macrophages from C3H/HeJ
mice, E. coli LPS stimulated no TNF production, but there was no significant difference in TNF production
from peritoneal macrophages from C3H/HeJ and C3H/HeN mice by Bacteroides LPS. In all cell populations,
there was a peak of TNF production after approximately 4 h of stimulation with all LPSs tested. However, other
peaks of TNF production were seen in MNL and THP-1 cells (with enhancement for CD14) after stimulation
with E. coli LPS only. In stimulation assays in which Bacteroides LPS was together with but in excess of E. coli
LPS, it was found that TNF production from MNL and THP-1 cells (with and without enhancement for CD14)
was comparable to that of Bacteroides LPS alone and not E. coli LPS alone. An anti-CD14 monoclonal antibody
did not inhibit Bacteroides LPS-stimulated TNF production. However, E. coli LPS-stimulated TNF release was
inhibited by an anti-CD14 monoclonal antibody, most noticeably in MNL and THP-1 cells (with enhancement
for CD14). We conclude that Bacteroides LPS can mask the effects of E. coli LPS when present in excess, can
produce only one peak of TNF production, and activates mononuclear cells by a pathway not dependent on CD14.
The gram-negative bacterium Bacteroides fragilis is the most
frequently isolated anaerobic species in many infectious pro¬
cesses, including intra-abdominal abscesses. Such infections
usually arise from fecal contamination. Anaerobes constitute
approximately 99% of the fecal bacterial mass; of this amount,
Bacteroides species (formerly members of the B. fragilis group)
account for 20 to 30% of species isolated (6). The genus Bac¬
teroides constitutes the opportunistic pathogen B. fragilis and
several other pathogenic and nonpathogenic species: B. vulga-
tus, B. caccae, B. uniformis, B. distasonis, B. thetaiotaomicron,
B. stercoris, B. ovatus, and B. merdae. Bacteroides species are
numerically more predominant (by at least 103-fold) in the gut
than members of the family Enterobacteriaceae such as Esche¬
richia coli, thus representing a potentially vast pool of biolog¬
ically active lipopolysaccharide (LPS).
Studies on LPSs from Bacteroides species and their biologi¬
cal activities have mainly concentrated on B. fragilis (14, 32). It
is well documented that B. fragilis contains different fatty acids
from enterobacterial LPS, is monophosphorylated, and is gen¬
erally accepted as being less endotoxic (100- to 1,000-fold less,
depending on the assay) (14).
* Corresponding author. Mailing address: Department of Medical
Microbiology, University of Edinburgh Medical School, Teviot Place,
Edinburgh EH8 9AG, Scotland. Phone: 0131 650 3128. Fax: 0131 650
3128.
In a recent study in our laboratory, we found that the chem¬
ical composition, appearance on sodium dodecyl sulfate
(SDS)-poIyacrylamide gel electrophoresis (PAGE) and biolog¬
ical activity of Bacteroides LPS were dependent on the extrac¬
tion method used (5). Comparison of three extraction methods
for LPS, the aqueous phenol method (33), the phenol-chloro¬
form-petroleum method (8), and the Triton-Mg2+ method
(31), showed that the phenol-chloroform-petroleum and Tri-
ton-Mg2+ methods produced LPS of low activity, in keeping
with previous studies, but the aqueous phenol method pro¬
duced LPS of much higher activity. All LPS preparations were
complex in PAGE, and the aqueous phenol-extracted material
tended to have a greater proportion of carbohydrate and 3-
deoxy-d-manno-octulosonic acid (2-keto-3-deoxyoctonic acid
KDO) than the other methods and generally to contain higher-
molecular-mass bands, especially those from the more biolog¬
ically active species such as B. fragilis and B. caccae (5).
LPS has been implicated as an important primary mediator
in the development of gram-negative sepsis, a clinical syn¬
drome frequently associated with serious sequelae such as mul-
tiorgan failure and death (2). Several lines of evidence indicate
that the biological effect of LPS may be mediated in part
through the release of host cytokines (19).
Tumor necrosis factor alpha (TNF-a) is a cytokine produced
primarily by monocytes and macrophages during the early
phase of the host response to endotoxin (19). Recent studies
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TABLE 1. Bacterial strains used"
Species Strain Source/origin
B. fragilis MPRL 1669 Appendix/NCTC 9343
B. vulgatus MPRL 1985 Blood
B. caccae MPRL 1555 Wound
B. uniformis MPRL 1721 7/ATCC 8492
E. coli 018K MPRL 1274 A. S. Cross, Walter Reed Army
(bort) Institute for Research,
Washington, D.C.
" MPRL, departmental stock culture; NCTC, National Type Culture Collec¬
tion, United Kingdom; ATCC, American Type Culture Collection.
suggest that CD 14, a myeloid cell differentiation antigen ex¬
pressed primarily by monocytes and macrophages, is involved
in the activation of monocytes to release large quantities of
TNF-a by interacting with complexes of LPS and LPS-binding
protein (12, 16, 35). Many of the sequelae of gram-negative
infection can be reproduced by the administration of TNF into
animals (28).
In this study, we examine the TNF-inducing capacity of an
aqueous phenol-extracted LPS complex, previously shown to
be the most biologically active extract (5), from several species
of Bacteroides, representing a range of biological activities and
pathogenic potential, to induce TNF secretion. This capacity
was compared with that of an E. coli 018K" LPS control in
three cell populations. The role of CD 14 in activation of cells
to produce TNF was also investigated.
MATERIALS AND METHODS
Bacterial strains and culture methods. The strains used are described in Table
1. Bacteria were grown in 15- to 16-liter batches in a 20-liter-capacity fermenter
(LH Engineering, Stoke Poges, United Kingdom). Bacteroides species were
grown in proteose-peptone yeast medium (13) anaerobically at 37°C in 100% N2.
E. coli 018K~ was grown in nutrient broth aerobically at 37°C at a p02 of 50%.
Strict purity checks were carried out for each organism at the end of each
fermentation run.
Extraction of LPSs. LPSs were extracted by the aqueous phenol method of
Westphal and Luderitz (33) as described by Hancock and Poxton (10). All native
LPSs (5 mg/ml) were made free from protein contamination by treatment with
proteinase K (20 |xg/ml) at 65°C for 2 h. Proteinase K was removed by two washes
with pyrogen-free water at 100,000 x g. Samples of each were analyzed by PAGE
on 14% polyacrylamide gels and stained with silver (10).
LPS-induced TNF secretion, (i) From human peripheral mononuclear leuko¬
cytes. Mononuclear leukocytes (approximately 30% monocytes) from freshly
collected human buffy coats (obtained from the Blood Transfusion Service,
Edinburgh, Scotland) were prepared by sedimentation on lymphocyte separation
medium (ICN Flow). Cells (8 x 106/ml) were cultured in RPMI 1640 (Blood
Transfusion Service) supplemented with penicillin (100 U/ml), streptomycin (100
fxg/ml), 1 mM L-glutamine, and 10% fetal calf serum (FCS) in the absence or
presence of various nanogram concentrations of LPS. Culture supernatants were
collected after 4 h or at 1- or 2-h intervals for time course experiments and stored
at — 20°C for TNF content determination.
(ii) From THP-1 cells with and without enhancement for CD14. THP-1 cells (a
human monocyte/macrophage cell line) were a gift from David Morrison, Uni¬
versity of Kansas Medical Center, Kansas City. Cells were grown routinely in
RPMI 1640 supplemented with penicillin (100 U/ml), streptomycin (100 pg/ml),
1 mM L-glutamine, and 10% FCS at 37°C in 5% C02. To induce expression of
CD14, cultures were grown in the presence of 0.1 pM 1,25-dihydroxyvitamin D3
(Sigma) for 72 h. Cells (2 x 106/ml) were cultured in RPMI 1640 supplemented
as before in the absence or presence of various nanogram concentrations of LPS.
Culture supernatants were collected after 4 h or at 2-h intervals for time course
experiments and stored at -20°C for TNF content determination.
(iii) From peritoneal macrophages from LPS responder and nonresponder
mice. The LPS nonresponder mice, strain C3H/HeJ, were obtained from Harlan
Olac, Germany. The LPS responder mice, strain C3H/HeN, were obtained from
Harlan Olac, England. Sodium thioglycolate (1 ml of 10% [wt/vol] in distilled
H20) was injected intraperitoneal^ to each mouse 4 days prior to collection of
peritoneal macrophages. To collect the macrophages, the mice were killed by
cervical dislocation, and the peritoneal cavity was washed several times with 5-ml
quantities of RPMI 1640. After being washed once in RPMI 1640, cells were
resuspended to 2 x 106/ml in RPMI 1640 supplemented as before, and the assay
carried out as described above.
Inhibition of TNF secretion with an anti-CD14 MAb. The CD14 mouse im¬
munoglobulin G clone BA8 monoclonal antibody (MAb) was obtained from the
Scottish Antibody Production Unit, Law Hospital, Carluke, Scotland. The CD 14
MAb was serially diluted 1:2 in RPMI 1640 and added to cell preparations (as
described above) so that the starting concentration was 75 pg/ml. Cell prepara¬
tions and MAb were preincubated for 30 min at 37°C on 5% C02 before addition
of an appropriate dilution of LPS and reincubation as before. Culture superna¬
tants were harvested at 4 h and stored at —20°C for determination of TNF
content.
Determination of TNF content. The L929 mouse fibroblast cell line, which is
sensitive to TNF, was cultured in growth medium (minimal essential medium
[Sigma] containing 5% FCS supplemented with penicillin [100 U/ml], strepto¬
mycin [100 p.g/ml] and 1 mM L-glutamine) and maintained by splitting 1:10 twice
weekly. Cells were dislodged by 0.005% trypsin-0.02% EDTA to avoid cell
clumping, washed, and resuspended in growth medium to 3 x 105 cells per ml.
Cells were dispensed in flat-bottom microplates (Greiner) at 100 |xl per well and
incubated at 37°C in 5% C02 for 20 h. The growth medium was then aspirated,
discarded, and replaced with 100 p.1 of assay medium (minimal essential medium
containing 5% FCS supplemented with 1 mM glutamine and 2 \xg of actinomycin
D per ml [to stop further cell growth without killing the cells]) per well. To
experimental wells, 100 p-l of test supernatant which had been diluted 1:5 in assay
medium was added. A standard of recombinant TNF (National Institute for
Biological Standards and Control, Potters Bar, United Kingdom) diluted serially
1:5 at a starting concentration of 1,000 IU/ml and wells without TNF were
included. Plates were covered and incubated at 37°C in 5% C02 for 24 h. The
medium was then discarded and replaced with, per well, 100 p.1 of filtered
(0.22-p.m-pore-size filter) crystal violet solution (0.5% crystal violet in 20%
[vol/vol] methanol in distilled water), which stains surviving cells. After 2 min, the
plates were washed vigorously under tap water and dried. The crystals were
dissolved by addition of 100 p.1 of 20% (vol/vol) acetic acid to all wells, and the
plate was read at 585 nm on a Vmax plate reader (Molecular Devices). The
content of TNF was calculated relative to the standard curve.
RESULTS
Inter- and intra-assay variation. Because of variations be¬
tween individual blood donors and between cell cultures pro¬
duced on different occasions, a degree of interassay variation in
the TNF assays was unavoidable. With the exception of the
results in Fig. 3, which have been analyzed statistically, the
results presented are means of two experiments performed
with the same cell preparations on the same day. Intra-assay
variation was not great, typically much less than 10% (see Fig.
3). All assays were repeated on at least two occasions with cell
supernatants derived from different stimulation experiments.
All results presented depict trends which have been confirmed
on at least two occasions.
Effect of amount of LPS on TNF production. The effects of
various nanogram amounts of LPS on TNF production were
examined for E. coli 018K and B. fragilis NCTC 9343 (Fig. 1).
Because of the heterogeneity in molecular mass of the E. coli
LPS (ladder pattern) and the complexity of the appearance on
SDS-PAGE (Fig. 2) and unknown chemical structure and mo¬
lecular composition of the Bacteroides LPS complex (5), these
results are compared on a weight-for-weight basis rather than
a molar basis. However, chemical analysis of the preparations,
which is detailed in reference 5 and summarized here, showed
that the two preparations were essentially similar in terms of
phosphorus (39.2 and 34 p,g/mg), KDO (3.8 and 2.4 p,g/mg),
and carbohydrate (172 and 260 p-g/mg) for B. fragilis and E.
coli, respectively. In all cell populations tested, more TNF was
produced as LPS levels increased. For human mononuclear
leukocytes (Fig. la), E. coli 018KT LPS produced more TNF
than B. fragilis NCTC 9343 LPS for all amounts tested. No
difference in TNF production by B. fragilis NCTC 9343 LPS
was seen for THP-1 cells with and without enhancement for
CD14 (Fig. lb). The level of TNF production by£. coli 018KC
LPS in THP-1 cells without enhancement for CD14 was com¬
parable to that produced by B. fragilis NCTC 9343 LPS. How¬
ever, the level of TNF production by E. coli 018K~ LPS was
greatly increased in THP-1 cells with enhancement for CD14
compared with B. fragilis NCTC 9343. No major difference in











FIG. 1. TNF production after LPS stimulation for 4 h by human mononu¬
clear leukocytes (a), THP-1 cells with ( ) and without (—) enhancement for
CD 14 (b), and peritoneal macrophages from C3H/HeJ ( ) and C3H/HeN
(—) mice (c) by LPS from E. coli 018K~ (•) and B. fragilis NCTC 9343 (A).
Each point is the mean of duplicate experiments performed with the same cell
preparations. Note different scales on y axes.
TNF production by B. fragilis NCTC 9343 LPS was seen be¬
tween peritoneal macrophages from C3H/HeJ (LPS nonre-
sponder) and C3H/HeN (LPS responder) mice (Fig. lc), but
consistently there was slightly more TNF produced by the
C3H/HeN cells. Note the different scales of the y axes. There
was no TNF production observed in C3H/HeJ peritoneal mac¬
rophages stimulated by E. coli 018KT LPS. However, in peri¬
toneal macrophages from C3H/HeN mice, the level of TNF
production was greatly increased after stimulation by E. coli
018KT LPS. No difference in results was found when the
assays were carried out in the presence of FCS or human
serum (data not shown). The amount of TNF produced by
peritoneal macrophages after stimulation by all LPSs tested
was considerably lower than that produced by the other cell
populations.
Time course of TNF production. Levels of TNF production
by human mononuclear cells were measured at hourly intervals
after stimulation with LPS (50 ng/ml) from E. coli OlSK " and
B. fragilis (Fig. 3a). The response produced by the E. coli LPS
showed a complex periodic rise and fall, with major peaks at
FIG. 2. Silver-stained profiles of aqueous phenol-extracted LPS preparations
from E. coli 018K- (track 1) and B. fragilis NCTC 9343 (track 2) analyzed by
PAGE on a 14% polyacrylamide gel. Note that the material in the upper part of
track 2 does not stain strongly with silver.
between 3 and 5 h and 8 h. The B. fragilis LPS showed one
major peak between 3 and 6 h, with a minor rise at 8 h. This
type of response for E. coli LPS has been seen by other workers
in other laboratories (9, 9a), and a second peak at 8 h is a
consistent finding that has been reproduced on numerous oc¬
casions in our laboratories by several different workers. To
confirm the periodicity of the TNF response to E. coli LPS, the
experiment was repeated on four occasions with mononuclear
leukocytes from different donors, sampling at 2-h intervals
until 8 h and then at 20 h (Fig. 3b and c). All mean TNF values
in international units per milliliter from duplicate estimations
were normalized to the value for E. coli LPS at 4 h, which was
given the arbitrary value of 100%. Statistical analysis by Stu¬
dent's t test for paired means showed that the differences
between peaks and troughs for the response to E. coli LPS
were highly significant: between 2 and 4 h, P = 0.0027; between
4 and 6 h, P = 0.0032; and between 6 and 8 h, P = 0.0312 (P
< 0.05 is significant).
TNF induction by LPSs from other Bacteroides spp. and E.
coli were also followed by sampling at 2-h intervals in other cell
populations (Fig. 4). In human mononuclear leukocytes (Fig.
4a and b), LPS from E. coli 018K" was, depending on the
occasion assayed, between two and four times as active as the
most active Bacteroides LPS, with LPS from B. fragilis NCTC
9343 being the most active and that from B. vulgatus MPRL
1985 being the least active. For THP-1 cells without enhance¬
ment for CD14, only one peak of TNF was stimulated at 4 h for
all LPSs tested. LPSs from E. coli 018K and II. uniformis
MPRL 1721 were the most active, and LPS from B. vulgatus
was the least active (Fig. 4a). In THP-1 cells with enhancement
for CD 14, a peak of TNF production was seen at 4 h for all
LPSs tested. However, a second peak of TNF production,
larger than the first, was seen at 8 h for E. coli OlSKT only.
LPS from E. coli 018K" was approximately three- to fivefold
more active than the most active Bacteroides LPS (Fig. 4b). In
peritoneal macrophages from both C3H/HeJ (LPS nonre-
sponder) and C3H/HeN (LPS responder) mice, a peak of TNF
production was seen at 4 h for the LPSs tested (Fig. 4c and d),
with the exception of E. coli 018K " in C3H/HeJ peritoneal
macrophages, in which case no TNF was produced. In perito¬
neal macrophages from C3H/HeN mice, E. coli OlSK LPS
was only twofold more active than B. fragilis NCTC 9343 LPS.
The difference in activity between B. fragilis NCTC 9343 and B.
vulgatus MPRL 1985 LPS was not as marked as previously
seen. In most cell populations, the amount of TNF production
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FIG. 3. Time course of TNF production after stimulation of human mononuclear leukocytes with LPS (50 ng/ml) from E. coli 018KT (•) or B. fragilis NCTC 9343
(A), (a) Samples taken hourly over 24 h from a single experiment. TNF values are means of duplicate TNF estimations (vertical bars indicate differences between
duplicate estimations), (b and c) Results from four separate experiments performed on different occasions with different cell preparations. Each point is the mean of
two TNF estimations, and all values have been normalized relative to the 4-h value for E. coli LPS, which has been defined as 100%.
fell to zero more quickly for Bacteroides LPS than for E. coli
018KT LPS.
Effect of TNF production by E. coli 018K" LPS with B.
fragilis NCTC 9343 LPS present in excess. When LPS from B.
fragilis NCTC 9343 was in excess of a constant amount of E.
coli 018KT LPS (40 ng/ml) in human mononuclear leukocytes
and THP-1 cells with and without enhancement for CD14,
TNF production was comparable to that of B. fragilis NCTC
9343 LPS alone and not that of E. coli OlSKT alone (Fig. 5a
to c). There appeared to be a lowering and masking effect of
a) 200 c) 40
Time (h) Time (h)
FIG. 4. Time course of TNF production by THP-1 cells without enhancement for CD14 (a), THP-1 cells with enhancement for CD14 (b), peritoneal macrophages
from C3H/HeJ mice (c), and peritoneal macrophages from C3H/HeN mice (d) after stimulation with LPS (50 ng/ml) from E. coli 018K~ (•), B. fragilis NCTC 9343
(A), B. caccae MPRL 1555 (♦), B. uniformis MPRL 1721 (■), and B. vulgatus MPRL 1985 (I). Each point is the mean of duplicate experiments performed with the
same cell preparations. Note different scales on y axes.
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FIG. 5. TNF production after LPS stimulation for 4 h by human mononu¬
clear leukocytes (a), THP-1 cells without enhancement for CD14 (b), THP-1
cells with enhancement for CD 14 (c), peritoneal macrophages from C3H/HeJ
mice (d), and peritoneal macrophages from C3H/HeN mice (e) after stimulation
with various amounts of LPS from B. fragilis NCTC 9343 (A) and various
amounts of B. fragilis NCTC 9343 LPS together with a constant amount of E. coli
018K~ (40 ng/ml) (a). , maximum amount of TNF produced by E. coli
018K- alone. Each point is the mean of duplicate experiments performed with
the same cell preparations. Note different scales on y axes.
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FIG. 6. Inhibition of TNF production after 4 h by a CD14 MAb from human
mononuclear leukocytes (a), THP-1 cells without enhancement for CD14 (b),
THP-1 cells with enhancement for CD14 (c), peritoneal macrophages from
C3H/HeJ mice (d), and peritoneal macrophages from C3H/HeN mice (e) after
stimulation with LPS (50 ng/ml) from E. coli 018K" (•), B. fragilis NCTC 9343
(A), and CD 14 MAb alone ( ). Each point is the mean of duplicate exper¬
iments performed with the same cell preparations. Note different scales on y
axes.
TNF production from E. coli 018K5 LPS when LPS from B.
fragilis NCTC 9343 was present in excess. This trend was also
seen for B. vulgatus MPRL 1985 and B. caccae MPRL 1555
(data not shown). For peritoneal macrophages from C3H/HeJ
mice, levels of TNF production for B. fragilis NCTC 9343 LPS
alone and B. fragilis NCTC 9343 LPS together with E. coli
018KL LPS were identical: E. coli 018K- LPS alone does not
cause TNF stimulation (Fig. 5d). The trend seen in the other
cell populations was not clear for peritoneal macrophages from
C3H/FleN mice, as the amount of TNF produced by E. coli
018KC LPS alone was lower than that produced by the highest
concentration of B. fragilis NCTC 9343 LPS (Fig. 5e).
Inhibition of TNF production by an anti-CD14 MAb. The
effect of a CD14 MAb in inhibiting TNF production was ex¬
amined. In all cell populations tested, the presence of a CD14
MAb did not affect the production of TNF stimulated by B.
fragilis NCTC 9343 LPS (Fig. 6). However, the production of
TNF stimulated by E. coli 018KT was inhibited as the concen¬
tration of CD14 MAb increased (apart from peritoneal mac¬
rophages from C3H/HeJ and C3H/HeN mice). This inhibition
of TNF production was more marked in human mononuclear
leukocytes and THP-1 cells with enhancement for CD14 (Fig.
6a and c). In the presence of high levels of the CD 14 MAb, the
second peak of TNF production, after stimulation with E. coli
018KT LPS seen in human mononuclear leukocytes and
THP-1 cells with enhancement for CD14 (Fig. 3a and b and
Fig. 4b), was absent (data not shown). The CD 14 MAb had no
effect on the kinetics of Bacteroides LPS-induced TNF release
(data not shown).
DISCUSSION
Bacteroides LPS has been disregarded by many authors as
being much less endotoxic than enterobacterial LPS (14, 32),
but in a recent study in our laboratory (5), we showed that the
biological activity of Bacteroides LPS was dependent on the
extraction method used, with the phenol-water method (33)
producing LPS with the highest biological activity and the
phenol-chloroform-petroleum (8) and the Triton-Mg2^ meth¬
ods (31) producing LPS with low biological activities, in keep¬
ing with previous studies. Which extracted LPS type, if any,
reflects that in vivo remains to be defined.
The term "Bacteroides LPS" is used throughout the study for
the aqueous phenol-extracted material. It must be stressed that
the "LPS" is not a single molecular species, even of heteroge¬
neous chain length, but is much more likely to be a complex of
surface LPSs both rough and smooth, as well as possibly lipid-
linked capsular polysaccharides (CP). In SDS-PAGE, the Bac¬
teroides LPS appears as a series of several different molecules
of high and low molecular mass (Fig. 2 and reference 5). To
add to the complexity, some of the molecules can be detected
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only by immunostaining, as they are not sensitive to staining by
silver (1). The comparison of activity with E. coli LPS on a
weight-for-weight basis is preferred to a comparison on a mo¬
lar basis because of the complexity of the different molecular
species. In a previous study (5), we used KDO concentration as
a basis of comparison and found the same magnitude of dif¬
ferences between E. coli and Bacteroides spp. Also, when we
consider the relative endotoxicity on a bacterium-for-bacte-
rium basis, weight for weight of phenol-extracted LPS is prob¬
ably more relevant.
From the work of Patrick (23) and Patrick and Reid (24), we
know that a pure laboratory culture of B. fragilis exists as a
collection of subpopulations expressing a range of surface an¬
tigens. These subpopulations can be separated on density gra¬
dients, and the different antigens can be identified with a series
of MAbs (15). The CP of B. fragilis has been seen to consist of
at least two different molecules (23, 29, 30). An intriguing
observation was made several years ago by Onderdonk and
colleagues (21), i.e., that the CP of B. fragilis could induce
sterile abscesses. This issue has recently been readdressed (29),
and Cross (4) has suggested that CP may induce proinflamma¬
tory mediators such as interleukin-1. We have previously re¬
ported that some preparations of CP are contaminated with
high-molecular-mass LPS (25). In 1984, Williamson and col¬
leagues (34) recognized that the polysaccharide and lipid A
fractions of B. fragilis LPS (prepared by aqueous phenol ex¬
traction) had different effects on spleen cells of C3H/HeJ mice:
the mitogenic response was only to the polysaccharide fraction
via macrophages.
Bacteroides LPS is capable of inducing mononuclear cells to
produce TNF. This seems to be independent of expression of
CD14, the 55-kDa glycosyl phosphatidylinositol-linked protein
expressed on the surface of monocytes, macrophages, and
polymorphonuclear leukocytes (11), which has been found to
serve as a specific binding site for complexes of LPS and LPS-
binding protein in serum (16, 35, 36). Although the functional
role of CD 14 has yet to be fully defined, it plays a very impor¬
tant role in LPS activation events.
In cell populations lacking CD14 (THP-1 cells without en¬
hancement for CD14) and in peritoneal macrophages from
C3H/HeN mice, E. coli Ol 8K LPS could induce only one
peak of TNF release at 4 h, compared with peaks at 4 and 8 h
in CD14-rich populations (human mononuclear leukocytes
and THP-1 cells with enhancement for CD14) (Fig. 3 and 4).
The peak of TNF release at 8 h was inhibited by high concen¬
trations of the anti-CD14 MAb (data not shown). Bacteroides
LPS could induce only one peak of TNF release at 4 h regard¬
less of the cell population, suggesting that it stimulates cells to
produce TNF via a pathway independent of CD 14 and that the
periodic response may be related to CD 14. The fact that TNF
release stimulated by Bacteroides LPS could not be inhibited by
an anti-CD14 MAb (compared with E. coli LPS, which could
be inhibited) is further evidence to support this concept. Of
note is that only in human cell populations rich in CD14 is
there a significant difference in TNF-inducing capability by
LPS from Bacteroides species and E. coli.
In a recent report by Lynn et al. (17), CD14 and serum were
shown not to be absolutely necessary for the activation of
mononuclear phagocytes by bacterial LPS. They suggested that
a CD14-independent pathway may be of importance in local
sites of infection where the concentration of LPS may be high,
for example, fecal soiling of the peritoneum. This fact is inter¬
esting when we consider our results obtained for peritoneal
macrophages from C3H/HeJ and C3H/HeN mice. Flere, TNF
release after stimulation with both Bacteroides and E. coli LPSs
appears to occur through a CD14-independent pathway: only a
single-peak response was seen for both LPSs (Fig. 4), and a
CD14 MAb had no effect on TNF release after stimulation
with either LPS (Fig. 6). The lack of effect by the CD14 MAb
on the TNF response to the E. coli LPS by the C3H/HeN
macrophages could suggest that the MAb does not recognize
the mouse CD14 analog. This has recently been confirmed by
flow cytometry (data not shown). Peritoneal macrophages may
differ in the ability to respond to LPS compared with circulat¬
ing macrophages. It has been reported that different macro¬
phage populations differ in their TNF responses to LPS: alve¬
olar macrophages, for example, produce a much higher level of
TNF with a faster response than Kupffer cells (3).
In peritoneal macrophages from C3H/HeJ mice, the B. fra¬
gilis LPS stimulates a low level of TNF production whereas E.
coli LPS stimulates no TNF production. It is well documented
that peritoneal macrophages from C3H/HeJ mice are unable
to respond to LPS from members of the family Enterobacteri-
aceae because of a genetic deficiency (27). However, a pathway
open to B. fragilis LPS is capable of stimulating TNF produc¬
tion. Which component of the B. fragilis LPS complex induces
this effect is not yet known. Fujiwara et al. (7) demonstrated
that LPS extracted by aqueous phenol from oral Bacteroides
species (now reclassified as Porphyromonas and Prevotella spe¬
cies) were highly mitogenic to spleen cells from C3H/HeJ mice.
Other Bacteroides spp. have yet to be investigated.
An excess of Bacteroides LPS blocked the effects of E. coli
018KT LPS on human mononuclear leukocytes and THP-1
cells (with and without enhancement for CD14) (Fig. 5).
Whether this was due only to the configuration of LPS in
solution or due to an effect at the cellular level is not known.
A well-documented synergistic relationship exists between E.
coli and B. fragilis, whereby B. fragilis inhibits the phagocytic
killing of E. coli (20, 26). Magnuson et al. also found that B.
fragilis NCTC 9343 LPS inhibits E. coli LPS-induced human
endothelial cell adhesiveness for neutrophils (18). However, in
that study, it was not found that B. fragilis LPS inhibited TNF
production, but the B. fragilis LPS was extracted sequentially
by the phenol-water method followed by the phenol-chloro¬
form-petroleum method. This may have some bearing on the
results found.
Our observations may be of some importance when we con¬
sider that Bacteroides species outnumber E. coli in the gut by at
least 1,000-fold. It is not yet known if the situation observed in
vitro will occur in vivo. However, it may be significant in terms
of immunotherapy if bacteria or their products translocate
from the gut into the bloodstream. If Bacteroides LPS is the
major inducer of cytokine responses, we should be targeting
them with antibody therapy instead of E. coli (la). However, if
the inhibition of the E. coli LPS response occurs in vivo, then
perhaps the Bacteroides LPS serves a protective role.
There are still several questions that remain to be answered,
(i) Why are there several peaks of TNF production after stim¬
ulation with E. coli LPS in CD14-rich cell populations? What
causes the troughs in the periodic TNF response? We acknowl¬
edge that there may be heterogeneity in the cell population or
different stages present in the cell cycle which may cause this
response. Also, TNF may be present during the trough but in
a bound form which would not be detectable in our bioassay.
The possibility that TNF is neutralized during the trough by
soluble TNF receptor appears unlikely (unpublished observa¬
tions). (ii) What is the activation pathway which is independent
of CD14, and how does Bacteroides LPS stimulate peritoneal
macrophages from C3H/HeJ mice to produce TNF? (iii) How
does an excess of Bacteroides LPS mask the effects of E. coli
LPS? There is still therefore much to be learned about Bacte¬
roides LPS and monocyte/macrophage activation pathways.
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In conclusion, the Bacteroides LPS complex activates mono¬
nuclear cells by an unknown route to produce TNF indepen¬
dently of CD14, and it can mask the effects of E. coli LPS. The
role of Bacteroides LPS in shock remains to be defined, but the
results of our previous and current studies indicate that Bac¬
teroides LPS may play an important and previously overlooked
role in endotoxic shock. B. fragilis has a history of debate and
some confusion as to the structure-function relationships of its
polysaccharide surface structures (14, 25), and it is perhaps too
early at this stage to suggest that individual molecules can
induce specific mediators. However, the recent work of Tzi-
anabos and colleagues has begun to resolve some of the com¬
plexity by identifying two distinct polysaccharides in the CP
complex of B. fragilis 9343 (30) and proposing a mechanism for
the formation of abscesses (29). However, until we can finally
fractionate, or clone, the various other constituent molecules,
little further progress can be made in determining their indi¬
vidual and combined functions in pathogenesis. This is the
important next step.
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Biological Activity of Bacteroides Lipopolysaccharide—Reappraisal
Ian R. Poxton and Diane M. Edmond From the Department ofMedical Microbiology, University ofEdinburgh
Medical School, Edinburgh, Scotland. United Kingdom
Lipopolysaccharide (LPS) was extracted from six species of Bacteroides by the phenol/water,
petroleum/chloroform/phenol, and Triton/magnesium methods. Yields and chemical analysis
demonstrated that the products were different. Biological activity (endotoxicity) was assessed by
the limulus amebocyte lysate (LAL) assay, induction of tumor necrosis factor (TNF) from human
mononuclear leukocytes, and a lethality model with galactosamine-sensitized mice. Results
showed that endotoxicity varied greatly depending on the species and the extraction method.
LPS prepared by the phenol/water method was most endotoxic and that from Bacteroides fragi-
lis had the greatest activity. Compared with Escherichia coli LPS, the phenol/water extract ofB.
fragilis was sevenfold more active in the LAL assay and marginally less active (five- to seven-fold)
in the bioassay for TNF induction. However, when B. fragilis LPS was added to E. coli LPS, the
induction ofTNF was inhibited. In the mouse model, B. fragilis LPS was 5,000-fold less toxic. If
the gastrointestinal tract is the source of the endotoxin in patients with systemic inflammatory
response syndrome, then the obligately anaerobic Bacteroides species, which outnumber the
facultative species such as E. coli by 1,000-fold, should not be overlooked.
In the past few years, it has become accepted that much of
the systemic endotoxin involved in the pathogenesis of sys¬
temic inflammatory response syndrome (SIRS) or sepsis in
the severely ill patient originates in the bowel. Bacteria and
their products may translocate during episodes of shock-in¬
duced gut ischemia [1] to the portal circulation where lipo-
polysaccharides (LPSs) and possibly other biologically active
molecules interact with, inter alia, Kupffer's cells, the macro¬
phages of the liver. Many of the subsequent pathophysiologi¬
cal changes characteristic of SIRS result from the induction
of the proinflammatory cytokines, of which TNF-a is one of
the most important [2].
In the gastrointestinal tract, the strictly anaerobic Bacte¬
roides species outnumber the enterobacteria by 1,000-fold.
However, the biological activity of the LPSs of Bacteroides is
generally considered to be low. In a variety of models, both
in vivo and in vitro, it has been reported that the endotox¬
icity of Bacteroides LPSs is 10,000- to 10-fold lower than the
activity of LPSs of the members of the family Enterobacteria-
ceae [3]. Arithmetically, this finding might suggest, even al¬
lowing for the much lower biological activity, that within the
gastrointestinal tract the pool of potential endotoxin may
originate as much from Bacteroides species as from Esche¬
richia coli and other facultative gram-negative bacteria on a
weight-for-weight basis.
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There has been a history of confusion and debate as to the
types, structures, and locations of the various surface polysac¬
charides of Bacteroides species, and Bacteroides fragilis, the
major pathogen of the genus, has been studied in most detail.
The following facts have been established: (i) Within a labo¬
ratory culture of B. fragilis, subpopulations exist that can be
separated by density gradient centrifugation with Percoll.
Immunogold electron microscopy, immunoblotting, and
flow cytometry with monoclonal antibodies have shown that
different subpopulations express different saccharide epi¬
topes and, possibly, different entire polysaccharides on their
surface and that antigenic variation may occur [4], (ii) The
structure of lipid A of B. fragilis LPS has been determined
and shown to be monophosphorylated; it has acyl substitu-
ents different from those ofE. coli. The lower endotoxicity of
B. fragilis LPS is thought to be a direct result of the chemical
structure of lipid A [3]. (iii) It has long been recognized that
the capsular polysaccharide of B. fragilis can induce the for¬
mation of abscesses, and recently it has been shown that two
different polysaccharides, each carrying a positive and a nega¬
tive charge, are present within a capsular polysaccharide
complex; these polymers, which carry the dual charges, act in
tandem to induce the abscess [5], (iv) The growth environ¬
ment influences the expression of surface polysaccharides
and changes the sensitivity of the bacteria to serum comple¬
ment [6].
At our laboratory, a major study is under way that is exam¬
ining the pathogenic potential of different species of Bacte¬
roides in several different models and is investigating the pos¬
sibility that Bacteroides species within the gastrointestinal
tract represent a vast reservoir of potential endotoxin. The
study reported here is a part of the larger study; the aim of
this study was the assessment of the biological potential of
Bacteroides LPSs by determining (1) if different extraction
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Table 1. Composition of samples of LPSs. (PCP) [8], and Triton/magnesium (TM) [9] methods; the
PW and PCP methods were performed as previously de¬
scribed [10]. Strict attention was paid to purity throughout
the growth, harvesting, and extraction procedures. Pyrogen-
free water (Milli-Q; Millipore, Bedford. MA) was used in
each procedure. Some protein contamination that was ini¬
tially present in the PCP and TM extracts was removed by
treatment with proteinase K followed by ultracentrifugation
and washing. The PW extract treated with proteinase K
served as a control and showed that the proteinase K treat¬
ment itself was not responsible for any biological activity.
The PW. PCP, and TM methods were chosen to produce
predominantly smooth, high-molecular-weight material; pre¬
dominantly rough, low-molecular-weight material; and un-
selected material by an extraction method much milder than
the PW or PCP method, respectively.
Each strain was cultured in a 15-L batch in an LH fer-
menter (L. H. Engineering, Stoke Poges, UK), and after har¬
vesting and freeze-drying, each batch was divided into three
Table 2. Results of LAL assay of LPS and induction ofTNF-a by
LPS.
No. of units per indicated
extraction method
LPS sample, substance
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NOTE. KDO = 3-deoxy-D-manno-2-octulosonic acid: LPS = lipopoly-
saccharide: MPRL = Department of Medical Microbiology culture collec¬
tion: NCTC = National Collection of Type Cultures: ND = not done: PCP
= petroleum/chloroform/phenol; PW = phenol/water: TM = Triton/mag¬
nesium: . . . = below detection limit of assay.
* Concentration measured after dephosphorylation by hydrofluoric acid.
methods influence the chemical composition of the product,
(2) the biological activity of the different LPSs, and (3) if
different growth media influence the chemical composition
and/or the biological activity of LPS.
During this study, we made no attempt to fractionate the
individual molecular species of the aqueous phenol-ex¬
tracted, ultracentrifuged LPS complex, and it may be wrong
even to name this material LPS; however, the term is re¬
tained by convention. Our intention was to determine the
overall properties of the polysaccharide that might represent
more accurately the properties of the material released from
the bacteria. Subsequently, we hope to be able to relate the
properties to individual structures.
LPS was extracted from six Bacleroides species (table 1) by
the phenol/water (PW) [7], petroleum/chioroform/phenol
NOTE. EU = endotoxin units; IU = international units; LAL = limulus
amebocyte lysate; LPS = lipopolysaccharide; MPRL = Department ofMedi¬
cal Microbiology culture collection; NCTC = National Collection of Type
Cultures; ND = not done; PCP = petroleum/chloroform/phenol; PW =
phenol/water; TM = triton/magnesium.
* Activity determined by LAL assay with a kinetic chromogenic endo¬
toxin kit (Coatest Endotoxin, Chromogenix) was measured in EU/5 ng of
LPS.
+ Activity determined by TNF-a induction via a bioassay with L929
mouse fibroblasts was measured in IU/50 ng of LPS.
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Figure 1. Profiles of silver-stained
samples of Bacleroides LPSs on
polyacrylamide gels. With the ex¬
ception of the samples in lanes 1-3
of the top figure, all bacteria were
cultured in proteose peptone-yeast
extract medium. Top: Lanes 1-3.
B. fragilis NCTC 9343 grown in
the medium chemically defined by
Van Tassell and Wilkins [11]; lanes
4-6. B. fragilis NCTC 9343; lanes
6-9. B. fragilis MPRL 1504; and
lanes 10-13. B. vulgatus MPRL
1985. Arrowhead = position of
high-molecular-weight material.
Bottom: Lanes 1-3. B. tlietaiolao-
tnicron MPRL 1720; lanes 4-6. B.
caccae MPRL 1555; lanes 7-9. B.
uniformis MPRL 1721; and lanes
10-12. B. ovatus MPRL 1709. The
first LPS sample in each group of
three was extracted by the phenol/
water method; the second, by
the petroleum/chloroform/phenol
method; and the third, by the
Triton/magnesium method.
equal samples for extraction. Yields by weight varied consid¬
erably; generally, the PCP method demonstrated the highest
yield, and the PW method demonstrated the lowest yield.
Examples of silver-stained samples of LPSs on polyacryl¬
amide gels are shown in figure 1; these samples were ex¬
tracted by the different methods from different species.
PAGE revealed a variety of different types of profiles. The B.
fragilis LPSs appeared predominantly rough, but in the PW
and TM preparations, high-molecular-weight bands (arrow¬
heads) were apparent. The Bacleroides vulgatus and Bacle¬
roides thetaiotaomicron LPSs had a ladder pattern reminis¬
cent of smooth LPSs of enterobacteria; however, their
molecular weights were relatively low, and these prepara¬
tions lacked the typical high-molecular-weight bands. When
immunoblotting with rabbit antiserum to whole bacteria was
performed on these preparations, a much more complex pic¬
ture was generally revealed, including ladder patterns, espe¬
cially in the higher-molecular-weight regions (E. Allan, S.
Riley, and I. R. Poxton. unpublished observations).
Chemical analyses for total concentrations of carbohy¬
drate [12], 3-deoxy-D-manno-2-octulosonic acid (after hy¬
drofluoric acid treatment [10, 13]), and phosphorus [14]
were performed. The concentrations of these substances var¬
ied greatly depending on the extraction method, with the
highest carbohydrate concentrations in the PW extracts and
the lowest concentrations in the PCP material (table 1).
Endotoxicity was measured in all samples by the standard
limulus amebocyte lysate (LAL) assay with use of a kinetic
chromogenic endotoxin kit (Coatest Endotoxin, Chromo-
genix. Molndahl. Sweden) (however, the clinical relevance
of this assay is being debated), the induction of the pivotal
proinflammatory cytokine TNF-a by human mononuclear
cells isolated from buffy coat preparations, and a lethality
model with D-galactosamine-sensitized mice [15], A stan-















B.fragilis NCTC 9343 LPS concentration (ng/mL)
Figure 2. TNF induction by E. coli LPS and B.fragilis LPS in human mononuclear cells: the induction was determined by a bioassay with
L929 mouse fibroblasts. A. time course ofTNF production (IU/mL) by human mononuclear leukocytes stimulated with LPS (50 ng/mL)
from E. coli 018K." (•) or B. fragilis NCTC 9343 (▲). B. TNF production (HJ/mL) after 4 hours by human mononuclear leukocytes
stimulated with varying amounts of LPS from B.fragilis NCTC 9343 (▲) and varying amounts of LPS from B.fragilis NCTC 9343 together
with a constant amount of LPS from E. coli 018KT (40 ng/mL) (A). = maximum amount of TNF induced by LPS from E. coli
018K~ alone.
dard preparation of the E. coli 018K" LPS extracted by the
PW method was used as a positive control for comparison in
all experiments. The choice of a suitable negative control
was considered. However, as so many bacterial components
from gram-positive as well as gram-negative organisms have
biological activity, it was decided to use the Bacteroides LPSs
themselves as comparators. All LPSs were prepared in paral¬
lel under identical conditions with the same batches of ex-
tractants and buffers. Retrospectively, the PW preparations
ofB. thetaiotaomicron or Bacteroides ovatus could be consid¬
ered negative controls because they provided background lev¬
els. It was shown that the biological activity was dependent
on both the species of origin and the extraction method. Re¬
sults of the LAL assay and induction ofTNF-a are shown in
table 2. In the LAL assay, the activity of all Bacteroides LPSs
extracted by the PCP method was much lower than that of
the standard E. coli LPS: however, B.fragilis and Bacteroides
caccae LPSs extracted by the PW method were approxi¬
mately sevenfold more active than E. coli LPS, while the
activity of B. thetaiotaomicron and B. ovatus LPSs was much
lower. When B. fragilis was cultured in the medium chemi¬
cally defined by Van Tassell and Wilkins [11], the activity
was 20-fold more than that of E. coli (results not shown).
B.fragilis and B. caccae LPSs extracted by the PW method
induced TNF-a, but this level of induction was five- to
sevenfold lower than that by E. coli LPS. In a time-course
experiment (figure 2A), the kinetics ofTNF induction by E.
coli LPS followed a complex periodicity compared with B.
fragilis LPS. An intriguing observation has been made when
increasing amounts of B. fragilis LPS were added to a stan¬
dard amount of E. coli LPS. Instead of the additive effect
expected, Bacteroides LPS inhibited the TNF induction by E.
coli LPS (figure 2B). The basis of TNF induction by Bacte¬
roides LPS and this observation of inhibition are the subjects
of another study [16],
In the mouse lethality model, the toxicity of all prepara¬
tions of Bacteroides LPS was much lower than that of E. coli
LPS; most preparations were at least 5,000-fold less toxic.
In the present study and in previously published studies
[16, 17], we have shown that the overall chemical composi¬
tion, appearance on polyacrylamide gels, and biological ac¬
tivity of preparations of Bacteroides LPS are very dependent
on the extraction method and growth environment. Differ¬
ent Bacteroides species produce LPSs with widely different
activity, and most importantly, the LPSs ofB.fragilis and B.
caccae in particular appear to be much more endotoxic than
hitherto realized. Although the clinical relevance is debat¬
able, the LAL assay demonstrates that some preparations of
Bacteroides LPS are even more active than E. coli LPS. The
capacity of Bacteroides LPS to induce TNF-a in human
mononuclear cells is certainly an important observation, and
its modulating effect on the biological activity of E. coli LPS
could have significant consequences in vivo. The lack of le¬
thality in the model of galactosamine-sensitized mice ap¬
pears contradictory to our thesis that Bacteroides LPS is more
active than previously thought. However, at present, the in¬
duction of low-dose lethality in this mouse model is not well
understood, and substances other than TNF and other proin¬
flammatory cytokines may play key roles [ 18], From work to
be published in detail elsewhere [16], we know that the in¬
duction of TNF by macrophages is independent of CD 14
expression and that macrophages of LPS-non-responder
mice (C3H/HeJ) are as refractile to Bacteroides LPS as are
those of responder mice (C3H/HeN). Therefore, pathways
CID 1995:20 (Suppl 2) Bacteroides Lipopolysaccharide SI 53
must exist that are different from those previously recog¬
nized for cytokine induction, and sensitivity to LPS in mouse
lethality models cannot be related directly to TNF induc¬
tion.
If bacterial translocation is an important source of endo¬
toxin in patients with the systemic inflammation characteris¬
tic of clinical sepsis, then the anaerobic gram-negative com¬
ponent of the gastrointestinal flora should not be overlooked
from the point of view of inducing and/or modulating the
response. Current studies are under way in our laboratory
that are extending these observations, and we are beginning
to develop methods for assessing the amount of exposure to
Bacteroides LPS in the patient. By analyzing the kinetics of
antibodies to Bacteroides antigens in the serum from patients
with sepsis who are in the intensive care unit, we have shown
indirectly that translocation of Bacteroides LPS has oc¬
curred [19].
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